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ABSTRACT OF THE DISSERTATION 
Negative Regulators of Colonic Peripheral Regulatory T Cell Development 
By 
Teresa Lei Ai 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2017 
Professor: Chyi-Song Hsieh, Chair 
Peripheral Treg cells (pTreg cells) maintain immune homeostasis at mucosal interfaces, 
where they can develop upon activation of naïve CD4
+
 T cells by bacteria antigen. However, the 
cellular and molecular requirements that govern their differentiation in inflamed and homeostatic 
contexts require further elucidation. To circumvent uncertainties in existing methods of 
distinguishing pTreg cells from thymic Treg cells (tTreg cells), we analyzed monoclonal cell 
populations of CT2 and CT6 transgenic (Tg) cells that develop into pTreg cells in response to 
different species of endogenously presented Helicobacter antigen.  In our comprehensive 
assessment of multiple intestinal inflammatory models, including infections and physical injury, 
we find that pTreg development against Helicobacter antigen is largely preserved. In one model, 
DSS coupled with a high-fat diet (HFD), we observed a TCR-specific defect in Treg cell 
development with CT6, but not CT2 Tg cells, adopting effector fates. The concurrent 
development of effector and pTreg cells during inflammation implicate that the cellular and 
molecular signals that govern pTreg cells and effector T cell development are highly sequestered, 
protecting the host from the aberrant generation of effector T cells against tolerogenic antigens. 
ix 
 
 
 
Transcriptional regulators regulate pTreg celll development by promoting FoxP3, 
antagonizing alternative effector fates, and stabilizing FoxP3 expression. Here, we capture 
transcriptional snapshots of activated monoclonal CT6 Tg cells pre and post FoxP3 expression to 
identify relevant transcriptional regulators during different stages of development. Early 
developing pTreg cells exhibit a burst of transcriptional activity that is not maintained in later 
stages. Furthermore, early developing pTreg cells transiently express Eomesodermin (Eomes) 
which restrains FoxP3 expression in activated, undivided cells and cells that have undergone one 
division. Eomes expression correlated with the expression of Nr4a family of transcription 
factors, which enhance FoxP3 expression. Thus, early developing pTreg cells concurrently 
express transcriptional regulators that promote or repress Treg cell development early in 
development.  
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Chapter 1: Introduction 
Introduction 
 The immune system is designed to mount rapid and functionally specialized defenses 
against invading pathogens or mutant cells to protect organisms from infectious diseases and 
cancers. Tolerance mechanisms are in place to firstly, prevent the immune system from 
mounting effector responses against healthy host cells and secondly, to restrain immune 
responses after threats have been eliminated. Regulatory T cells (Treg cells), whose development 
require the FoxP3 transcription factor (1–4), are necessary for the tolerogenic branch of the 
immune system to function effectively. Defects in FoxP3 lead to death in both human and mice 
(5–10) , and depletion of FoxP3+ cells from mice result in multi-organ failure (11). 
 Treg cells are thymically derived, known as thymic Treg cells (tTreg cells), or 
extrathymically derived in the periphery, known as peripheral Treg cells (pTreg cells). During 
thymic negative selection, developing T cells with very high affinity to self-antigen are 
eliminated, preventing the egress of self-reactive T cells into peripheral circulation. Cells with 
moderate to high affinity to self-antigens are directed to express FoxP3, exiting the thymus into 
peripheral circulation as tTreg cells. In contrast, pTreg cells originate from naive, pluripotent 
CD4
+
 T cells that can differentiate into effector T cells or Treg cells.  When naïve CD4
+
 T cells 
encounter their antigen, they receive specification signals that allow them to differentiate into 
functionally appropriate cell fates. 
 Both thymic and peripheral Treg cells require FoxP3 for their development, but regulate 
FoxP3 expression through distinct enhancers and may be specialized for distinct functions (12). 
pTreg cells are emerging to be uniquely critical for immune tolerance at mucosal interfaces. An 
increasing number of bacteria species and byproducts in mammalian microbiota are being found 
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to induce pTreg cells and/or promote pTreg function (13–21). Their selective deletion by 
ablating the CNS1
-/- 
enhancer, critical for FoxP3 upregulation in pTreg cells, (12) leads to 
spontaneous type 2 inflammation at mucosal interfaces (22).  
 The appropriate selection and development of pTreg cells is thus, an important area of 
study. Perturbing this process may compromise tolerance at mucosal interfaces, which are 
constitutively encountering bacteria, food, and self-antigens. Aberrant immune reactivity to such 
antigens may contribute towards the manifestation and/or amplification of intestinal diseases, 
including inflammatory bowel disease (IBD) and celiac disease.  My research aimed to 
understand what factors inhibit appropriate pTreg differentiation and development against 
commensal bacteria. I evaluated both cell-extrinsic conditions, specifically intestinal 
inflammation, and cell-intrinsic factors, specifically genes transcribed prior to FoxP3 in pTreg 
cells developing in vivo.  
 My thesis work found that pTreg development by Helicobacter-reactive TCR Tg cells are 
largely able to differentiate in multiple models of intestinal inflammation. Their development 
into pTreg cells is negatively affected in one model, the DSS model of colitis coupled with high 
fat diet (HFD), which uniquely induces a dramatic expansion of Enterobacter species in the 
microbiota. Additionally, early stages of pTreg development are more transcriptionally active 
than later stages. Eomesodermin (Eomes), which can inhibit Treg cell development, is expressed 
early in developing T cells upon TCR engagement, restricting the rate of FoxP3 expression in 
undivided or recently divided cells.  
 
Microbiota and T cells 
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 Mammalian microbiota is composed of trillions of bacteria species that promote host 
health by aiding with digestion, nutrient extraction, and protection from gastrointestinal 
pathogens (23–25). Hosts and bacterial communities have evolved to co-exist in a state of 
symbiosis. Thus, mechanisms are in place to prevent the uncontrolled outgrowth of commensal 
bacteria, without eradicating them from the host. The mucus and epithelial layers provide a 
passive layer of protection, serving as a barrier that protects the microbiota and host by largely 
sequestering bacteria from the host immune system.  However, the immune response also plays 
an active role in regulating commensal bacteria by adopting effector or Treg fates when 
encountering bacteria antigens (25, 26). 
 Numerous human and mouse species of bacteria stimulate T cell responses and direct 
either effector or tolerogenic cell fates. Notably, segmented filamentous bacteria (SFB), which 
adhere to intestinal epithelial cells, elevate the number of Th17 cells in the small intestine (27–
29). Th17 responses exacerbate inflammation and tissue damage by recruiting neutrophils and 
activating epithelial cells (30). SFB antigen is directly presented to T cells and is able to 
specifically instruct Th17 development due to the environment in which it is presented (31). 
Interestingly, bacteria prevalent in oral bacterial communities can induce robust Th1 responses in 
the gut (32). Antibiotic resistant strains of Klebsiella pneumoniae trigger Th1 proliferation in the 
gut of germ-free (GF) —a phenotype recapitulated in GF mice colonized with saliva samples 
from human ulcerative colitis patients (32). These saliva samples also contained strains of 
Klebsiella, supporting the plausibility that oral bacteria that colonizes the gut, which likely lacks 
tolerogenic mechanisms required for their control, may promote disease through Th1 generation 
(32).  
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 Clusters IV and XIVa of Clostridium species on the other hand, are sequestered from the 
epithelial layer and induce Treg responses in the large intestine (13, 14). The Treg cells induced 
are primarily Helios
-
(Ikzf2), a transcription factor that marks Treg cells that are thymically 
derived, produce anti-inflammatory IL-10, and are sufficient to reduce the severity of TNBS-
mediated colitis (13). However, whether the pTreg cell enrichment is the result of antigen-
specific processes, or the non-specific expansion of pre-existing Treg cells present in the colon, 
remains a point of debate.  Treg TCRs isolated from the tTreg cell population are reactive to 
antigen from numerous Clostridium species in vitro (33), but studies from our laboratory 
identified that the CT6 TCR, which reacts to Clostridium antigen, can instruct naïve CD4
+
 T 
cells to differentiate into pTreg cells. The tTreg TCRs have never been verified to react to 
Clostridium in vivo, and the CT6 TCR has since been found to react more potently to 
Helicobacter antigens in vivo (18). pTreg and tTreg cells both contribute towards intestinal 
tolerance, evidenced by the  delayed inflammation in CNS1
-/-
 mice (12). However, whether 
Clostridium is predominantly inducing the expansion of pre-existing pTreg cells or generation of 
new pTreg cells specific to Clostridium antigen remains a point of debate. 
 Interestingly, commensals that can act as pathobionts also induce Treg responses (18, 
34).  Treg cells generated by Helicobacter hepaticus antigen more effectively suppress colitis 
driven by effector T cells specific to Helicobacter hepaticus antigen in lymphodeficient mice 
than Treg cells not specific to Helicobacter hepaticus (34). Our laboratory further found that two 
TCRs which instruct naïve CD4
+ 
T cells to differentiate into pTreg cells (35–37) react to 
Helicobacter antigen in vitro and develop in mice colonized with Helicobacter spp. (18). Naïve 
CT2 and CT6 TCRs Tg cells, which recognize Helicobacter typhlonius and Helicobacter 
apodemus, respectively, differentiate predominantly into Treg cells in the lymph node that drains 
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the cecum (dMLN)–the primary site of Helicobacter colonization. However, both species of 
Helicobacter exacerbate intestinal disease despite their robust induction of IL-10 producing Treg 
cells. This contrasts starkly with the protection conferred by Clostridium colonization. A 
prevalent school of thought with regards to the function of commensal-specific Treg cells, is that 
Treg induction balances Th17-mediated inflammation caused by commensals or pathogens (29, 
38). A second proposal is that Treg cells  promote colonization of certain species given that Treg 
depleted mice and CNS1
-/-
 mice have microbiota distinct from healthy counterparts (22, 39).  
Although it is possible that Helicobacter induces a greater number of effector T cells than pTreg 
cells to drive disease, the insufficiency of Treg induction by Helicobacter to protect hosts from 
intestinal disease highlights that the functional significance of Treg cells specific to commensal 
bacteria has not been rigorously studied. 
 Although the functional significance of bacteria-specific pTreg cell responses remains a 
future area of study, the body of literature demonstrates that intestinal bacteria play an active role 
in shaping mucosal adaptive immune responses. These processes occur in homeostatic contexts, 
supporting that the bi-directional dynamic of immune-commensal interactions promotes a 
balanced environment suitable for both the promotion and restraint of commensal bacteria.  
 
TCR T cell repertoires 
 T cell receptor repertoires need to acquire a level of diversity that maximizes the 
probability that immune responses will be launched against foreign antigens and tolerance 
enforced against self-antigens. Mechanisms that ensure this diversity include somatic 
rearrangements of the V, D, and J chains via VDJ recombination, non-germline encoded coded 
point mutations at the juncture of these gene segments, and combinatorial pairing of TCR alpha 
6 
 
and beta chains. In mice, 2x10
15
 different TCRs are generated during T cell development in the 
thymus, a number reduced to approximately 2x10
6
 TCRs based on in silico estimation (40) after 
thymic negative selection and death by neglect in the periphery. 
 The development of appropriate TCR repertoires is critical for effective immune 
responses against pathogens and tolerance. Mice with  restricted repertoires due to the insertion 
of a TCR-β transgene (4x105 TCRs) are less able to reject bone marrow transplants, or clear viral 
infections (40).  Presumably, fewer T cells recognize diverse epitopes presented by pathogens, 
which have adapted to escape immune responses by producing highly various epitopes and/or 
mutations. Interestingly, mice with limited TCR diversities, including TCRβ  TCRα-/-  and TCR 
Tg mice develop spontaneous colitis, suggesting that Treg populations in these mice are not 
sufficient to restrain what are likely, limited effector responses  (41–44). Spontaneous colitis 
caused by limited TCR diversity enriches for Th2 cytokines (42, 44). This observation is 
abrogated in TCRβ  TCRα-/- mice in germ-free conditions, suggesting that limited Treg diversity 
leads to Th2 responses against commensal bacteria (42).  
Disruptions of TCR repertoire diversity or composition alter the antigen specificities of 
Treg cell populations, and potentially its function. Treg cells have been shown to be more 
effective at suppressing effector T cells when they are antigen specific in the context of colitis, 
and autoimmune disease like diabetes (34, 45, 46).  The relevance of these studies to tolerance 
against commensals is unclear.  However, the intestinal Treg cell population has characteristics 
that implicate the importance of antigen specificity in its maintenance of gut homeostasis. Treg 
TCR repertoires are more diverse than effector T cells, and are relatively similar between mice to 
mice  (35, 37). In contrast, effector TCR repertoires are less diverse, with Th17 cells exhibiting 
the least diversity. Effector TCR repertoires also show more variation from mouse to mouse, 
7 
 
suggesting that effector TCR repertoires in the periphery are selected through a process that is 
stochastic relative to the selection of the intestinal Treg TCR repertoires. Thus, the maintenance 
of Treg cell populations in the intestine during homeostasis may be highly shaped by a conserved 
pool of homeostatically accessible antigens, whereas effector TCR repertoires are relatively 
shaped by stochasticity. Disruptions in the homeostatic processes that shape Treg TCR 
repertoires are likely to impair peripheral tolerance. 
 
Inflammation and Treg cells 
 Intestinal inflammation elevates inflammatory cytokines, some of which can impair Treg 
cell development. Th1 and Th2 cytokines block FoxP3 induction in vitro through transcriptional 
targets of Tbet and GATA3 (47, 48). IFNγ signaling, which increases Tbet expression and can 
interfere with Smad3-mediated transcription (49, 50), is also sufficient to inhibit FoxP3 
expression (50). However, IFNγ is not necessary for Tbet blockade, given that IL-12 treatment of 
IFNγ -/-  T cells continues to block FoxP3 expression in vitro (47).Furthermore, IL-6 addition to 
Tgfβ in cultures induces Th17 differentiation programs by amplifying IL-21, IL-23, and 
subsequently, Rorγt (51). Cumulatively, effector cytokines can overwhelm Tgfβ signals, block 
Treg differentiation programs, and divert cells to effector fates. 
The impact of inflammation on Treg cells at a population level has resulted in different, 
although not necessarily conflicting, results. One study, generating a FoxP3 lineage-tracing 
FoxP3-GFP-Cre x Rosa26-YFP transgenic mouse found that a significant population of cells that 
once expressed FoxP3, lose their FoxP3 expression and became effector T cells in the context of 
EAE, a mouse model for multiple sclerosis (52, 53). Alternative studies have reported that Treg 
cells are long-lasting and stable. Instead of becoming destabilized, Treg cells process 
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inflammatory signals and undergo transcriptional changes that enhance their tolerogenic function 
(54, 55). Another study has argued that priming naïve CD4
+ 
T cells with type 1 interferon signals 
can enhance Treg numbers, with increased Treg number correlating with delayed tumor rejection 
(56). It is important to note that these studies evaluate Treg cells at a population level, and do not 
characterize Treg cells at the resolution of an individual T cell clone.  
It is possible that Treg stability at a population level depends on the model being 
evaluated, given that the signals that drive pathology in different tissues and organs vary 
significantly.  Furthermore, seeming contradictions may also be related to the different ratios of 
pTreg cells, which are enriched in tissues at mucosal interfaces relative to lymphoid tissues, to 
tTreg cells (57). Mucosal and non-mucosal tissues contain different proportions of early 
developing vs. mature tTreg cells. pTreg cells in intestinal tissue, but not lymphoid organs, 
increase with age, suggesting that pTreg cells are constitutively being generated against intestinal 
antigen (36). Thus, populations of pTreg cells in the intestine will include a significant 
population of cells at early stages of development, mixed with mature pTreg and tTreg cells. 
Deciphering the impact of inflammation at early and late developmental stages can be 
approached with monoclonal cells by controlling the timepoint at which disease is induced, 
either prior or after Tg cell transfer. Our laboratory has investigated the development of naïve 
CT2 and CT6 Tg cells in the context of strong intestinal insult, induced by a combination of DSS 
and α-IL10R treatment (18). The naïve Tg cells develop into Th17 cells, and not pTreg cells, 
demonstrating that in extreme models of inflammation, pTreg development from naïve cells can 
be blocked (18). However, it was not determined how inflammation affected mature, FoxP3
+
 
populations of monoclonal Tg cells. 
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Inflammatory models 
Infection models 
Citrobacter rodentium is a murine model pathogen used to study host responses to 
enteropathogenic Escherichia coli (58–60). It colonizes along epithelial cells and belongs to a 
class of pathogens that utilize a type III secretion system to penetrate cell membranes and inject 
effector molecules into infected cells  (58, 61). Thus, Citrobacter has served as an effective 
organism for the study of bacterial virulence factors, the pathogenesis of enteropathogenic 
(EPEC) and enterohemorrhagic (EHEC) diseases, and the immunological requirements for its 
clearance (59–61).   
Citrobacter infection stimulates different effector cytokines at early and late timepoints 
after infection. IL-22, IL-6, IL-23, and IL-12 peak early after infection on day 4 (62). However, 
IL-17 cytokines are elevated later on at day 12 post infection  (62).  Innate mechanisms of 
defense are mediated by cytokines like IL-22, which maintains epithelial integrity. IL22
-/- 
 mice 
exhibit exacerbated colitis and increased morbidity in response to Citrobacter infection (59). 
Cytokines, including IL-23, IL-12, and IL-6, produced by innate cells, direct the development of 
adaptive responses. Effector T cells activate innate responses and generate antigen-specific IgG 
and IgM antibodies to clear the pathogen. (63).  However, Th1 cytokines directly produced by 
CD4
+
 T cells specific to Citrobacter antigen are also important for host defenses (60, 63–65) , 
given that deficiencies in CD4
+
 T cell sources of IFNγ led to higher bacteria burden upon 
Citrobacter infection (60).   
Toxoplasma gondii is an intracellular coccidian parasite that infects the gut epithelial 
cells of many different mammalian hosts (66). Failure to control T. gondii infection virtually 
always leads to host death (66). Lymphodeficient mice that lack T cells are extremely susceptible 
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to T. gondii infection, demonstrating that T cell responses are critically important for its control. 
Furthermore, T.gondii specifically induces a strong Th1 response, characterized by high levels of 
IFNγ, TNFα, IL-18, and IL-12, which likely activate macrophages to control intracellular 
parasite replication (66–68).   The sustaining of IFNγ levels during T. gondii infection requires 
IL-12 signaling, given that IL-12 p40 deficient mice experience increased brain cyst burdens 
before eventual morbidity (69).   
 
DSS and DSS and HFD 
The dextran sulfate sodium (DSS) is a chemically induced model for acute and chronic 
colitis. It is a sulfated polysaccharide composed of approximately 17% sulfur, with on average, 3 
sulfur groups per glucose molecule (70, 71).  DSS most potently affects gut epithelial cells by 
compromising the mucus layer and damaging the basal crypts, which results in apoptosis of 
colonic epithelium cells (71, 72). Mice administered DSS in their drinking water between 1-10% 
will develop inflammation of varying severity primarily limited to the colon, accompanied by 
cellular infiltration of mucosa and submucosa with innate immune cells and relatively few 
number of lymphocytes (70).  DSS-mediated colitis is characterized by elevated Th1 and Th2 
responses (73), but does not require these T cell responses for disease, given that Rag
-/-
 mice 
develop disease that is more severe than in lymphoreplete hosts (72). Thus, DSS is widely 
considered to be a suitable model for assessing innate responses in acute and chronic colitis. 
High fat diet (HFD) coupled with DSS exacerbates the severity of intestinal diseases. 
Dietary fats, independently of DSS, can elevate the circulation of inflammatory cytokines like 
IL-6 and TNF-α and accelerate or exacerbate spontaneous colitis and colon tumorigenesis (74–
76). HFD weakens tight junctions, increasing intestinal permeability and susceptibility to barrier 
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breach (77, 78). HFD can additionally enrich the gut microbiota for pathobionts, including 
Helicobacter species and Bilophila wadsworthia, which is sufficient to increase numbers of Th1 
cells in GF conditions.  Microbiota shaped by HFD is sufficient to transmit increased disease 
susceptibility, showing that microbiota changes, independently of stromal damaged caused by 
HFD, is sufficient to increase disease risk (79). Thus, DSS and HFD worsens disease due to a 
combination of factors, that include compromised barrier function, enrichment of pathobionts 
that can further damage the epithelial layers, and elevated effector T cell responses.  
 
FoxP3 and Treg development 
FoxP3 is the hallmark transcription factor required for both tTreg and pTreg 
development. Evidence of a T-cell mediated tolerogenic function first arose with a spontaneous 2 
bp insertion that shortens FoxP3 into a non-functional protein, resulting in the Scurfy mouse 
model (7–9) . Scurfy mice lack CD4+CD25+ cells, have enlarged organs, and undergo premature 
death within 3 weeks of birth (7, 8, 80).  This phenotype parallels that of IPEX patients 
(immune-mediated polyendocrinopathy X-linked syndrome), who have naturally occurring 
mutations in FoxP3, undergo multi-organ failure, and have shortened life expectancies (9). The 
failure of FoxP3
- 
bone marrow cells, transplanted into wild-type hosts, to acquire CD4
+
CD25
+
 
regulatory phenotypes,  provided additional early evidence that FoxP3 is the central 
transcriptional regulator for CD4
+
CD25
+ 
regulatory T cells (1). 
FoxP3 is also necessary for the suppressive function of Treg cells. Ectopic 
overexpression of FoxP3 into human naive CD4
+ 
 T cells is sufficient to confer suppressive 
function and cells with non-functional FoxP3 protein are deficient in their ability to suppress 
effector T cells (1, 3, 81, 82). In the absence of FoxP3, these cells produce inflammatory 
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cytokines and IL-2, which are hallmark characteristics of CD4
+ 
effector T cells (6).  However, 
the level of inflammatory cytokine production remains less than that of effector T cells, 
suggesting that the failure to develop into FoxP3 is not the result of a complete diversion of cells 
to effector cell fates.(83) 
Tgfβ, which exists in 3 isoforoms (TGFB1, TGFB2, TGFB3), is a critical signal for 
FoxP3 induction in CD4
+
 naïve T cells (84). Tgfβ is secreted in a latent form as a complex with 
the latent Tgfβ binding protein (LTBP) and the latency associated peptide (LAP). When Tgfβ 
reaches a cell surface, it is cleaved by proteinases, dimerizes, and activates the Tgfβ receptor and 
subsequently, FoxP3 transcription in CD4
+
 T cells (84, 85).  
An important signaling pathway downstream of Tgfβ is through the Smad family of 
transcription factors. Smad transcription factors can bind to activated Tgfβ receptors, and are 
subsequently phosphorylated by the kinase domains on the cytoplasmic region of the Tgfβ 
receptors (86).  Smad3 and Smad2 dimerize, and then bind to Smad4 for nuclear translocation to 
initiate transcription. Subsequently, they interact with the FoxP3 promoter and the CNS1 
enhancer region to regulate FoxP3 expression (12).  
However, Tgfβ can also signal through Smad independent mechanisms. Including MAP 
kinase (MAPK) pathways, Rho-like GTPase signaling pathways, and phosphatidylinositol-3-
kinase (PI3K)/AKT pathways (84). Notably, Smad3 deletion does not result in loss of FoxP3 
expression in T cells activated with Tgfβ in vitro, nor were Smad proteins critical for Th17 or 
Treg cells in vivo (87, 88). This is in part explained by redundancy in Smad2 and Smad3 
function for FoxP3 induction (89). However, selective targeting of non-Smad pathways, 
including ERK and JNK pathways, resulted in defects in Tgfβ-mediated FoxP3 induction and 
Th17 development despite the presence of Smad3 (90, 91). These studies, however, did not 
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validate that Smad3 was being properly phosphorylated, leaving open the possibility that 
deficiencies in these alternative pathways indirectly affect Smad-mediated FoxP3 expression. 
Nonetheless, evidence is supportive that Smad proteins, although important, may not be required 
for Treg development. 
 
Co-regulators of Tgfβ signaling in Treg cells 
FoxP3 induction by Tgfβ can be amplified by co-factors. Notably, retinoic acid and Ahr 
ligands amplify FoxP3 expression by in vitro cultured CD4
+
 T cells. Retinoic acid induces 
FoxP3 independently of IL-2 and concurrently antagonizes the expansion of contaminating 
effector cells or memory cells in cultures (92–96). Specifically, retinoic acid contributes towards 
the suppression of Th17 differentiation profiles by inhibiting IL-6 and IL-23 receptor 
upregulation (94–96). Additionally, Ahr ligands promote Treg or Th17 differentiation depending 
on the type of ligand, with TCDD promoting Treg development and FICZ promoting Th17 
development (97, 98). This differential outcome may be dependent on the affinity of the ligand 
for Ahr, which can further regulate  retinoic acid receptors (99). However, it should be noted 
endogenously found Ahr ligands are processed from food antigens, whereas the tested Ahr 
ligands are synthetic ligands (97). 
Short chain fatty acids (SCFAs),  produced by certain species of commensal bacteria, 
have emerged as an additional contributor to FoxP3 induction in the intestine (15, 17, 100).  
SCFA’s are sufficient to increase the numbers of FoxP3+ cells in GF mice and in vitro activated 
naïve CD4
+
 T cells (15, 16).  SCFA’s may promote FoxP3 expression by signaling through 
GPR43 to inhibit histone deacetylases (HDACs), which can also increase Treg gene expression 
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and suppressive function (101). Thus, FoxP3 induction is initiated by Tgfβ and can be further 
enhanced by a variety of co-regulators prevalent in the intestine.  
 
Regulation of FoxP3 induction 
In addition to its promoter, FoxP3 expression in tTegs and pTreg cells is regulated by a 
series of conserved, non-coding sequences found downstream of the FoxP3 promoter (12). These 
regions are highly conserved in the FoxP3 locus across different species, hinting at their 
functional importance in regulating FoxP3 transcription, and are bound to permissive H3 
modifications (H3K4me3, H3K9/14Ac) (12). CNS3 promotes FoxP3 expression in tTreg cells, 
potentially through interactions with c-Rel induced by co-stimulatory molecules (12). CNS1, 
downstream of CNS3, contains a Tgfβ-NFAT response elements and  is critical for pTreg cell 
development but dispensable for tTreg cell development (12). CNS2 maintains FoxP3 expression 
in Treg cells that originate from dividing Treg cells, supporting that its molecular partners 
stabilize FoxP3 (12). Deletion of the CNS1 region ablates pTreg cells, but this deficiency is 
compensated for by an increased number of tTreg cells and FoxP3
- 
IL-10 producing cells, known 
as Tr1 regulatory T cells (12). 
The Nr4a family of transcription factors (Nr4a1, Nr4a2, Nr4a3) interacts with the CNS 
regions and FoxP3 promoters to regulate FoxP3 expression in both pTreg cells and tTreg cells 
(102–104). Nr4a1 expression is directly proportional to the strength of TCR signaling, and has 
transcriptional targets that are characteristic of Treg cells, including Ikzf2 (103, 105). Nr4a2 
directly induces FoxP3 transcription by binding to the FoxP3 promoter and incorporating 
permissive histone modifications (102).  All 3 Nr4a proteins can induce FoxP3, with Nr4a2 
induction being the most potent, Nr4a3 inducing intermediate levels, and Nr4a1 having the 
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mildest effect (102). Deficiency in one of the Nr4a proteins does not result in Treg deficiency, 
but deletion of all three has a deleterious effect on Treg cells, and similarly to Scurfy mice, 
results in morbidity in approximately 30 days (104, 106).    
Nr4a response elements were identified in both the FoxP3 promoter and in the CNS 
regions. However, the response elements in the CNS1, but not CNS2 region, most potently 
enhanced FoxP3 promoter activity (102). Binding of Nr4a proteins to the CNS1 region was 
supported with ChIP data, which further verified that Nr4a proteins do not bind to the CNS3 
regions (102). Thus, Nr4a proteins, most effectively Nr4a2, promote FoxP3 expression in both 
tTergs and pTreg cells, but may also enhance pTreg cell induction by incorporating permissive 
histone modifications at H3 regions that interact with the CNS1 enhancer.   
 
Antagonism of effector phenotypes to promote Treg development 
 Treg development is orchestrated by the concurrent induction of FoxP3 and the 
antagonism of alternative fates. Transcriptional regulators not required for the development of 
Th1 and Th2 cells, can antagonize Th1 and Th2 fates and promote Treg cells. Musculin2 (Msc
-/-
), which antagonizes Th2 differentiation, is expressed within 10 hours of Tgfβ signaling via the 
Smad3 signaling pathway in CD4
+
 T cells activated in vitro (107). Musculin2 deficient mice 
exhibit autoimmune pathology, including increased cellular infiltration in tissues, most 
significantly at mucosal interfaces like the small intestine and lungs. This correlates with reduced 
numbers of FoxP3
+
 cells. This is a cell-intrinsic phenomenon, evidenced by reduced efficiency 
of Tgfβ induced FoxP3 expression by musculin2 deficient cells in vitro. Populations of 
musculin2 deficient CD4
+
 T cells more effectively adopt Th2 profiles, with increased numbers 
producing IL-4, IL-5, and IL-13 in vitro and in vivo.  Enhanced Th2 responses at mucosal 
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interfaces in CNS1
-/- 
mice (22), further supports that Th2 and Treg differentiation programs 
antagonize one another. 
 The PHD family of transcription factors, which serve as oxygen sensors in T cells, 
promote Treg responses by antagonizing Th1 profiles (108). Mice with T-cell specific deletions 
of PHD1, PHD2, and PHD3 proteins had increased serum antibodies and spontaneous pathology 
in the lung. Numbers of IFNγ producing CD4+ T cells increased in the lungs and colon lamina 
propia, which correlated with a 2-fold reduction of Nrp1
lo
 FoxP3
+
 cells, a population that is 
predominantly pTreg cells. Enhanced IFNγ production was argued to be cell-intrinsic, given that 
PHD deficient cells show increased Th1 and reduced Treg responses in vitro. An unaddressed 
caveat here however, is that the decreased Treg responses may be the result of enhanced IFNγ 
levels in cell cultures, which can block Treg induction  independently of PHD protein activity. 
 Although transcriptional regulators can antagonize alternative fates at a population level, 
the extent of their physiological relevance at a monoclonal level remains uncertain. Our 
laboratory assessed differentiation by CNS1
-/- 
CT6 Tg cells, which as expected, exhibit 
dramatically reduced FoxP3 expression after 1 week of development in wild-type hosts (36). The 
activated, FoxP3
- cells mildly expressed IFNγ, suggesting that the absence of Treg induction can 
lead to the spontaneous adoption of effector cells despite the absence of effector inducing 
signals. However, the fraction of IFNγ producing cells was insignificant, at only 1-2% (36). In 
contrast, 40-60% of Tg cells become FoxP3
+
 cells 1 week after transfer (36). Thus it remains 
unclear if mechanisms that antagonize effector differentiation are relevant in vivo, or if these 
mechanisms are not activated in the absence of effector cytokines in the environment of 
CT6:pMHC engagement.  
 
17 
 
FoxP3-independent factors in Treg development 
Cells deficient for the FoxP3 protein are still able to adopt Treg signature genes, 
implicating that genes independent of FoxP3 contribute to the transcriptional profiles of mature 
Treg cells (109).  Treg signatures were defined by evaluating the transcriptional profiles of cells 
retrovirally overexpressed with FoxP3, ex vivo isolated Treg cells, as well conventional T 
effector cells. Treg signature genes include factors unique to Treg cells including CTLA4, IL2rb, 
Socs2, and Ikzf2 (109). A significant portion of Treg signature genes are however, activated by 
FoxP3 independent signals, including TCR signaling, co-stimulation, and/or Tgfβ signaling 
(109). A number of genes differentially expressed in response to Tgfβ signaling were blunted in 
CD4
+
 T cells isolated from Scurfy mice, supporting that FoxP3 promotes Treg development in 
part by amplifying gene networks triggered independently of FoxP3 (109). A more recent study 
verified that FoxP3 independent gene targets, which are potentially amplified by FoxP3, are 
sufficient to downregulate effector responses in the context of diabetes (110).  This study 
observed that conditional deletion of Tgf-β receptor II (TβRII) in genetic mouse models for 
diabetes resulted in disease that was more severe than in FoxP3 deficient mice. The implication 
here is that Tgfβ targets, independently of FoxP3, are sufficient to confer a level of tolerance. 
Thus, Foxp3 can likely promote tolerance by amplifying FoxP3 independent targets in 
conjunction with activating and repressing its own target genes (111).  
 
Eomesodermin and CD4
+
 T cells 
Eomesodermin (Eomes) is a member of the Tbx family of transcription factors, which 
serve critical functions in embryogenesis (112, 113). Eomes is regulated by Tgfβ and can interact 
with Smad2/3 targets (114). In addition to their developmental functions, Tbx transcription 
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factors, Eomes and Tbet, serve critical functions in the development and differentiation of 
immune cells. Tbet is the hallmark transcription factor for Th1 differentiation (115), and is also 
expressed in subsets of NK cells (116). Eomes and Tbet share numerous transcriptional targets, 
and serve complementary functions in CD8
+
 T cell development, with their co-expression 
increasing  production of effector molecules like IFNγ, granzyme, and perforin relative to mice 
with single deletions of Tbet or Eomes (117).  
In CD4
+
 T cells, Eomes has emerged to be promiscuously expressed in multiple lineages 
and can both antagonize and promote effector cell functions.  Eomes is suppressed by Tgfβ 
signaling in Smad2
-/-
Smad3
-/-
 mice through the c-Jun N-terminal kinase (JNK)-c-Jun signaling 
pathway, promoting Th17 cell development (91).  Eomes overexpression blocks Th17 
development by potentially recapitulating the effects of strong Tgfβ signaling, which would 
skew cells towards a Treg fate (118, 119). Eomes also regulates effector CD4
+
 T cell responses 
by negatively regulating IL-5 production by memory Th2 cells (120). Eomes is specifically 
expressed in memory Th2 cells, defined by CD62L
lo
CXCR3
lo
 Th2 cells, and prevents GATA3 
from binding to the IL-5 locus (120). 
In addition to antagonize effector phenotypes, Eomes expression actively promotes 
tolerogenic phenotypes. Eomes deficiency increases FoxP3 expression, with Treg cells numbers 
increasing in older mice relative to Eomes sufficient littermate controls (121). Eomes mediated 
enhancement was sufficient to alleviate EAE severity, which authors attribute towards elevated 
Treg numbers in the mice (121). However, a more recent study finds that Tbet and Eomes 
cooperate to induce IL-10 production by FoxP3
-
CD4
+
  Tr1 cells (122).  In this study, Eomes 
deficiency increased the severity of GVHD, which authors attribute to deficiencies in Tr1 cells 
(122). One possibility for these different results is the usage of different conditional knockouts. 
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In the study with alleviated EAE symptoms, Eomes 
fl/fl
 mice (123) were crossed to Lck-Cre
+
 
mice, whereas the study with exacerbated GVHD utilized mice crossed to the CD4 Cre. It is 
additionally possible that enhanced Treg cells are more effective at protecting against Th17 
mediated disease in the context of EAE (124), and Tr1 responses are more critical for 
antagonizing Th1 responses, which are critical for GVHD (125).  
However, Eomes can also amplify effector responses by increasing IFNγ production by 
Th1 cells independently of Tbet (126–128). Eomes deficiency also increases Th1 cell plasticity, 
promoting Th1 destabilization towards IL-6 mediated Th17 differentiation (126). This is 
consistent with the aforementioned study, which reported Eomes suppression promotes Th17 
differentiation. It is possible that this increased Th17 differentiation in response to Eomes 
suppression is through the destabilization of Th1 cells in vivo. Cumulatively, the literature shows 
that Eomes can facilitate both effector and tolerogenic responses, and thus, serves a multi-faceted 
function in CD4
+
 T cell differentiation and development. 
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Chapter 2: The impact of inflammation on colonic 
peripheral Treg cell development 
 
Abstract 
Peripheral regulatory T (pTreg) cell differentiation in response to intestinal commensal 
bacteria is important for gut homeostasis. However, it remains unclear if environmental factors 
that trigger intestinal inflammation, such as dietary fats, physical insults, and enteric infections, 
interrupt this process universally or only under select conditions. In this study, we found that 
pTreg cell differentiation to Helicobacter is generally preserved in multiple models of intestinal 
inflammation or infection. However, colitis caused by DSS coupled with high fat diet (HFD) led 
to a selective blockage of pTreg cell generation of TCR transgenic cells that respond to 
Helicobacter apodemus (CT6), but not Helicobacter typhlonius (CT2). This phenomenon was 
also observed with analysis of polyclonal Treg TCR repertoires, in which distinct subsets of 
TCRs either expand or contract in clonal frequency during DSS and HFD. DSS and HFD 
promoted a marked expansion of Enterobacter species. A possible explanation for these results is 
suggested by the fact that CT6, but not CT2, is weakly cross-reactive to Enterobacter species in 
vitro, which could result in TCR stimulation of CT6 in an environment favoring effector, and not 
pTreg, cell development. Thus, these data show that TCR specificity can determine regulatory vs 
effector T cell fates in the same host, and imply the existence of multiple microenvironments that 
direct distinct T cell differentiation pathways during intestinal inflammation.   
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Introduction 
The gastrointestinal tract is a complex environment that constitutively exposes the host to 
bacteria, food, and self-antigen. FoxP3
+ 
regulatory T (Treg) cells play a critical role in inhibiting 
unwanted immune responses to these intestinal antigens, which can lead to afflictions such as 
inflammatory bowel disease (9, 22, 129, 130). The gut Treg cell population appears to be shaped 
by intestinal antigens, as the colonic Treg TCR repertoire is more conserved from mouse to 
mouse relative to effector T cell TCR repertoires (18, 35). Moreover, TCR transgenic (Tg) 
studies have suggested that antigens from gut commensal bacteria can directly facilitate colonic 
Treg cell selection (18, 21, 36, 37). Thus, intestinal antigens appear to play a critical role in 
inducing Treg cell selection important for maintaining gut homeostasis (13, 14, 21, 28, 131, 
132).   
  Specific species of commensal bacteria shape gut TCR repertoires by selecting for T cell 
clones which adopt either effector or tolerogenic fates (21, 31, 33, 133). Colonization with 
segmented filamentous bacteria (SFB), which induce Th17 responses (27, 28), is sufficient to 
exacerbate colitis, whereas colonization with Clostridium, which induce Treg responses (13, 14, 
21, 33) is sufficient to ameliorate colitis. Although these species also affect the innate immune 
response (29, 134), these data suggests that commensal-driven shaping of the intestinal TCR 
repertoire of effector and Treg populations may contribute to disease susceptibility. 
 Intestinal inflammation has been reported to influence the differentiation of T cells 
selected on bacterial antigen. For example, CBir Tg cells, which react to Clostridium antigen 
upon barrier breach with Toxoplasma gondii infection, differentiate into a long-lasting 
population of Th1 cells (133). In addition, we have found that intestinal inflammation can affect 
the differentiation of T cells from two TCR Tg lines, CT2 and CT6, which react to Helicobacter 
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typhlonius and Helicobacter apodemus, respectively (18). When naïve CT2/6 TCR Tg cells are 
adoptively transferred into hosts colonized with Helicobacter, they rapidly differentiate into 
peripheral Tregs (pTregs) (36). However, the Tg cells aberrantly differentiate into Th17 cells 
instead of Treg cells in mice with blocked IL-10 signaling and DSS mediated mucosal injury 
(18). Together, these data suggest that T cell responses against bacterial antigen can be 
influenced by an inflammatory environment.  
 Early life incidences of intestinal inflammation from environmental sources, including 
infections, physical insults, and dietary fats, have been correlated with increased risk for 
intestinal disorders (135). Although current data suggest that intestinal inflammation can direct 
effector responses against commensal bacteria, it remains unclear whether this is a general 
outcome of all triggers of intestinal inflammation. Here, we investigated the differentiation of 
CT2 and CT6 cells in multiple infectious and non-infectious models of intestinal inflammation. 
Unexpectedly, these studies found that pTreg cell selection is generally preserved in multiple 
models of intestinal inflammation, suggesting an important role for T cell developmental 
microenvironments in protecting immune responses from environmental perturbations.  
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Materials and Methods 
 
Mice 
CT2 (36) and CT6 Tg (21) mice were generated as described (136) and bred to Rag1
–/–
 [the 
Jackson Laboratory (JAX) #002216] and FoxP3
IRES-GFP 
(JAX #006772) or FoxP3
IRES-Thy1.1  
(137), 
IL-17A
IRES-GFP 
(JAX #18472), and IFNIRES-YFP(GREAT) (138). TCli TCRβ Tcra+/– mice (139) 
were bred to FoxP3
IRES-Thy1.1
 IL-17A
IRES-GFP
 and IFNIRES-YFP. CT6 Tg mice were also bred to 
Tbx21
–/– 
(JAX #004648) or Rorc
GFP
 mice (JAX #007572). FoxP3-DTR mice (11) were bred onto 
a CD45.1 background. IFNIRES-YFP mice were a gift from R. Locksley (University of California, 
San Francisco); FoxP3
IRES-Thy1.1 
and FoxP3-DTR mice were gifts from A. Rudensky (Memorial 
Sloan Kettering Cancer Center). FoxP3
IRES-GFP 
CD45.1 (JAX #006772) host mice used for 
adoptive transfer experiments were interbred in our colony to maintain their microbiota. Animal 
experiments were performed in a specific pathogen-free facility in accordance with the 
guidelines of the Institutional Animal Care and Use Committee at Washington University. 
 
Adoptive transfer experiments 
Naive (CD4
+
FoxP3
–
CD25
–
CD44
lo
CD62L
hi
) T cells were FACS purified from the draining 
lymph nodes and spleens from CD45.2 or CD45.1/2 Tg mice bred to FoxP3
IRES-GFP 
Rag1
–/– 
or  
FoxP3
IRES-Thy1.1
 IL-17A
IRES-GFP 
IFN IRES-YFP Rag1–/–. Cells were labeled with Cell-Trace Violet 
(ThermoFisher) to assess proliferation and 10
5
 cells were retro-orbitally injected into 3-4 weeks 
old wild-type CD45.1 FoxP3
IRES-GFP 
hosts unless otherwise indicated. All experiments were 
conducted with littermate controls. For experiments evaluating the impact of CD4 effector 
polarizing cytokines on Tg cells, naïve cells were sorted as described above and plated in α-CD3 
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(Bio X Cell #BE0001-1; 10 µg/ml) coated 24 well tissue culture plates at 1x10
6
 cells/well in 1ml. 
Additives to the culture included soluble α-CD28 (Bio X Cell #BE0015-1; 1 µg/ml), anti-
cytokine antibodies [all Bio X Cell; α–transforming growth factor– (20 g/ml; #BE0057), α-
IFN (5 g/ml; #BE0054), α–IL-4 (5 g/ml; #BE0045), and α–IL-12 (5 g/ml; #BE0052)] 
and/or cytokines [Peprotech; IL12 (10 ng/ml, #210-12), IFNγ (50 ng/ml, #500-M90), IL-4 (10 
ng/ml, #214-14), muTNF-α (50 ng/ml, #310-12)]. After 48 hours in culture, 1x105 cells were 
retro-orbitally injected into 3-4 week old congenic CD45.1 FoxP3
IRES-GFP 
mice. For all transfer 
experiments, the distal mesenteric lymph node (dMLN), which drains the cecum, and/or colon 
lamina propria were harvested at various time points after transfer and Tg cells (CD45.2 or 
CD45.1/2, CD4
+Vα2+) were analyzed on a BD FACSAria IIu (BD Biosciences). 
 
Lamina propria cell isolation 
Colon lamina propria tissue was flushed with PBS to remove fecal content. To remove 
intraepithelial lymphocytes, lamina propria tissue was incubated in RPMI 1640 media containing 
3% FBS, 20 mM HEPES, 1 mM DTT, and 50 mM EDTA for 20 min at 37˚C, and washed with 
RPMI 1640 plus 22.5 mM EDTA. Lymphocytes were isolated from remaining stromal tissue by 
mincing and digesting in 28.3 µg/ml Liberase TL (Roche) and 200 µg/ml RNase 1 (Roche) for 
30 min at 37˚C. Suspended cells were filtered through a 40 m filter prior to use. 
 
Infections and inflammatory models 
For Citrobacter infections, 3-4 week old congenic CD45.1 FoxP3
IRES-GFP 
mice were infected 
with 2x10
9
 CFU C. rodentium or OVA-C. rodentium (60) via oral gavage. For Toxoplasma 
gondii infections, 3-4 week old congenic CD45.1 FoxP3
IRES-GFP 
mice were orally gavaged with 1 
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tissue cyst per mouse. Tissue cysts were obtained from the brain of mice harboring chronic 
infection with of the type II ME49 strain. For DSS and high fat diet (HFD), mice were 
maintained on HFD from Harlan-Tekland (TD.88137) (140). Mice fed HFD were either 
maintained on water or switched onto 2% DSS water on day 7. 
 
TCR sequencing  
Naïve (CD44
lo
CD62L
hi
), CD44
hi
 (FoxP3
–
CD44
hi
), CXCR3
+
 (FoxP3
–
CD44
hi
IL17A
–
CXCR3
+
) 
and IL-17
+
 (FoxP3
–
CD44
hi
IL-17A
+
CXCR3
–
) cells were sorted from the MLN of wild type, HFD 
treated, or DSS and HFD treated TCli TCR FoxP3IRES-Thy1.1 IL-17AIRES-GFP IFNIRES-YFP Tcra+/− 
mice using BD FACSAria IIu. TCR amplicons were sequenced as described (18), and unique 
TCRα sequences identified via unique TRAV and CDR3 sequences. TCR sequences were 
rarefied to 10,000 reads to normalize for experimental variation and analysis of reproducible 
TCRs limited to TRAV_CDR3 species found in 50% or more of mice per condition. Primer bias 
was corrected by multiplying TCR frequencies with a correction factor as described (18). 
 
T cell hybridoma stimulation assay 
NFAT-GFP T cell hybridomas cells (141) transduced with CT6 or CT2 TCR (21) chains. 
1.5x10
4
 cells were cultured with in vivo flt3 ligand-expanded CD11c
+ 
DCs (5x10
4
) in 96 well flat 
bottom tissue culture plates. 20 µg of antigens generated by autoclaving bacteria isolates were 
added. TCR stimulation by CD4
+ 
V6+ cells was assessed by GFP expression after 72 hours in 
culture. 
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16S rRNA sequencing 
Colon and cecum were cut longitudinally with sterile scissors and fecal content from lumen was 
harvested with sterile forceps. To harvest mucosal-associated bacteria, lumen content was 
washed 3x with sterile PBS from colon and cecum tissues. Mucosal-associated bacteria was 
obtained by washing the tissue vigorously 2x for 20 minutes with PBS + DTT (1 M/ml) 
+EDTA (5 M/ml) at 37°C, filtering through 40 m filter, and removing epithelial cells via 
centrifugation at 1500 rpm for 10 minutes. The supernatant, which includes bacteria in 
suspension, was harvested and pelleted at 2500 rpm for 15 minutes. Pellets were washed with 
PBS and resuspended in 30% glycerol for storage. Bacteria DNA was isolated from mucosal-
associated and luminal bacteria using the ISOLATE Fecal DNA Kit (Bioline). The V4 region of 
16S rRNA gene was PCR-amplified and sequenced on the Illumina MiSeq Platform (2x250–bp 
paired-end reads). Operational taxonomic units (OTU) picking was performed as described (18, 
36).  
 
Statistical analysis 
GraphPad Prism v6 was used for statistical and graphical analysis. Statistical significance was 
calculated using the Student T test, *P<0.05, ** P<0.005, ***P≤0.001, **** P ≤0.0001; ns = 
not significant. Error bars = ± SEM. PCoA analysis of 16S sequencing data was done using 
Bray-curtis distance using Phyloseq (BioConductor).  Hierarchical clustering of TCR sequences 
was conducted using Euclidean distance with R.   
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Results  
 
Peripheral induction of FoxP3 by Helicobacter-reactive T cells is not markedly impaired by 
gastrointestinal infections. 
Intestinal infections facilitate the development of effector T cells reactive to commensal 
bacteria that are presented to the immune system for the first time after mucosal injury (133).  
However, the effect of infection on the development of pTreg cells that react to commensal 
antigens constitutively presented during homeostasis, such as Helicobacter (21, 36), remains 
unknown. We hypothesized, based on the aforementioned study (133), that infection would favor 
effector differentiation of T cells that would normally become pTreg cells, which would allow us 
to study the physiologic signals that determine effector vs pTreg cell differentiation in the gut.    
We tested this by studying the development of adoptively transferred naïve CT2/6 TCR 
Tg cells in hosts infected with Citrobacter rodentium, a murine model for human infection with 
enteropathogenic E. coli, or Toxoplasma gondii, a parasite that infects the gut and induces a 
strong Th1 response (61). Contrary to our hypothesis, we saw no reduction in the frequencies of 
FoxP3
+ 
cells of TCR Tg cells. FoxP3 frequencies were not decreased in Tg cells transferred at 
early stages of Citrobacter infection (day 4) and increased in FoxP3
+
 CT2 cells transferred at 
peak infection (day 9) (Fig. 2.1A, 2.1B) (60, 62).  Similarly, in Toxoplasma infected hosts, CT2 
cells showed a modest decrease in pTreg cell generation, whereas CT6 cells increased (Fig. 
2.1A). We confirmed that Citrobacter infection elicited effector cell responses by showing that 
OTII cells became FoxP3
–
CD25
+
 in response to OVA-expressing Citrobacter (60) (Fig 2.1B), 
whereas CT6 cells co-transferred into the same mouse underwent pTreg cell generation. Thus, 
this data demonstrates that Citrobacter elicits effector T cell responses without generating a 
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global environment that impairs pTreg cell generation to commensal antigens.   
We did observe some changes in TCR Tg responses during Citrobacter infection, 
including decreased cell numbers, lower CD25 level in FoxP3
+
 Treg cells, and decreased T cell 
proliferation based on Cell Trace Violet dilution (Fig. 2.1C-F; 2.8C, 2.8D). Like Citrobacter 
infection, Tg cell numbers decreased in Toxoplasma infected mice (Fig. 2.8A). One 
interpretation is that there is a relative decrease in the presentation of Helicobacter antigens 
during Citrobacter and Toxoplasma infection, but the proportion of cells that become FoxP3
+
 in 
response to Helicobacter is not altered. Thus, although Toxoplasma infection has been reported 
to drive T cells selected on commensal antigen towards effector lineages (133), our data shows 
that the intestinal environment during infections can still be permissive to pTreg cell selection by 
commensal antigen. 
We next verified that Helicobacter-reactive T cells can respond to inflammatory 
cytokines by stimulating naïve CT2/6 TCR Tg cells in vitro in the presence of Th1 and Th2 
polarizing cytokines. Cytokine-exposed Tg cells were transferred into wild-type hosts where the 
cells encounter in vivo pTreg differentiation signals. Exposure to Th1 or Th2-promoting 
cytokines in vitro inhibited pTreg cell differentiation in vivo, with Th1 conditions being more 
stable in their blockade (Fig. 2.1G; Fig 2.8E). As the infection models are not known to induce 
Th2 responses (59, 142), we assessed individual Th1-promoting cytokines and found that IFNγ is 
a primary factor that blocks in vivo pTreg cell selection (Fig. 2.1G; Fig 2.8F). We further 
validated that polarized CT6 cells can adopt a Th1 phenotype based on IFNγIRES-YFP (GREAT) 
(138) expression (Fig. 2.1H). Thus, these data suggest that pTreg cell generation to Helicobacter 
during infection is not due to the inability of Tg cells to differentiate into and maintain effector 
cell phenotypes.  
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Selective effect of high-fat diet and DSS on CT6, but not CT2, pTreg cell differentiation. 
 We next examined if non-infectious models of intestinal inflammation affect pTreg cell 
differentiation. Given that Th1 signals can block FoxP3 induction in naïve T cells, we focused on 
models that favor a Th1 environment, characterized by cytokines such as IL-12 and IFNγ (47, 
143, 144). As acute Treg cell depletion has been reported to increase the numbers and 
frequencies of IFNγ producing cells (11, 145), we treated FoxP3-DTR mice with 1 dose of DT 
followed by adoptive transfer of naïve CT2 TCR Tg cells 24 hours later. TCR Tg cells exhibited 
a moderate decrease in FoxP3 frequency, and showed a marked increase in the expression of the 
Tbet regulated gene, CXCR3 (146, 147), in both the FoxP3
+
 and FoxP3
–
 fractions of Tg cells 
(Fig 2.9A). Thus, acute Treg cell depletion induces an environment in the gut that is antagonistic 
to normal pTreg cell selection.   
 Another model associated with enhanced colonic Th1 responses is DSS in the context of 
high fat diet (HFD) (11, 140). As we previously reported (18), DSS by itself is not sufficient to 
inhibit Treg cell development of CT2/CT6 cells (Fig. 2.2A). However, CT6 Tg cells transferred 
into 2% DSS treated hosts proliferated more relative to Tg cells in untreated controls, indicating 
that the inflammatory environment does not block pTreg cell development by Helicobacter-
reactive T cells despite potential changes in cytokine levels or antigen presentation (Fig. 2.2B). 
To assess the effect of diet, we added HFD for only 1 week prior to DSS to limit secondary 
effects such as changes in food intake or obesity that occurs around 3 and 19 weeks, respectively 
(148). Notably, DSS and HFD inhibited FoxP3 upregulation by naïve CT6, but not CT2 cells 
(Fig. 2.2C).  In addition, FoxP3
+
 CT2, but not CT6, cells showed increased CD25 expression 
30 
 
with DSS and HFD (Fig. 2.2D). Thus, DSS colitis in the context of HFD can selectively impair 
antigen-specific pTreg cell differentiation to commensal bacteria. 
Loss of antigen presentation is unlikely to explain the defect in pTreg cell generation by 
CT6 cells because we observed robust cell division and expansion in both FoxP3
–
 and FoxP3
+
 
fractions (Fig. 2.2D, Fig 2.9B). Another possibility is that transferred CT2 or CT6 cells are 
affecting the global inflammatory response to DSS and HFD in different ways. To exclude this 
possibility, the aforementioned DSS and HFD experiments were performed using co-transfer of 
both CT2 and CT6 naive cells into the same mouse. This also rules out the possibility that the 
defect seen with CT6 is due to mouse to mouse variation in DSS water consumption or global 
inflammatory state. Together with the infection results, these data demonstrate that in a 
population of CD4
+
 T cells, effector and pTreg cells can concurrently develop during colonic 
inflammation. This suggests that the phenotypic outcome of T cell selection against intestinal 
antigen during DSS and HFD is dictated by whether the T cell is encountering its antigen in a 
Treg or effector-selecting microenvironment.  
 
Effector cell phenotypes of CT6 cells in DSS and HFD 
 Given our findings that CT2/6 Tg cells can differentiate into effector cells under 
conditions such as Treg cell depletion (Fig 2.9A), DSS + α-IL-10R, and lymphopenia (18, 21), 
we asked whether CT6 FoxP3
– 
cells were differentiating into Th1 or Th17 cells during DSS and 
HFD treatment. We addressed this by using the IFNγIRES-YFP (138) and IL-17AIRES-GFP reporters 
and found that ~4% of FoxP3
–
 CT6 cells were IL-17A
IRES-GFP+
 in the dMLN, increasing to 15% 
in the colon lamina propria (Fig. 2.3A). Since the Tg cells are first activated in the dMLN (36), 
this is consistent with the notion that Th17 development is a multi-step process involving signals 
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from both the lymph node and intestinal tissues. Unexpectedly, FoxP3
–
 IL-17A
–
 CT6 cells did 
not adopt Th1 properties, with no expression of IFNγ by reporter (Fig. 2.9C), even though there 
was a trend towards increased Th1 frequencies in the polyclonal colonic T cell population in 
DSS and HFD treated mice (Fig 2.9D). Moreover, Tbet deficiency in CT6 cells did not abrogate 
the effect of DSS and HFD on FoxP3 expression, suggesting that the inhibition of FoxP3 
induction was not due to Th1 differentiation (Fig. 2.3B). FoxP3
–
IL-17A
– 
cells were highly 
proliferative and upregulated CD44 (Fig. 2.3C, 2.3D), indicating that they were antigen 
experienced. In addition, Rorc-deficiency led to a modest increase in CT6 conversion, but largely 
did not rescue the defect in FoxP3-induction (Fig. 2.3E). Thus, this result, in addition to the lack 
of FoxP3 rescue by Tbet-deficiency (Fig. 2.3B), suggests that canonical Th1 or Th17 
differentiation is not solely responsible for the inhibition of FoxP3 induction.  
 
Population stability of pre-existing FoxP3
+
 and FoxP3
– 
TCR Tg cells during inflammation.  
 Given the lack of evidence supporting blockade of naïve CT6 development by canonical 
effector differentiation, we considered whether the Treg cell subset (52, 149) of CT6 cells can be 
maintained during DSS and HFD. To investigate the impact of DSS and HFD on antigen 
experienced FoxP3
+
 CT6 cells, naïve CT2/6 transgenic cells were co-transferred into wild-type 
hosts at weaning and allowed to develop normally over 2 weeks. At this timepoint, they are 
comprised mostly of FoxP3
+
 cells (36). In contrast to our observations of naïve TCR Tg cells, 
exposure of antigen experienced cells to DSS and HFD did not affect the proportion of FoxP3
+
 
CT2 or CT6 cells (Fig. 2.4A, 2.4B). We then tested the DSS and αIL-10R model of colitis, 
which impairs pTreg cell selection of both CT2 and CT6 naïve T cells (18). As with DSS and 
HFD treatment, Tg cells did not exhibit a decrease in FoxP3 frequencies relative to controls (Fig. 
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2.4C). Thus, in two models of intestinal inflammation known to impair naïve CT2 or CT6 
development, Tg Treg cells maintained a stable population of FoxP3
+
 cells, implying that the 
effects of inflammation are on T cell selection at the time of initial T cell activation.  
 
Properties of polyclonal Treg TCR selection in DSS and HFD conditions. 
Although we observed a marked reduction in the efficiency of CT6 Treg differentiation 
during DSS and HFD, the frequency of polyclonal Treg cells in the colon undergo a moderate 
increase relative to wild-type controls (Fig 2.9D), which could reflect expansion of existing Tg 
Treg cells (Fig. 2.4A). Together with the CT2 TCR Tg data, the polyclonal data are consistent 
with the notion that DSS and HFD treatment does not globally block Treg generation. Thus, we 
asked whether the different behavior of CT6 and CT2 are reflective of DSS and HFD induced 
changes in polyclonal Treg cell selection, which could represent alterations in development, 
expansion, and survival.   
To better understand how T cell selection is affected by DSS and HFD, we analyzed the 
TCR repertoires in control, HFD, and DSS and HFD conditions. As before (18, 35), we utilized a 
fixed TCRβ model to overcome the limitations of TCR diversity and alpha-beta pairing inherent 
to analyzing the fully polyclonal TCR repertoire, with the caveat that the polyclonal repertoire in 
this model has reduced diversity. TCli-β TCR Tg mice were weaned onto HFD and administered 
DSS as described above. T cells from the mesenteric LN were sorted into FoxP3
+
and FoxP3
–
 
(naïve: CD44
lo
CD62L
hi
; CD44
hi
: FoxP3
–
CD44
hi
; CXCR3
+
: FoxP3
–
CD44
hi
IL17A
IRES-GFP–
CXCR3
+
; IL-17
+
: FoxP3
–
CD44
hi
IL-17
IRES-GFP+
CXCR3
–
) subpopulations. We analyzed “intra-
population” similarities, i.e. between mice of the same T cell subset and experimental condition, 
using the Morisita-Horn similarity index (1 = completely similar, 0 = completely dissimilar). 
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Consistent with prior reports (18, 35), Treg TCR repertoires were more similar than effector 
TCR repertoires when analyzed between control mice (Fig. 2.5A, 2.5B).  
Interestingly, the intra-population similarity in DSS and HFD mice exhibited a decrease 
for Treg, but not FoxP3
–
, TCR repertoires, relative to control mice (Fig. 2.5A, 2.5B). One 
possibility for the increased mouse-to-mouse variability in the Treg TCR repertoire is that DSS 
and HFD treatment stochastically induces the appearance of TCRs in only a fraction of the mice, 
i.e. private TCRs. Consistent with this hypothesis, we observed a 50% reduction in the number 
of TCR sequences that could be reproducibly found, arbitrarily defined as ≥50% of mice, in DSS 
and HFD vs control Treg TCR repertoires (Fig. 2.5C), without a decrease in the total number of 
detected TCR sequences or alpha diversity (Fig. 2.5C; Fig. 2.10A). Furthermore, we found that 
over a quarter of reproducibly detected control Treg TCRs were undetectable in DSS and HFD 
conditions (Fig. 2.5D), suggesting that Treg cell selection to those homeostatic antigens are 
reduced. Collectively, this data verifies that the Treg cell population is not globally affected by 
DSS and HFD treatment, but does stochastically result in the loss and gain of TCR specificities 
in the Treg cell population.     
 We further characterized the reproducibly detected Treg TCRs in control and DSS and 
HFD conditions. Notably, 14% of reproducibly found Treg TCRs in control mice behaved like 
CT2 (Fig. 2.5E), with Treg clonal frequencies that were maintained or expanded in DSS and 
HFD. ~5% of control Treg TCRs behaved like CT6, which showed reduced Treg and increased 
CD44
hi
 clonal frequencies with DSS and HFD (Fig. 2.5E). CT2-like TCRs and the cluster of 
new Treg TCRs found in DSS and HFD conditions were enriched in the TRAV12 subset (Fig. 
2.5E; Fig. 2.10D, 2.10E). CT6-like TCRs and the control Treg TCRs lost in DSS and HFD were 
preferentially TRAV6 (Fig. 2.5E; Fig 2.10D, 2.10E). Thus, these data support the notion that 
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different subsets of TCRs are subject to unique selective or developmental microenvironments, 
which are represented in part by CT2 and CT6.   
 
Treg and FoxP3
– 
TCR repertoires remain distinct during DSS and HFD. 
 Given that HFD worsens the severity of intestinal disease (140, 150, 151), and that a 
subset of TCRs are like CT6, which are Treg under homeostasis but become effector with DSS 
and HFD, we asked whether effector cells utilize the same TCRs as Treg cells during colitis.  In 
contrast with our prior study (18), Morisita-Horn analysis did not reveal increased similarity 
between Treg and FoxP3
–
 populations in DSS and HFD conditions (Fig. 2.5F). This was 
supported by principal components analysis, which further showed that Treg TCR repertoires 
were most distinct from CXCR3
+
 and Th17
+
 TCR repertoires, and distinct, but more closely 
related to CD44
hi
 cells (Fig. 2.10F). Additionally, DSS and HFD treatment did not increase the 
proportion of TCRs that overlap in Treg and FoxP3
–
 TCR repertoires (Fig. 2.5G; Fig 2.10G, 
2.10H). Cumulatively, the data supports our monoclonal observations: DSS and HFD treatment 
alters Treg TCR selection without abrogating the distinction in TCR usage between pTreg and 
effector T cells. However, as noted above, DSS and HFD treatment does induce a subset of 
TCRs that are Treg during homeostasis to adopt a CD44
hi
 phenotype. In conjunction with the 
TCR Tg data, these TCR repertoire analyses suggest that blending of the Treg and effector TCR 
repertoire is not a general feature of DSS and HFD colitis.  
 
Increased bacterial frequency does not explain lack of pTreg cell selection by CT6. 
We next hypothesized that alterations in Treg TCR repertoire with DSS and HFD are 
driven by changes in the microbiota, and therefore performed 16S rRNA profiling of the mucosal 
35 
 
and luminal bacteria as before (18). We first focused on Helicobacter spp. to determine whether 
an increase in frequency might predict the loss of pTreg cell selection in CT6 but not CT2 with 
DSS and HFD, based on previous studies showing that increased antigen presentation could limit 
the frequency of Foxp3
+
 cells generated from naïve TCR Tg cells at a non-mucosal site (152). 
Contrary to this hypothesis, the bacteria recognized by CT6, H. apodemus, actually decreased in 
frequency with DSS and HFD, whereas the H. typhlonius recognized by CT2 increased (Fig. 
2.6A). We then asked whether there were changes in the biogeography of these two Helicobacter 
spp. The frequency of these Helicobacter spp. in the cecum vs distal 1/3 of the colon were 
similarly affected by DSS and HFD, although  H. apodemus appeared to preferentially shift 
towards becoming more abundant distally (Fig. 2.6B). Whether this is relevant for pTreg cell 
selection is uncertain, as the dMLN still remains the primary site of CT6 (Fig. 2.6C) 
accumulation as previously reported (36). While we cannot exclude other changes with DSS and 
HFD that can affect the expression of the TCR Tg epitopes or their acquisition and presentation 
by antigen presenting cells, these data suggest that changes in Helicobacter abundance do not 
provide a ready explanation for the differential pTreg cell development of CT2 and CT6 with 
DSS and HFD.
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HFD induces Enterobacter expansion during DSS-mediated colitis. 
One hypothesis for the expansion of CT6 cells in the cecum draining lymph node despite 
reduction in H.apodemus abundance is that the TCR is being stimulated by non-Helicobacter 
antigens. Analysis of the mucosal and luminal 16S rRNA profiles revealed that DSS and HFD 
induced marked changes in both the mucosal-associated and luminal bacterial communities (Fig. 
2.7A; Fig. 2.11A). Contrary to published reports, we did not observe a significant decrease in 
Clostridium species in DSS and HFD relative to control mice (Fig. 2.11B) (140). Rather, we 
observed a dramatic bloom of Enterobacter species in the mucosal-associated and luminal 
bacteria of DSS and HFD treated mice (Fig. 2.7B, 2.7C). The 16S sequences were confirmed by 
culture of the mucosal-associated bacteria (~1.8 x 10
4
 CFUs/ml) (Fig. 2.7D). Thus, the loss of H. 
apodemus with DSS and HFD colitis is associated with a strong expansion of Enterobacter spp. 
Interestingly, the bloom of Enterobacter was not nearly as marked with DSS alone, 
although we did observe some increase (Fig. 2.7D, 2.7E) consistent with previous studies (153). 
In addition, we did not observe Enterobacter in mucosal-associated bacteria from Treg cell 
depleted hosts by 16S rRNA sequencing (Fig 2.11C).  The magnitude of Enterobacter expansion 
is therefore driven by the combination of DSS and HFD and not by inflammation alone. Notably, 
DSS and HFD colitis also leads to a blurring of the mucosa-associated and luminal community 
(Fig. 2.7A), and suggests that the Enterobacter bloom may have direct access to adaptive 
immune cells during DSS and HFD colitis. 
 Our prior studies found that CT6 is weakly cross-reactive to Clostridium (21). Since the 
abundance of Clostridium species was not increased, we tested the reactivity of CT6 TCR 
expressed on NFAT-GFP hybridoma cells to Enterobacter species presented by dendritic cells in 
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vitro (141) (Fig. 2.7F). CT6, in contrast with CT2, showed cross-reactivity to E. coli. Thus, these 
data raise the possibility that a subset of commensal-reactive TCRs such as CT6 encounters 
dysbiotic microbes such as Enterobacter during DSS and HFD in a microenvironment that is not 
conducive for Foxp3 induction.   
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Discussion 
In this study, we found that pTreg cell development to commensal bacterial antigens was 
remarkably preserved in the context of multiple models of intestinal inflammation, including 
infections and experimental colitis. However, in one colitis model using DSS and HFD, we 
found that development of pTreg cells was selectively lost with CT6, but not CT2, TCR Tg cells. 
Our analysis of polyclonal T cell repertoires supported these monoclonal findings, revealing that 
the Treg and FoxP3
–
 TCR repertoires did not become overall more similar upon DSS and HFD 
treatment. Thus, these data predict the existence of microenvironments that preserve pTreg cell 
development to homeostatic commensal antigens even in the face of infection or other intestinal 
inflammation.  
Our monoclonal TCR Tg data are consistent with previous reports showing that Th17 
differentiation against antigen from SFB is highly preserved in Th1 skewing environments 
caused by Listeria infections (31). One common feature is that both SFB and Helicobacter 
derived antigens induce T cell responses during homeostasis in the absence of disease (18, 31, 
36). In contrast, Clostridium flagellin antigen is presented in adults only upon mucosal injury 
(133).  In this prior study, infection with Toxoplasma led to activation of Th1 effector cells that 
responded to commensal-specific flagellin epitopes, although such responses are normally not 
present in the absence of infection. In contrast, we observed that Treg cells that recognize 
Helicobacter antigens remain intact, and T effector cells that recognize Helicobacter do not 
emerge following Toxoplasma infection. Therefore, it is possible that the resilience of T cell 
differentiation in the context of environmental inflammation is dependent on the homeostatic 
accessibility of the antigen. We speculate that homeostatic vs “inflammation-associated” 
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antigens may be delivered and presented to the immune system through distinct mechanisms, 
leading to different microenvironments that facilitate pTreg vs effector cell development.  
 However, DSS and HFD did lead to a loss of pTreg cell development of CT6, but not 
CT2, cells, both of which react to homeostatic commensal antigen. As this occurred within the 
same animal, this finding demonstrates that TCR specificity, and therefore, properties associated 
with the antigen or the mechanism of antigen uptake, can determine the outcome of T cell 
development in inflammatory environments. The differential effect of CT2 and CT6 was 
mirrored in the polyclonal population, which had clusters of TCRs that were both lost and 
expanded during DSS and HFD. Although the specific mechanisms behind Treg induction by 
intestinal bacteria remain elusive, we believe that T cell differentiation is dictated by the 
environment in which the antigen is being presented, and not intrinsic to the antigen or TCR. The 
lack of FoxP3-induction of CT6 cells is unlikely due to antigen loss, as CT6 cells proliferate 
more during DSS and HFD. One hypothesis is that CT6, which has previously shown weak 
reactivity to a Clostridium spp. (21), may react with non-Helicobacter derived antigens in 
different microenvironments. In support of this hypothesis, CT6, but not CT2 Tg cells, were 
weakly cross-reactive in vitro with Enterobacter spp. that bloom during DSS and HFD. This may 
reflect antigen presentation in an effector microenvironment context similar to that seen for CBir 
discussed above (133). Although future studies are required to test this hypothesis, there appears 
to be a subset of T cells that may see their homeostatic antigens or “inflammation-associated” 
antigens in the context of an inflammatory microenvironment that can suppress FoxP3 or lack 
FoxP3 inducing signals, potentially leading to effector T cell development.   
In summary, our study demonstrates that 1) homeostatic Treg differentiation against 
bacteria antigen is maintained in multiple models of intestinal inflammation 2) TCR specificity 
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can determine the outcome of T cell differentiation during intestinal inflammation, and 3) HFD 
can selectively alter T cell development and Treg TCR repertoires. Our data suggests that there 
are robust mechanisms to preserve microenvironments to protect the host from aberrant immune 
responses to homeostatic antigens. Understanding the cellular and molecular features of these 
microenvironments may be useful for therapy of inflammatory bowel disease.   
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Figures 
Figure 2.1 
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Figure 2.1: Helicobacter reactive TCR transgenic cells develop into pTreg cells during 
Citrobacter rodentium infection. (A-F) CD45.1 wild-type mice were infected with 2x10
9 
CFU 
of Citrobacter rodentium. 1x10
5
 Congenically marked CT2 (CD45.1/2) and CT6 (CD45.2) naïve 
cells (CD44
lo
CD62L
hi
) were stained with Cell-Trace Violet, mixed 1:1, and retro-orbitally 
injected into wild-type and experimental mice on day 4 or 9 of infection. Shown are summary 
plots and representative FACS plots of FoxP3
IRES-Thy1.1 
expression and CD25 expression of Tg 
cells isolated from cecum draining mesenteric lymph (dMLN) node 1 week after transfer. Cells 
were gated on congenically marked CD4
+Vα2+ TCR Tg cells. Graphs are percentages of all Tg 
cells, FoxP3
IRES-Thy1.1+
 or FoxP3
IRES-Thy1.1– 
fractions of Tg cells (replicates = 2 for each infection 
timepoint, n = 4-6). (G, H) Congenically marked CT2 FoxP3
IRES-GFP
 or CT2 IFNγIRES-YFP 
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FoxP3
IRES-Thy1.1 
naïve cells were sorted as described above and activated in polarizing conditions 
(see methods) for 48 hours before retro-orbital transfer (1.5 x 10
5
 into wild-type CD45.1 hosts). 
Tg cells were analyzed via flow cytometry from the dMLN 1 week post transfer. Representative 
FACS plots of FoxP3
IRES-GFP+
 percentages were gated on congenically marked CD4
+Vα2+. CT2 
IFNγIRES-YFP+ percentages were gated on CD4+Vα2+FoxP3IRES-Thy1.1- (replicates = 2, n = 1-3 for 
all). Statistical significance was calculated using Student T test, *P<0.05, ** P<0.005, *** P 
≤0.001, **** P≤0.0001; ns = not significant. Error bars = ±SEM. 
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Figure 2.2 
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Figure 2.2: DSS coupled with high fat diet (HFD) inhibits pTreg cell development by 
Helicobacter apodemus (CT6), but not Helicobacter typhlonius (CT2) reactive TCR 
transgenic cells. (A-D) CD45.1 wild-type mice were weaned onto control or high fat diet (HFD) 
chow. Experimental mice were treated with 2% DSS via drinking water 7 days after weaning 
(replicates = 5, n = 2-5). Naïve CT2 (CD45.1/2) and CT6 (CD45.2) Tg cells were prepared as 
described in Figure 2.1 and transferred on day 4 of DSS treatment. Flow cytometric analysis was 
done as described in Figure 2.1 from dMLN 7 days after Tg cell transfer— the equivalent of d18 
after weaning. Two or more divisions were considered to be proliferated cells based on Cell-
Trace-Violet dilution. Statistical significance was calculated using Student T test, *P<0.05, ** 
P<0.005, *** P ≤0.001, **** = P≤0.0001; ns = not significant. Error bars = ±SEM. 
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Figure 2.3 
Figure 
2.3: FoxP3
– 
CT6 cells adopt effector phenotypes in DSS and HFD treated hosts. (A, C, D) 
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Naive CT2 FoxP3
IRES-Thy1.1 
IL-17A
IRES-GFP IFNγIRES-YFP and CT6 FoxP3IRES-Thy1.1 IL-17AIRES-GFP 
IFNγIRES-YFP Tg cells were sorted and transferred into DSS and HFD treated mice as described in 
Figure 2 (replicates = 3; n = 2). (A) Flow cytometric analysis and representative FACS plots of 
IL-17A production by CD4
+Vα2+ FoxP3IRES-Thy1.1– Tg cells. Graphs are percentages of IL-17A+ 
of Foxp3
IRES-Thy1.1– 
Tg cells. (B) 1x10
5
 naïve CT6 Tbx21
–/– 
FoxP3
IRES-GFP 
and CT6 Tbx21
+/+
 
FoxP3
IRES-GFP
 Tg cells were sorted and retro-orbitally injected into DSS and HFD treated mice as 
described in Figure 2.2. Shown is flow cytometric analysis of congenically marked CD4
+Vα2+ 
Tg cells from dMLN 7 days after Tg cell transfer (replicates = 2; n = 2-3). (C) Representative 
FACS plots of CD44 expression by CD4
+Vα2+ FoxP3IRES-Thy1.1–IL17AIRES-GFP– Tg cells. (D) Flow 
cytometric analysis and representative FACS plots of proliferation by CD4
+ Vα2+ FoxP3IRES-
Thy1.1– 
IL17A
GFP– 
Tg cells. Cells undergoing 2 or more divisions based on Cell-Trace-Violet 
dilutions were considered to be proliferated. (E) Naïve CT6 Rorc
–/– 
FoxP3
IRES-GFP 
and CT6 
Rorc
+/+
 FoxP3
IRES-GFP
 Tg cells were sorted and injected into DSS and HFD treated mice as 
described above. Flow cytometric analysis of CD4
+Vα2+ Tg cells from dMLN 7 days after Tg 
cell transfer (replicates = 2; n = 2-4). Statistical significance was calculated using Student T test, 
*P<0.05, ** P<0.005. ***P ≤0.001, ****P ≤0.0001; ns = not significant. Error bars = ± SEM. 
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Figure 2.4 
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Figure 2.4: Defects in transgenic pTreg development is not due to reduced transgenic Treg 
population stability (A, B) Naïve CT2 FoxP3
IRES-Thy1.1 
and CT6 FoxP3
IRES-Thy1.1 
cells were 
sorted and injected into mice on control or HFD chow as described in Figure 2.1. Two weeks 
after transfer, experimental mice were administered 2% DSS in drinking water. Tg cells from 
dMLN analyzed for FoxP3
IRES-Thy1.1
 expression 11 days after DSS treatment. Flow cytometric 
analysis and representative facs plots were of congenically marked Tg cells from dMLN 11 days 
after DSS treatment (replicates = 2; n = 2-4). (C) Naïve CT2 FoxP3
IRES-Thy1.1 
and CT6 FoxP3
IRES-
Thy1.1 
cells were sorted as described above and transferred into mice weaned onto control chow. 2 
weeks after transfer, mice were administered 1.5% DSS in drinking water and 1mg α-IL10R 
injected intraperitoneally. Controls were injected with 1 mg of IgG isotype controls (replicates = 
2; n = 2-4). Flow cytometric analysis and representative FACS plots of Tg cells from dMLN 7 
days after antibody injection. Statistical significance was calculated using Student T test, 
*P<0.05, ** P<0.005, *** P≤0.001; ns = not significant. Error bars = ± SEM. 
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Figure 2.5 
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Figure 2.5: Polyclonal Treg TCR repertoires are altered by DSS and HFD treatment, but 
remain distinct from effector TCR repertoires. (A-G) CD4
+
 T cells were sorted into  
FoxP3
IRES-Thy1.1+ 
(Treg), FoxP3
IRES-Thy1.1– 
CD44
hi 
IL-17A
IRES-GFP– 
CXCR3
+ 
(CXCR3
+
), FoxP3
IRES-
Thy1.1– 
CD44
hi 
IL-17A
+ 
(IL-17
+
), and FoxP3
IRES-Thy1.1– 
CD44
hi
 IL-17A
IRES-GFP–
CXCR3
– 
(CD44
hi
) 
subsets from mesenteric lymph nodes of 3-4 weeks old TCli TCRβ Tcra+/– mice on control 
chow, HFD, or 2% DSS and HFD at the same timepoint as Tg cell analysis for adoptive transfer 
experiments (replicates = 4, n = 1-2 mice). (A, B, F) Intra-population (between same T cell 
population, same condition) Morisita-Horn (MH) similarity index (0 = complete dissimilarity, 1 
= identical) of rarefied TCR sequences (10,000 reads) between FoxP3
IRES-Thy1.1+ 
and FoxP3
IRES-
Thy1.1–
 TCR populations for each condition.  (C) Total number of TCRs determined from sum of 
unique TCRs found in each mouse. Reproducible TCRs were defined as those found in ≥ 50% 
mice in each control and/or experimental condition. (D) Reproducible TCRs were analyzed for 
responsiveness to DSS and HFD conditions. TCRs lost in DSS and HFD were reproducibly 
found in control Treg TCR repertoires, but undetectable in any mice in DSS and HFD 
conditions. TCRs new to DSS and HFD were reproducibly found in DSS and HFD Treg TCR 
repertoires, but undetectable in control Treg TCR repertoires. “Other” TCRs in Ctrl Treg TCR 
diagram are TCRs not lost in DSS and HFD. For DSS and HFD diagram, “Other TCRs” include 
TCRs not new to Control conditions, (E) Proportion and number of reproducibly found Treg 
TCRs that are CT2 and CT6-like. CT2-like TCRs were defined as TCRs with clonal frequencies 
that fall within the union of the following parameters: Ctrl Treg < DSS and HFD Treg, Ctrl Treg 
> Ctrl CD44
hi
, and DSS and HFD Treg > DSS and HFD CD44
hi
. CT6-like TCRs were defined as 
TCRs with clonal frequencies that fall within the union of the following parameters: Ctrl Treg > 
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DSS and HFD Treg, Ctrl Treg > Ctrl CD44
hi
, DSS and HFD Treg < DSS and HFD CD44
hi
, Ctrl 
CD44
hi
 < DSS and HFD CD44
hi
. (F) Inter-population (between different T cell populations and 
conditions) MH index of rarefied TCR sequences (10,000 reads) between FoxP3
IRES-Thy1.1+ 
and 
FoxP3
IRES-Thy1.1–
 TCR populations for each condition. Statistical significance was calculated 
using Student T test, *P<0.05, ** P<0.005; ns = not significant. Error bars = ±SEM. (G) Top 50 
reproducibly found TCRs in Treg or CD44
hi
 repertoires ranked on average clonal frequencies 
(adjusted for TRAV primer bias) were identified. Plots display the clonal frequencies of top 
ranked TCRs, ordered by decreasing frequency towards the center of the graph, and their clonal 
frequencies in the alternate T cell population. Statistical significance was calculated using 
Student T test, *P<0.05, *** P≤0.001; ns = not significant. Error bars = ±SEM. 
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Figure 2.6 
 
Figure 2.6: Helicobacter apodemus and Helicobacter typhlonius are differentially affected by 
DSS and HFD. (A) 16S rRNA percentages of Helicobacter operational taxonomic units (OTUs) 
that stimulate CT2 and CT6 Tg cells as a percentage of total 16S rRNA sequences derived from 
the mucosal-associated preparation of the entire large intestine. Bacteria were harvested at same 
timepoint as Tg cell analysis (replicates = 3; n = 2-4). (B) 16S rRNA percentages of 
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Helicobacter OTUs from mucosal-associated preparations cecum or distal sections of the large 
intestine, which were segmented as indicated. (C) Naïve CT2 and CT6 Tg cells were sorted and 
transferred into DSS and HFD treated mice as described in Figure 2. Tg cell numbers were 
counted from lymph nodes that drain antigen from either the distal colon (LN1 = lymph node 
more proximal to rectum along descending colon, LN2 = adjacent to small intestine draining 
lymph nodes) (154) or cecum (dMLN) of the large intestine (n = 2). Statistical significance was 
calculated using Student T test, *P<0.05, ** P<0.005. ***P ≤0.001, ****P ≤0.0001; ns = not 
significant. Error bars = ± SEM. 
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Figure 2.7 
 
 
 
56 
 
 
Figure 2.7: Microbiota of mice treated with DSS and HFD are characterized by a large 
expansion of Enterobacter. (A, B) 16S rRNA sequences of bacteria families were derived from 
the lumen and mucosal-associated preparation of DSS and HFD treated mice. Bacteria were 
harvested at the same timepoint as Tg cell analysis from adoptive transfer experiments. 16S 
rRNA percentages of bacterial families analyzed (replicates = 3; n = 2-4). (C) Single dominant 
Enterobacter OTU percentage displayed as a proportion of total 16S rRNA sequences. Statistical 
significance was calculated using Student T test, *P<0.05, ** P<0.005; ns = not significant. 
Error bars = ± SEM. (D) CFU counts and representative images for mucosal-associated bacteria 
from control and experimental mice plated onto Enterobacter-selecting MacConkey agar plates. 
CFUs were counted after 18 hours of incubation at 37ºC. (E) 16S rRNA sequences of mucosal-
associated bacteria families from mice on control chow treated with 2% DSS. Bacteria collected 
at same timepoint as Tg cell from adoptive transfer experiments. (F) Hybrids transduced with 
CT2 and CT6 TCRα chains were co-cultured with ex vivo isolated flt3L expanded dendritic cells 
and autoclaved antigen generated from known Enterobacter strains. TCR stimulation was 
determined by NFAT-GFP expression (replicates = 3).  
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Figure 2.8 
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Figure 2.8 
 
Figure 2.8: Expansion of CT2 and CT6 cells, but not FoxP3 induction, is reduced during 
Citrobacter rodentium and Toxoplasma gondii infection. (A) CD45.1 wild-type mice were 
infected with Toxoplasma gondii by oral gavage of 1 brain cyst per recipient mouse. 1x10
5
 
congenically marked CT2 FoxP3
IRES-GFP 
(CD45.1/2) and CT6 FoxP3
IRES-GFP 
(CD45.2) naïve cells 
were prepared and transferred as described in Figure 2.1 into control and experimental mice on 
day 4 of Toxoplasma gondii infection. Tg cells were analyzed from the MLN 6-7 days after 
transfer. Flow cytometric analysis performed on congenically marked CD4
+Vα2+ Tg cells 
(replicates = 2; n = 1-3). (B) CD45.1 wild-type mice were infected with 2x10
9 
CFU of OVA-
expressing Citrobacter rodentium. Naïve CT6 FoxP3
IRES-GFP 
and OT-II FoxP3
IRES-GFP 
cells were 
mixed 1:1, and retro-orbitally injected into wild-type and experimental mice on d4 of infection. 
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Flow cytometric analysis and representative FACS plots of FoxP3, CD25, and CD62L 
expression are displayed as a percentage of all congenically marked Tg cells (replicates = 4, n = 
6-8 mice pooled for one datapoint). (C, D) CD45.1 wild-type mice were infected with 2x10
9 
CFU of Citrobacter rodentium. Naive CT2 FoxP3
IRES-Thy1.1 
IL-17A
IRES-GFP  IFNγIRES-YFP and CT6 
FoxP3
IRES-Thy1.1 
IL-17A
IRES-GFP IFNγIRES-YFP Tg cells were sorted and transferred as described in 
Figure 1 in control and experimental mice on day 4 or day 9 of infection. Tg cells were analyzed 
in dMLN 7 days after transfer. Graphs are percentages of all Tg cells, FoxP3
IRES-Thy1.1+
 or 
FoxP3
IRES-Thy1.1– 
fractions of Tg cells (replicates = 2; n = 4-6).  (E) Congenically marked CT2 
FoxP3
IRES-GFP
 or CT2 IFNγIRES-YFP FoxP3IRES-Thy1.1 naïve cells were sorted as described above 
and activated in polarizing conditions (see methods) before retro-orbital transfer (1.5 x 10
5
 into 
wild-type CD45.1 hosts). Tg cells were analyzed via flow cytometry from the dMLN 2 or 4 
weeks post transfer (replicates = 2; n = 1-2) (F) Tg cells were sorted, polarized, and transferred 
as described in (E) and analyzed in the dMLN 1 week post transfer (replicates = 2, n = 1-2 for 
all). Representative FACS plots of FoxP3
GFP+
 percentages gated on congenically marked 
CD4
+Vα2+ Tg cells. Statistical significance was calculated using Student T test, *P<0.05, ** 
P<0.005, *** P < 0.001; ns = not significant. Error bars = ± SEM. 
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Figure 2.9 
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Figure 2.9: Additional analyses of polyclonal and Tg cells during intestinal inflammation. 
(A) CD45.1 FoxP3-DTR mice were injected with one dose of DT (40 ng/g mouse). 24 hours 
later, naïve CT2 FoxP3
IRES-GFP 
cells were transferred as described in Figure 1 (replicates = 3; n = 
2-4). (B, C) Mice were treated with DSS and HFD and naïve CT2 FoxP3
IRES-Thy1.1 
IL-17A
IRES-GFP 
IFNγIRES-YFP and CT6 FoxP3IRES-Thy1.1 IL-17AIRES-GFP IFNγIRES-YFP or CT6 RorcGFP cells co-
transferred as described in Figure 2.1. GFP (replicates = 2, n = 2-3) and YFP (replicates = 3; n = 
2-3) expression was assessed in the dMLN one week after transfer. (D) CD45.1 wild-type mice 
were treated with HFD as described before and analyzed on day 5 after 2% DSS treatment. T 
cells from the MLN and colon lamina propria were isolated and analyzed for FoxP3, Tbet, Rorc, 
and GATA3 expression via transcription factor staining (replicates = 2; n = 2-3).  Statistical 
significance was calculated using Student T test, *P<0.05, ** P<0.005, *** = P ≤0.001, **** = 
P ≤0.0001; ns = not significant. Error bars = ± SEM. 
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Figure 2.10 
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Figure 2.10 
 
 
 
Figure 2.10: Characteristics of TCR repertoires in DSS and HFD. (A-G) TCR sequences 
acquired and data rarefied to 10,000 reads as described in Figure 2.5 (replicates = 4, n = 1-2 
mice). (A) Shannon diversity calculated for respective populations per condition. (B) 
Hierarchical clustering (distance = Euclidean) by clonal frequency of top 50 reproducible TCRs 
(≥ 50% of mice) (C-E) TRAV distribution of respective TCR categories, described in Figure 5.  
(F) PCA analysis of reproducibly found TCRs from rarefied dataset. (G) Top 50 reproducibly 
found TCRs in Treg or CXCR3
+
 TCR repertoires ranked on average clonal frequencies (adjusted 
for TRAV primer bias) were identified. Plots display the clonal frequencies of top ranked TCRs, 
ordered in decreasing rank towards the center, and their clonal frequencies in the other T cell 
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population. (H) Frequency of reproducibly found control Treg TCRs that are also reproducibly 
found in control FoxP3
–
 repertoires. The same analysis was done for reproducibly found DSS 
and HFD Treg TCRs.  
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Figure 2.11 
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Figure 2.11: DSS and HFD treatment alters mucosal-associated and luminal bacteria 
communities. (A) PCoA analysis (distance = Bray) for 16S rRNA sequences from mucosal-
associated bacteria (replicates = 3; n = 2-4) and lumen bacteria (replicates = 2; n = 2-3 mice) 
isolated from control and DSS and HFD treated mice. Bacteria DNA was isolated at the same 
timepoint as Tg cell from adoptive transfer experiments. (B) Select Clostridium OTUs detectable 
in the mucosal-associated preparation in ≥ 50% of mice treated with DSS and HFD. The OTU 
percentage of total 16S rRNA sequences are shown. (C) 3-4 weeks old FoxP3-DTR mice were 
intraperitoneally injected with 20ng DT/g mouse every other day for a week. A total of 5 
treatments were administered before mucosal-associated bacteria were harvested for 16S rRNA 
sequence analysis. Controls were injected with equal volumes of PBS (replicates = 3; n = 2-3). 
Statistical significance was calculated using Student T test, ** P<0.005, **** P ≤0.0001; ns = 
not significant. Error bars = ± SEM. 
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Chapter 3: Transcriptional regulators of peripheral Treg 
cells in vivo 
ABSTRACT 
Peripheral T regulatory (pTreg cells) develop from pluripotent naïve CD4
+
 T cells, which 
can differentiate into either tolerogenic or effector lineages. pTreg development is a process that 
involves the concerted induction of the FoxP3 program and suppression of effector T cell 
lineages. However, the transcriptional profiles of early and late developmental stages of in vivo 
derived pTreg cells have never been characterized. Therefore, the in vivo relevance of known 
transcriptional regulators, their expression patterns throughout pTreg development, and identity 
of correlating gene networks are molecular details that remain unclear. In this study, we capture 
the transcriptional profiles of activated FoxP3
-
 and FoxP3
+
 CT6 TCR transgenic (Tg) cells which 
differentiate into pTreg cells in wild-type hosts against constitutively presented antigen. We find 
that early activated (FoxP3
-
) and mature (FoxP3
+
) pTreg cells show marked differences in 
enriched functional pathways, although Treg signature genes were enriched in both fractions. 
Interestingly, we did not observe the differential expression of known transcription factors 
reported to antagonize Th1 and Th2 responses, but verified that Nr4a family of transcription 
factors, which promote FoxP3 transcription, are enriched in early developmental stages prior to 
FoxP3 expression. Lastly, Eomes restriction of FoxP3 correlates with its expression in early 
FoxP3
-
CD25
lo 
Tg cells, with its deficiency predominantly increasing FoxP3 percentages in cells 
that have undergone 0 or 1 divisions. Thus, early stages of pTreg development are characterized 
by the enrichment of both Treg promoting and antagonizing transcription factors, but not 
regulators known to antagonize canonical effector T cell lineages.  
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Introduction 
 T cells undergo extensive proliferation and clonal expansion upon activation while 
acquiring the transcriptional profiles that commit them to effector or tolerogenic fates (155–157). 
Gene networks that coordinate activation, proliferation, and differentiation are differentially 
regulated in early and late developmental stages. Transcriptional networks that modulate 
differentiation decisions need to be initiated early, whereas genes that stabilize lineage decisions 
are likely to become more prevalent at later stages of development.   
 FoxP3 is necessary for Treg development and function (1, 81, 82, 158), but additional 
genes expressed early during development, independently of FoxP3 upregulation, also serve 
critical roles. Cells that express a functionally null version of FoxP3 are unable to effectively 
suppress effector responses, but still express hallmark Treg signature genes (3). Furthermore, 
numerous transcription factors have been identified to regulate FoxP3 expression by blocking 
effector fates, or by inducing FoxP3’s expression through the promoter and/or CNS1 enhancer 
(12, 103, 104, 106).  Identifying additional genes that co-regulate or initiate the transcription of 
critical genes in early developing Treg cells can further contribute to elucidating the molecular 
networks prevalent during early stages of pTreg development.   
 These gaps in knowledge persist, in part, because of limitations of in vitro and ex vivo 
polyclonal studies. In vitro studies are limited to Tgfβ derived signals, which may not capture 
transcriptional changes that result from in vivo signals that can vary from tissue to tissue. This is 
particularly relevant for Treg cells, which have tissue-specific transcriptional profiles which may 
drive tissue specific suppressive or repair functions (159–161). Polyclonal studies isolating Treg 
cells ex vivo depend on FoxP3 reporters (3), which limit analysis to cells in more mature stages, 
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or surface markers that are enriched for Treg precursors (162), but likely include contaminating 
cells processing non-Treg signals. 
 To circumvent these limitations, our study examines developing monoclonal TCR 
transgenic cells that differentiate into pTreg cells against commensal antigen in vivo under 
homeostatic conditions. We defined early and late developmental populations, captured their 
transcriptional profiles, and identified highly expressed transcription factors in different 
developmental stages. With this approach, we were able to clarify that Eomesodermin is induced 
early in developing T cells, reducing Treg frequencies by reducing the rate of FoxP3 expression 
after TCR engagement. 
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Materials and Methods 
 
Mice 
CT2 (36) and CT6 Tg (21) mice were generated as described (136) and bred to Rag1
–/–
 [the 
Jackson Laboratory (JAX) #002216] and FoxP3
IRES-GFP 
(JAX #006772) or FoxP3
IRES-Thy1.1
. CT6 
Tg mice were also bred to FoxP3
CNS1-/-;GFP
, CD4-Cre Eomes 
fl/fl 
(123)
 
mice, or CD4-Cre 
IFNAR
fl/fl 
mice. Eomes
fl/fl
 mice were a gift from W. Yokoyama (Washington University, St. 
Louis); IFNAR
fl/fl 
mice were a gift from M. Diamond (Washington University, St. Louis); 
FoxP3
CNS1-/-;GFP
 were a gift from A. Rudensky (Memorial Sloan Kettering Cancer Center). 
CD45.1 (JAX #006772) host mice used for adoptive transfer experiments were interbred in our 
colony to maintain their microbiota. Animal experiments were performed in a specific pathogen-
free facility in accordance with the guidelines of the Institutional Animal Care and Use 
Committee at Washington University. 
 
Adoptive transfer experiments 
Naive (CD4
+
FoxP3
–
CD25
–
CD44
lo
CD62L
hi
) T cells were FACS purified from the draining 
lymph nodes and spleens from CD45.2 Tg mice bred to FoxP3
IRES-GFP 
Rag1
–/– 
or  FoxP3
IRES-Thy1.1
 
Rag1
–/–
. When indicated, cells were labeled with Cell-Trace Violet (ThermoFisher) to assess 
proliferation and 10
5
 cells were retro-orbitally injected into 3-4 weeks old wild-type CD45.1 
FoxP3
IRES-GFP 
hosts unless otherwise indicated. All experiments were conducted with littermate 
controls. For all transfer experiments, the distal mesenteric lymph node (dMLN), which drains 
the cecum, MLN, Spleen, and/or colon lamina propria were harvested at various time points after 
transfer and Tg cells (CD45.2
+
CD4
+Vα2+) were analyzed on a BD FACSAria IIu (BD 
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Biosciences). For cells harvested for gene-chip hybridization, 2x10
5
 naïve CT6 or CT6- 
FoxP3
CNS1-/-;GFP
 cells were retro-orbitally transferred into 6-10 CD45.1 wild-type hosts. dMLN 
were harvested on d3 post transfer and DN, FoxP3
-
CD25
+
, FoxP3
int
CD25
-
, and FoxP3
hi
CD25
+ 
cells were sort-purified into lysis buffer from RNAqueous Ambion Total RNA Isolation Kit 
(ThermoFisher; AM1219)  with vortexing every 20 minutes throughout sort duration. 
 
Gene chip hybridization 
RNA was extracted from sort purified Tg cell population using the RNAqueous Ambion Total 
RNA Isolation Kit. cDNA was reverse transcribed and amplified using the Complete Whole 
Transcriptome Amplification Kit (Sigma-Aldrich). Degraded samples were removed before 
submission to the Washington University Genome Technology Access Center (GTAC) for 
hybridization on the Agilent 4x44k mouse genome array.  
 
Retroviral overexpression and adoptive transfer experiments 
Naïve CT6 Tg cells were sorted as described above and plated in α-CD3 (Bio X Cell #BE0001-
1; 10 µg/ml) coated 24 well tissue culture plates at 1x10
6
 cells/well in 1ml. Additives to the 
culture included soluble α-CD28 (Bio X Cell #BE0015-1; 1 µg/ml), anti-cytokine antibodies [all 
Bio X Cell; α–transforming growth factor– (20 g/ml; #BE0057), α-IFN (5 g/ml; #BE0054), 
α–IL-4 (5 g/ml; #BE0045), and α–IL-12 (5 g/ml; #BE0052)]. After 27 hours in culture, cell 
supernatant was aspirated and replaced with virus packaging overexpression constructs. Cells 
were spinfected for 2 hours at 37º. Immediately after spinfection, 3x10
5
 cells were retro-orbitally 
transferred into CD45.1 wild-type hosts. At 1 week after transfer, dMLN were harvested and 
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transduced or untransduced Tg cells (CD45.2
+
CD4
+Vα2+) were analyzed on a BD FACSAria IIu 
(BD Biosciences). 
 
Lamina propria cell isolation 
Colon lamina propria tissue was flushed with PBS to remove fecal content. To remove 
intraepithelial lymphocytes, lamina propria tissue was incubated in RPMI 1640 media containing 
3% FBS, 20 mM HEPES, 1 mM DTT, and 50 mM EDTA for 20 min at 37˚C, and washed with 
RPMI 1640 plus 22.5 mM EDTA. Lymphocytes were isolated from remaining stromal tissue by 
mincing and digesting in 28.3 µg/ml Liberase TL (Roche) and 200 µg/ml RNase 1 (Roche) for 
30 min at 37˚C. Suspended cells were filtered through a 40 m filter prior to use. 
 
Powrie transfer model 
Polyclonal CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP
,
 
CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
naïve cells 
(CD45.2: CD4
+
FoxP3
IRES-GFP-
CD44
lo
CD62L
hi
) and Treg cells (CD45.1/2; CD4
+
FoxP3
IRES-GFP+
) 
were FACs purified using the BD FACSAria IIu (BD Biosciences). 2.5x10
5 
Eomes deficient or 
sufficient CD4
+
 naïve cells were mixed with 0.5x10
5
 wild-type Treg cells and retro-orbitally 
transferred into CD45.1 Rag
-/-
 hosts. Weight loss was evaluated up to 18 days post transfer. Cells 
were stimulated with PMA, Ionomycin, brefeldin (Biolegend), and monensin (Biolegend) for 3 
hours. Cells were fixed with 1.5% PFA and membranes permeabilized with Permeabilization 
Buffer (eBioscience) for intracellular cytokine staining. Cells were analyzed on a BD FACSAria 
IIu (BD Biosciences). 
 
Statistical analysis 
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GraphPad Prism v6 was used for statistical and graphical analysis. Statistical significance was 
calculated using the Student T test, *P<0.05, ** P<0.005, ***P≤0.001, **** P ≤0.0001; ns = 
not significant. Error bars = ± SEM. Quantile normalization of microarray data was performed 
with Arraystar. ANOVA and Student T tests were FDR adjusted using the Benjamini-Hochberg 
test using Arraystar, with p<0.05 considered to be significant.  Genesets for Gene Set 
Enrichment Analysis (GSEA) (163, 164) were downloaded from the GSEA database or curated 
from prior studies (2, 109, 113).  GSEA analysis, statistical significance, and heat maps were 
generated with the GSEA Java Desktop Application. Plots were also generated with Microsoft 
Excel 2010.  
 
 
 
 
 
‘ 
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Results 
 
Monoclonal FoxP3
-
CD25
+
 CT6 Tg cells cells exhibit a burst of transcriptional activity. 
To understand the transcriptional activity that coordinates Treg development prior to 
FoxP3 expression, we examined the transcriptional profiles of a monoclonal population of CT6 
transgenic (Tg) cells activated during homeostasis in vivo. Naive CT6 Tg cells, after transfer into 
wild-type hosts, preferentially differentiate into pTreg cells in response to in vivo derived signals 
in the cecum draining mesenteric lymph node (dMLN) (21, 36). We first defined populations of 
monoclonal TCR Tg cells by 4 discernable quadrants of FoxP3 and CD25 expression—FoxP3-
CD25
-
 (DN), FoxP3
-
CD25
+
, FoxP3
int
CD25
-
, and FoxP3
hi
CD25
+
 (Fig. 3.1A).  As previously 
reported, CT6 Tg cells transferred into wild-type hosts first express CD25 24 hours and FoxP3 
48 hours after transfer  in the dMLN (36). As cells develop further, FoxP3
hi
CD25
+
 cells are 
enriched in the most proliferated fraction of Tg cells (36).  Although it remains unclear if 
FoxP3
hi
CD25
+
 cells originate from the FoxP3
-
CD25
+
 fraction or the FoxP3
int
CD25
-
 populations 
of Tg cells, the detection of CD25 prior to FoxP3 supports that the DN and FoxP3
-
CD25
+
 
populations represent the earliest developmental stages, and FoxP3
int
CD25
-
 and FoxP3
hi
CD25
+
 
represent later developmental stages. 
The DN population, which will include the earliest activated FoxP3
-
CD25
-
 cells, FoxP3
-
CD25
+
, FoxP3
int
CD25
-
, and FoxP3
hi
CD25
+
 populations of monoclonal cells were sort purified 
from the dMLN on day 3 after transfer and submitted for gene-chip hybridization on the Agilent 
platform.  We isolated Tg cells from the dMLN to capture cells from the anatomical site of 
antigen encounter and to minimize contamination by circulating naïve, non-activated cells. Gene 
expression of FoxP3
hi
CD25
+
, FoxP3
-
CD25
+
, and FoxP3
int
CD25
- 
cells were normalized to the DN 
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population and differentially expressed genes selected based on FDR-adjusted ANOVA p-values 
(<0.05) (Fig. 3.1B).  The cell populations showed significant and distinct transcriptional 
differences. 153 genes were differentially expressed relative to the DN population by all 3 
populations. Interestingly only 395 genes total were differentially expressed in the 
FoxP3
int
CD25
-
 population. In contrast, F
-
CD25
+
 cells differentially expressed the most at 2,831 
genes and FoxP3
hi
CD25
+
 cells differentially expressed 1201 genes.  FoxP3
hi
CD25
+
 cells, which 
represent the latest developmental stages in our analysis, shared a greater number of 
differentially expressed genes (excluding the 153 genes shared by all) with FoxP3
-
CD25
+
 than 
with FoxP3
int
CD25
- 
cells, with 854 and 46 shared, respectively. FoxP3
-
CD25
+
 cells also 
differentially expressed the greatest number of uniquely differentially expressed genes, with 
1705 genes uniquely altered out of 2,831 (49%) genes. FoxP3
hi
CD25
+
 cells, in contrast, only 
uniquely differentially expressed 194 genes (16%) (Fig. 3.1B).  
We evaluated the robustness of these observations by conducting pairwise comparisons 
of differentially expressed genes with Student T tests adjusted for false discovery with the 
Benjamini Hochberg test (Fig. 3.1C). FoxP3
-
CD25
+
 cells still had the largest number of 
significantly differentially expressed genes (1,882 genes) relative to FoxP3
int
CD25
+
 (0 genes, 
data ns) and FoxP3
hi
CD25
+
 (29 genes) populations. This data shows that early and late 
developmental stages for in vivo derived pTreg cells exhibit significant transcriptional 
differences, with the most pronounced transcriptional activity occurring at the time of CD25 
upregulation prior to FoxP3 expression. Interestingly, FoxP3 expression by itself did not elevate 
significant transcriptional activity, supporting proposals that FoxP3 largely facilitates Treg 
development through gene repression (111) or by amplifying gene expression triggered by non-
FoxP3 signals like Tgfβ (109, 158) (Fig. 3.1B). 
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FoxP3
+
 and FoxP3
-
 Tg cells exhibit distinct functional pathways. 
To gain insight on the functional differences of gene networks in these populations, we 
examined the relative enrichment of known functional pathways between the isolated FoxP3
+
 
and FoxP3
-
 Tg cell populations. Gene set enrichment analysis (GSEA) (163, 164) was performed 
with 674 pathways from the Reactome database by doing pairwise comparisons between the 4 
populations (Fig. 3.1D, Fig. 3.8A). FoxP3
hi
CD25
+
 and FoxP3
-
CD25
+
 cells were positively 
enriched (majority of genes in the gene set are upregulated) for DNA/RNA processing gene sets 
relative to the double negative population, consistent with their significant transcriptional activity 
(Fig. 3.8A) We further compared the two CD25
+ 
populations to each other to identify the top 15 
enriched functions that may be IL-2 independent. The FoxP3
-
CD25
+
 cells were dominated by 
gene sets involved in nucleotide processing, which is also consistent with their higher levels of 
transcriptional activity, whereas the FoxP3
hi
CD25
+
 cells were relatively enriched for signaling 
pathways, including cytokine signaling in the immune system and type 1 interferon signaling 
(Fig. 3.1D, Fig. 3.8B) We evaluated the cell-intrinsic impact of IFNAR deficiency on the 
development of CT6 cells, and observed no impact on FoxP3 frequencies during homeostasis, or 
in mice treated with Poly:IC (Fig. 3.8C data n.s.). This suggests that genes in the type 1 
interferon pathway may be differentially expressed in response to alternative receptors that signal 
through targets that intersect multiple pathways. Cumulatively, the data supports that FoxP3
-
CD25
+
 cells are becoming equipped to rapidly initiate transcription, consistent with the notion of 
clonal expansion and proliferation, whereas FoxP3
hi
CD25
+ 
cells are processing signals from the 
environment to fine-tune their phenotype. 
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Treg signature genes are expressed prior to FoxP3 upregulation. 
Next, we assessed the expression of Treg signature genes (109) in the 4 Tg populations to 
determine when in development Treg cells begin to adopt Treg profiles. As expected, the 
FoxP3
hi
CD25
+ 
cells were more enriched for Treg signature genes relative to FoxP3
-
CD25
+
 cells, 
but to our surprise, de-enriched when compared to DN cells (Fig. 3.2A). This indicated that DN 
cells express more Treg signature genes than the FoxP3
-
CD25
+ 
cells. We confirmed this 
observation, finding 181 Treg signature genes that were positively enriched in the DN population 
(Fig. 3.2A). This demonstrates that a significant portion of genes characteristic to mature Treg 
cells are expressed predominantly in the DN population prior to FoxP3 upregulation.  
We next investigated whether the DN cells may also express genes that are later 
amplified by, but not dependent on FoxP3. These genes, as expected, are more positively 
enriched in FoxP3
hi
CD25
+
 cells relative to DN cells and FoxP3
-
CD25
+
 cells (Fig. 3.2B). 
Consistent with the Treg signature GSEA results, DN cells are also relatively enriched for 
FoxP3-amplified genes (2), 60% of which are Treg signature genes, including Tcf7, Ctla4, and 
Gpr15.  We further observed that activated CT6 CNS1 deficient cells, which have dramatically 
reduced FoxP3 frequencies (36), continue to express a number of Treg signature genes, including 
Soc2, despite the absence of FoxP3 expression (Fig. 3.9D). Thus, Treg signature genes, which 
can be amplified by FoxP3 and/or expressed independently of FoxP3, are expressed in early 
activated cells, but relatively de-enriched in FoxP3
- 
cells expressing CD25.  
 
Transcription factors are prevalently expressed in the DN population of CT6 Tg cells. 
Given the enrichment of Treg signature and FoxP3-amplified genes in the DN 
population, we sought to identify transcription factors that may modulate the transcriptional 
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landscape of early activated cells. Similar numbers of transcription factors were enriched in 
FoxP3
hi
CD25
+
 cells (46 genes) and  DN cells (47 genes), including IL-10 regulators, Ahr and 
Maf (165, 166), and Uhrf1, a FoxP3 stabilizer (167) (Figure 3.3A). In DN cells, transcription 
factors belonging to the Nr4a family, which regulate FoxP3 expression in pTreg cells through 
interactions with the CNS1 enhancer and FoxP3 promoter (103, 104, 106), were enriched relative 
to FoxP3
hi
CD25
+ 
cells. Comparisons of FoxP3
hi
CD25
+ 
cells with FoxP3
-
CD25
+ 
determined that a 
greater number of transcription factors were enriched in FoxP3
hi
CD25
+ 
cells, with 92 genes 
relative to FoxP3
-
CD25
+
 cells’ 70 genes. Notably, neither PHD nor Musculin proteins, which 
antagonize Th1 and Th2 transcriptional programs respectively (107, 108), were amongst the 
most significantly differentially expressed. However, there were approximately twice as many 
transcription factors upregulated in DN relative to FoxP3
-
CD25
+ 
cells, with 208 upregulated in 
DN cells, but only 123 upregulated in FoxP3
-
CD25
+
 cells. Of the 208 and 123 differentially 
expressed genes, 62 and 31 genes, respectively, reached FDR-adjusted statistical significance. 
Cumulatively, the significant number of transcription factors expressed in the DN population and 
expression of the Nr4a family of transcription factors demonstrate that 1) DN cells express a 
significant number of transcription factors that are downregulated in other populations, and 2) 
DN cells express transcription factors that are known to regulate FoxP3 transcription. 
 
Eomes is expressed in FoxP3
-
CD25
lo
 population of CT6 Tg cells.   
Eomesodermin was the transcription factor that underwent the largest fold change, 
expressing a signal ~11x greater in DN and FoxP3
-
CD25
+ 
cells relative to FoxP3
hi
CD25
+
 cells 
(Figure 3.3A). We verified the microarray results for Eomes in vivo via intracellular staining of 
CT6 Tg cells. Consistent with the microarray, Eomes expression was absent in the FoxP3
+
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fraction of CT6 Tg cells (Fig. 3.9A, Fig. 3.3B). In CT6-Nur77
GFP 
mice, which express Nur77 
signal in direct proportion to increasing strength of TCR stimulation (103, 168), we further 
observed that Eomes expression is limited to Nur77
GFP+ 
cells that express low levels of CD25. 
Unexpectedly, high levels of Nur77
GFP
 did not correlate with high levels of CD25 expression, 
suggesting the possibility that CD25 expression either precedes TCR stimulation, or is 
downregulated when TCR engagement increases in strength. It is likely that that Eomes is 
detected in the DN fraction of the microarray due to the capture of a contaminating CD25
lo
 
population. Thus, Eomes protein is highly expressed in a FoxP3
-
CD25
lo
Nur77
GFP+
 population of 
cells and absent in FoxP3
+
 Tg populations. 
 
Eomes negatively regulates FoxP3 expression in developing CT6 Tg cells.  
We next asked whether this potentially transient expression of Eomes has a functional 
impact on pTreg development by CT6 Tg cells. We verified that retroviral overexpression of 
Eomes in CD4
+ 
T cells in vitro reduced FoxP3 upregulation, as previously reported, in the cells 
transduced with the overexpression construct (121) (Fig. 3.9B). FoxP3 expression was 
completely eliminated in cells expressing the highest levels of Eomes, but untransduced cells 
showed no FoxP3 defect, demonstrating that Eomes blockade of FoxP3 is cell-intrinsic. Eomes 
deficient cells activated in Th0 conditions also exhibited elevated levels of spontaneous FoxP3 
expression in the absence of Tgfβ, given the inclusion of α-Tgfβ in the culture (Fig. 3.9C). This 
validates prior reports that Eomes restriction of FoxP3 is through cell-intrinsic mechanisms and 
not the result of extracellular signals in the culture (121).  
Eomes restriction of Foxp3 has been reported in vitro and in the context of monoclonal 
OT-II cells differentiating into pTreg cells in response to exogenously introduced oral antigens 
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(121). However, it remains unknown if Eomes serves a function in pTreg induction against 
antigen endogenous to the host. To evaluate the impact of Eomes for pTreg cells derived against 
homeostatically presented endogenous antigen, we retrovirally overexpressed Eomes-GFP or an 
empty Mig-GFP vector into CT6 Tg cells activated in Th0 conditions that preserves in vivo Treg 
differentiation (Fig. 3.10A). The cells were transferred 27 hours after retroviral spinfection into 
wild type hosts, and FoxP3 upregulation in transduced cells was assessed. Consistent with our in 
vitro results, cells overexpressed with Eomes exhibited a 2-fold reduction in FoxP3 percentages 
when analyzed one week post transfer (Fig 3.4A). We further overexpressed additional targets, 
with reported T cell functions, including BCL-6, NR4A1, and IRF8 into CT6 cells (102, 104, 
169, 170). Cells overexpressed with BCL-6 exhibited no reduction in FoxP3 frequencies, 
showing that the reduction of FoxP3 in Eomes-overexpressed cells is not an artifact of 
transcription factor overexpression (Fig 3.10C). As expected, cells overexpressed with NR4A1 
exhibited an increase in FoxP3, and IRF8 drove the expression of CXCR3, which traffics cells to 
sites of Th1 inflammation (Fig. 3.10D, 3.10E). Thus, this experimental approach recapitulates 
expected functions of transcription factors on Treg development, and verifies that FoxP3 
reduction is function of Eomes.  
To evaluate the effect of Eomes deficiency in vivo, CT6-CD4-Cre Eomes
fl/fl
 mice were 
generated and naïve cells transferred into wild-type hosts. Eomes deficient cells exhibited a 
significant 1.5-fold increase in FoxP3 frequencies in the cecum draining lymph node and upward 
trended in the colon lamina propria 1 week after initial transfer (Fig. 3.4B). Increased FoxP3 
percentages extended beyond the intestinal tissues, with a larger, 2-fold increase in FoxP3 
percentages in cells isolated from the spleen (Fig 3.11A). Neither the FoxP3
+
 nor FoxP3
-
 fraction 
of cells exhibited increased Cell-Trace Violet dilution, CD25 upregulation, or cell numbers in 
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any of the examined tissues (Fig. 3.4C, Fig. 3.11B). Thus, increased frequencies of FoxP3 is 
unlikely the result of enhanced proliferation or activation. This data demonstrates that Eomes 
expression is not required for pTreg development in vivo, but reduces the efficiency of Treg 
maturation.  
 
Eomes mediated FoxP3 restriction is not a universal property of Tbx transcription factors. 
Considering that Tbet and Eomes share overlapping transcriptional targets (117) and the 
reported blockade of pTreg differentiation by Tbet (47, 143), we asked whether Eomes-mediated 
FoxP3 restriction is due to universal properties of the Tbx domain, or due to shared 
transcriptional targets specific to Tbet and Eomes. To address this question, we overexpressed 
Tbet proteins that cannot initiate transcription—a function predominantly conferred to the C-
terminus region of the Tbet protein (146, 147). We use a dominant negative mutant with the 
carboxy terminus replaced with a drosophila engrailed domain (117), a mutant with a truncated 
C-terminus (146), and a mutant with a point mutation (Y182) in the Tbx domain (147). This 
mutation impairs the recruitment of epigenetic modifiers and therefore, transcription. The 
dominant negative mutant completely blocked FoxP3 upregulation, but the cells overexpressed 
with the Y182 point mutant expressed FoxP3 at similar percentages as those overexpressed with 
an empty vector (Fig. 3.5A). Interestingly, the Y182 mutant, contrary to prior reports (147), was 
able to drive the transcription and expression of CXCR3 (Fig. 3.5A). The retained transcriptional 
abilities point towards the possibility that FoxP3 blockade is the result of functions specific to 
the Tbx domain. However, the mutant with a truncated C-terminus did not reduce FoxP3 (Fig. 
3.5B). Furthermore, additional Tbx proteins, Tbx5, Tbx6, and Tbx10 failed to block FoxP3 
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upregulation (Fig. 3.12A). This data supports that FoxP3 blockade is not a universal property of 
Tbx proteins and is a function unique to share transcriptional targets of Tbet and Eomes. 
 
Genes repressed by Eomes are enriched in FoxP3
hi
CD25
+
 and FoxP3
-
CD25
+ 
cells 
To determine if a transcriptional target shared by Tbet and Eomes is necessary for FoxP3 
restriction, we activated Eomes deficient CD4
+
 T cells in Th1 polarizing conditions that induce 
Tbet. Interestingly, the Eomes deficient cells still exhibited enhanced spontaneous FoxP3 
upregulation even in Th1 polarizing conditions (Fig 3.5C). Although it cannot be ruled out that 
shared transcriptional targets play a role in FoxP3 blockade, this data cumulatively suggests that 
there are non-overlapping targets of Tbet and Eomes that can restrict FoxP3. To gain insight on 
whether Eomes is mediating FoxP3 restriction through the activation or suppression of genes, we 
analyzed the expression patterns of genes regulated by Eomes during endoderm development 
(113), with the caveat being that endoderm cells may lack the expression of T cell genes 
regulated by Eomes. Targets downregulated in Eomes deficient cells, which would represent 
genes activated regulated by Eomes, did not exhibit substantial differential expression (Fig. 
3.12B). In FoxP3
hi
CD25
+
 cells and DN cells, equal numbers were differentially expressed, but 
only 1 gene reached statistical significance. When comparing FoxP3
-
CD25
+ 
to the DN 
population, there was a slight increase in the number of genes enriched in the DN population, 
with 52 enriched with a 2-fold difference in the DN population and 41 in FoxP3
-
CD25
+
 cells.  Of 
the 52 and 41 genes, 22 and 12 reach statistical significance, respectively (Fig.3.12B). 
Interestingly, genes that are up in Eomes deficient cells, representing genes repressed by Eomes, 
were enriched in the FoxP3
hi
CD25
+
 population, with 52 genes up in FoxP3
hi
CD25
+
 and 28 in DN 
cells (Fig 3.5D). 5 reached statistical significance in the FoxP3
hi
CD25
+
 population, and 1 was 
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significantly enriched with a 2-fold difference in the DN population. This trend was consistent in 
comparisons of the FoxP3
-
CD25
+
 cells compared to DN cells, where there was a ~2-fold 
difference in genes enriched in DN vs. FoxP3
-
CD25
+
 cells (Fig 3.5D). This difference increased 
to 4-fold when analysis was restricted to statistically significant genes, with 12 enriched in 
FoxP3
-
CD25
+
, but 46 enriched in DN cells (Fig 3.5D). Although this gene set is unlikely 
comprehensive for T cell gene expression, this assessment suggests that Eomes in CT6 cells is 
predominantly executing gene repression. 
 
Eomes deficiency enhances FoxP3 independent of effector T cell polarization. 
We next sought to understand if Eomes regulates FoxP3 expression by promoting 
effector fates in CT6 Tg cells that ultimately fail to develop. We chose to address this question 
by examining differentiation of Eomes deficient polyclonal cells in an inflamed environment that 
favor effector cells. If Eomes modulates pTreg differentiation by driving alternative effector 
fates, we would expect to see increased effector cells corresponding with increased FoxP3 
expression. Here, we did not use CT6 cells because Treg differentiation by CT6 monoclonal cells 
can differentiate into pTreg cells in multiple models of intestinal inflammation, suggesting they 
do not receive T effector specifying signals. Eomes deficient naïve cells were co-transferred with 
wild-type Treg cells into lymphopenic hosts to allow them to differentiate in a moderately 
inflamed environment. Like with our monoclonal observations, Eomes deficient naïve cells 
exhibited a 2-fold increase in Foxp3 frequencies relative to wild-type naïve cells (Fig. 3.6A). 
Despite reports that Eomes can promote IFNγ production in cooperation with Tbet, Eomes 
deficient cells did not exhibit reductions or elevations in IFNγ producing cells (117) (Fig. 3.6B). 
Furthermore, the mice with transferred Eomes deficient cells exhibited reduced weight loss 
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relative to mice transferred with Eomes wild-type cells (Fig. 3.12A). This data suggests firstly 
that Eomes deficiency can promote FoxP3 in a cell-intrinsic fashion in the context of 
inflammation, and secondly, the increase is not the result of a defect in effector T cell 
development. 
 
Eomes regulates FoxP3 expression in early cell divisions. 
One hypothesis is that Eomes expression temporarily suppresses FoxP3 until it can be 
downregulated by Tgfβ (121), slowing the rate of FoxP3 upregulation. To address this question, 
we evaluated FoxP3 expression in Eomes deficient and wild-type cells by each cell-division of 
TCR Tg cells stained with Cell-Trace-Violet prior to transfer into wild type hosts. Cells were 
analyzed 1 week post transfer for FoxP3 expression by GFP reporter from the dMLN. FoxP3 
expression could be discerned in peak one (division 0), which contains undivided cells that are a 
mixture of activated and non-activated cells. The FoxP3 frequency increases with each division 
in wild-type cells. In Eomes deficient cells, the frequency of FoxP3 expression is elevated 2-fold 
in division 0 and 1 but not at later cell divisions (Fig. 3.7A). We further analyzed Eomes 
deficient cells at later timepoints during week 2 and 3 post transfer. The increase in FoxP3 
frequencies by Eomes deficient cells was most pronounced at week 1 post transfer in intestinal 
tissues, with virtually no differences observed in the mesenteric lymph nodes by week 3 after 
initial naïve cell transfer (Fig 3.7B, Fig. 3.14A). The increase in FoxP3 percentages was 
maintained only in the spleen (Fig. 7B, Fig. 3.14A). Cells could not be recovered from the colon 
lamina propria, potentially due to cell death.  This in contrast with observations of increased age 
positively correlating with increased FoxP3 frequencies (121). Interestingly, Eomes deficient 
cells displayed a mild decrease in CD25 expression, and no significant increase in CXCR3 
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expression (Fig. 3.14A). Thus, Eomes deficient FoxP3
+
 cells show a slight defect in maintaining 
their activation, but do not show signs of destabilizing to effector fates. Collectively, the reduced 
difference in FoxP3 frequencies at later time points and increase in FoxP3 percentages at early 
cell divisions clarifies that Eomes’ function is limited to early stages of pTreg development. One 
possibility explaining the difference in polyclonal and our monoclonal observations is that 
Eomes is enhancing the constitutive generation of new pTreg cells developing in response to 
altered self-antigen or matured microbiota.  
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Discussion 
Treg cells differ in their transcriptional profiles in a tissue specific fashion, indicating that 
developing and mature Treg cells are constitutively processing signals from their environment 
(171). Thus, the gene networks relevant to in vivo derived pTreg cells are likely to differ from in 
vitro derived Treg cells which are generated with the singular addition of Tgfβ. Given the 
difficulty of distinguishing early from late developing pTreg cells from polyclonal populations, 
information on the transcriptional maturation of in vivo developing pTreg cells has remained 
poorly characterized. 
In this study, we captured the transcriptional profiles of a monoclonal population of 
colonic, pTreg cells. As expected, the profiles of early and late developing cells were highly 
distinct in terms of transcriptional targets and function. Early stages of FoxP3
-
CD25
+
 cells 
exhibited a burst of transcriptional activity, differentially expressing ~2.5x more genes than 
FoxP3
hi
CD25
+ 
cells. However these later FoxP3
hi
CD25
+
 cells were more enriched for immune 
signaling processes, including type 1 interferon signaling. Deficiency in type 1 interferon 
signaling did not alter FoxP3 expression despite prior reports that type 1 interferon can enhance 
FoxP3 expression (56). These observations support that mature Treg cells process additional 
cytokine or co-stimulatory signals from their environment that are not necessary for FoxP3 
induction. Another possibility explaining the discrepancy between prior reports and our 
assessment of IFNAR signaling in CT6 Tg cells is that pTreg development is process that may 
vary from tissue to tissue, or even T cell clone to clone.  
We identified further discrepancies, having not observed differential expression of 
transcription factors that promote Treg development by suppressing effector lineages, including 
Msc2 and PHD proteins. This was surprising given that CNS1 deficient CT6 Tg cells do not 
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effectively divert to effector cell lineages, and actually generate a greater percentage of FoxP3
+
 
cells over time (36).  Thus, we hypothesized that CT6 cells would employ cell-intrinsic 
mechanisms preventing the adoption of effector fates in the form of these transcriptional 
regulators. Since this was not the case, it begs the question of whether the failure to adopt 
effector lineages by CT6 Tg cells, despite impaired Treg development, is due to the absence of 
effector polarizing signals, or a cell-intrinsic process that primes the cells to adopt a Treg fate 
prior to FoxP3 expression. It is interesting to consider that there are epigenetic mechanisms 
induced upon Tgfβ signaling, prior to FoxP3 induction, which prime the cells to develop into 
Treg cells without additional transcriptional regulators.  
Eomes was the transcription factor whose expression levels were highest in FoxP3
-
 
populations relative to FoxP3
+
 populations. Our study clarified that Eomes is upregulated upon 
TCR engagement, and restricts FoxP3 upregulation prior to extensive cell division. Its deficiency 
accelerates the rate of FoxP3 upregulation, with non-divided cells exhibiting increased FoxP3 
frequencies relative non-divided Eomes sufficient cells. Furthermore, targets repressed by Eomes 
are upregulated in FoxP3
hi
CD25
+
 cells that no longer express Eomes, supporting the possibility 
that Eomes’ function in early developmental stages is largely repressive. One interpretation of 
this data is that Eomes upregulation transiently suppresses Treg development genes until it can 
be downregulated, potentially by Tgfβ.  What remains unclear, however, is the evolutionary 
advantage of Eomes induction in developing pTreg cells as opposed to simply restricting its 
expression to effector T cells. We speculate that its upregulation in developing Treg cells is a 
vestigial process and that the primary role of Eomes is to regulate effector T cell development 
and function.  
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Given the recent advances of single-cell sequencing, it would be intriguing to further this 
study by investigating early developing pTreg cells at the single cell level by cell-division. 
Single cell analysis can further clarify relevant molecular networks and identify additional 
targets that may prime the epigenetic landscape of activated cells to favor Treg development. 
Furthermore, manipulation of transcription factors like NR4A1 and Eomes are sufficient to 
enhance Treg development in vivo, even in the context of inflammation. It is intriguing to 
consider the possibility of using gene-editing technology in conjunction with chimeric antigen 
receptor technology to design cell-based immunotherapies that can robustly maintain tolerogenic 
profiles in inflammatory contexts. 
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Figures 
 
Figure 3.1 
Figure 3.1: Transcriptional profiles of a monoclonal population of developing peripheral 
Treg cells. (A) 1.8 x 10
6 
CT6 (CD45.2) naïve Tg cells (CD44
lo
CD62L
hi
) were sorted and 
transferred into 6-8 CD45.1 FoxP3
IRES-GFP 
wild-type hosts colonized with Helicobacter antigen. 
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The dMLN, the initial site of CD25 upregulation by CT6 Tg cells, were harvested on day 3 post 
transfer and pooled from 6-10 hosts (replicates = 2, n = 3). 4 populations were defined by FoxP3 
and CD25 expression: DN, FoxP3
-
CD25
+
, FoxP3
int
CD25
-
, and FoxP3
hi
CD25
+
. Monoclonal cells 
were sorted from pooled dMLN directly into lysis buffer and RNA/cDNA processed for gene 
chip hybridization. (B) 5,129 differentially expressed genes were selected by statistical 
significance (FDR adjusted p-value < 0.05). Duplicate probes with lower significance values 
were removed from analysis. Gene expression of FoxP3
-
CD25
+
, FoxP3
int
CD25
-
, and 
FoxP3
+
CD25
+
 cells were normalized to their gene expression values in DN populations. Genes 
with 1.5-fold change in gene expression were considered differentially expressed, and the 
numbers of differentially expressed genes and their overlap with each analyzed population was 
assessed. (C) Pairwise comparisons of differential gene expression for FoxP3
hi
CD25
+
, FoxP3
-
CD25
-
, and DN populations. Probes with expression values that fell below an arbitrary threshold 
were removed from analysis. Robustness of differential gene expression was evaluated with FDR 
adjusted Student T-test for pairwise comparisons. Genes differentially expressed by 
FoxP3
int
CD25
- 
cells did not reach statistical significance and are not shown here. Red denotes 
genes whose differential expression reached statistical significance (FDR adjusted p<0.05) and 
grey denotes genes that failed to reach statistical significance. Dotted lines mark 1.5 fold-change. 
(D) Gene Set Enrichment Analysis comparing FoxP3
hi
CD25
+
 cells with FoxP3
-
CD25
+
 cells. 
Analysis was done with 674 Reactome gene sets, with gene sets with less than 15 genes excluded 
from analysis. The Normalized Enrichment Score (NES) of the top 15 gene sets (ranked based on 
enrichment values) enriched in each population are displayed. Higher NES values signify greater 
enrichment.  
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Figure 3.2 
 
Figure 3.2: Treg signatures are expressed in early developing stages of in vivo generated 
peripheral Treg cells. (A) Gene Set Enrichment Analysis was performed with Treg signature 
gene set (640 probes). Genes in analyzed populations were ranked in accordance to the Broad 
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Institute’s signal-to-noise metric and the enrichment for each gene assessed. The green line 
denotes the Enrichment Score for each gene, with values of 0 signifying no enrichment and 
positive enrichment scores signifying enrichment in the population listed first. The number of 
genes with positive or negative enrichment scores reflects the relative enrichment of the Treg 
signature gene set in each population. (B) Gene Set Enrichment Analysis was performed with a 
gene set consisting of FoxP3-amplified genes (233 probes). Significantly enriched genes 
displayed in heat maps, with red representing high expression and blue representing low 
expression. 
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Figure 3.3 
 
Figure 3.3: Eomesodermin expression is elevated in FoxP3
-
CD25
lo 
cells but absent in FoxP3
+
 
stages of peripheral Treg development. (A) Log2 expression values of known transcription 
factors. Transcription factors differentially expressed in FoxP3
+
 vs. FoxP3
- 
cells were 
highlighted, in addition to genes undergoing more than 2-fold change. Eomes is highlighted as 
the gene that undergoes differential fold change of the greatest magnitude. (B) CT6 Tg Nur77
GFP
 
naïve (CD44
lo
CD62L
hi
) cells were sorted and transferred into CD45.1 FoxP3
IRES-GFP 
WT hosts 
(replicates = 2, n = 1-2). dMLN was harvested and Tg cells stained intracellularly for Eomes 
expression. Eomes expression was quantified as a percentage of Tg cell populations, as 
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illustrated in representative FACs plots. Representative FACs plots are of Tg cells, distinguished 
by congenic markers, and gated on CD4
+Vα2+.  
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Figure 3.4 
 
Figure 3.4: Eomes can restrain pTreg development against endogenously presented 
bacteria antigen. (A) CT6-FoxP3
IRES-GFP 
or CT2-FoxP3
IRES-GFP
 naïve Tg cells were sorted and 
activated in conditions that maintain Treg differentiation by Tg cells in vivo (see methods) for 27 
hours before retroviral spinfection with an Eomes-Thy1.1 overexpression construct or an empty 
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Mig-Thy1.1 vector. Cells were retro-orbitally transferred (3x10
5
 cells) into CD45.1 wild-type 
hosts immediately after spinfection Tg cells were analyzed via flow cytometry from the dMLN 1 
week post transfer (replicates = 2, n = 2-3). Representative FACS plots of FoxP3
IRES-GFP+
 
percentages were gated on congenically marked CD4
+Vα2+Thy1.1+ cells. (B) CT6 CD4-Cre+ 
Eomes
 fl/fl 
FoxP3
IRES-GFP  and 
CT6 CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP  
naïve cells were sorted, 
labeled with Cell-Trace-Violet and transferred (1x10
5
 cells) into wild-type hosts as described 
above (replicates = 2, n = 3-4). Shown are summary plots of FoxP3
IRES-GFP 
expression, CD25 
expression of Tg cells, and proliferated cells (2 or more cell divisions based on Cell-Trace Violet 
dilution) isolated from the dMLN node 1 week after transfer. Representative FACs plots are of 
FoxP3
IRES-GFP 
expression. Cells were gated on congenically marked CD4
+Vα2+ TCR Tg cells. 
Graphs are percentages of all Tg cells, FoxP3
IRES-GFP+
 or FoxP3
IRES-GFP- 
fractions of Tg cells. 
Statistical significance was calculated using Student T test, *P<0.05, ** P<0.005; ns = not 
significant. Error bars = ±SEM. 
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Figure 3.5
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Figure 3.5: Eomes represses gene transcription through unique targets independently of 
Tbet. (A-B) CT6-FoxP3
IRES-Thy1.1
 naïve Tg cells were sorted, in vitro activated, and retrovirally 
transduced with overexpression constructs on the Mig-GFP backbone as described in Figure 3.4 
(replicates = 2-3, n = 2-3).  Summary plots and representative FACs plots are of Tg cells isolated 
from the dMLN 1 week after transfer. FoxP3
IRES-Thy1.1+ 
percentages were gated on 
CD4
+Vα2+GFP+ cells. The FoxP3 percentages used to determine the ratio of FoxP3 percentages 
in transduced and untransduced cells were derived from CD4
+Vα2+GFP+ (transduced) or 
CD4
+Vα2+GFP- (untransduced) gates. A value of 1 indicates little difference in FoxP3% between 
the untransduced and transduced cell populations. (C) Polyclonal CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-
GFP 
and CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
naïve cells were sorted and activated in polarizing 
conditions (see methods). Cells were analyzed for FoxP3
IRES-GFP 
expression after 3 days in 
culture. Summary plots and representative FACs plots are gated on CD4
+
 cells. Statistical 
significance was calculated using Student T test, *P<0.05, ** P<0.005, *** P ≤0.001, **** 
P≤0.0001; Error bars = ±SEM.  (D) Log2 expression values of transcription factors that are 
repressed by Eomes in FoxP3
hi
CD25
+
 and FoxP3
-
CD25
+
 cells relative to DN cells. Gene 
expression data generated as described in Figure 1. Blue dots indicate transcription factors whose 
expression are 2-fold or greater and reach statistical significance by FDR-adjusted student T test 
(p<0.05) 
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Figure 3.6 
 
 
Figure 3.6: Eomes deficient cells sustain enhanced Treg differentiation in inflammatory 
contexts. (A-B) Polyclonal CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP  
and CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
naïve cells (CD45.2: CD4
+
FoxP3
-
CD44
lo
CD62L
hi
) and wild-type congenically 
marked Treg cells (CD45.1/2: CD4
+
FoxP3
IRES-GFP+
) were sorted. Either 2.5x10
5 
CD4-Cre
+
 
Eomes
 fl/fl 
FoxP3
IRES-GFP   
CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
were mixed with 0.5x10
5 
Treg cells 
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and retro-orbitally transferred into Rag
-/-
 hosts (replicates = 2, n = 5). MLN and colon were 
harvested at 18 days after transfer when mice lost 30% of their weight. 5x10
6 
cells were cultured 
with PMA, Ionomycin, brefeldin, and monensin for 3 hours before intracellular cytokine 
staining. Summary plots and representative FACs plots are gated on CD4
+
CD3
+
CD45.2
+
 (sorted 
naïve cells) for FoxP3
IRES-GFP 
analysis or CD4
+
CD3
+
CD45.2
+
FoxP3
IRES-GFP-
 for evaluation of 
IFNγ and IL-17A production. Statistical significance was calculated using Student T test, ** 
P<0.005, ns = not significant; Error bars = ±SEM.   
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Figure 3.7 
 
 
Figure 3.7: Eomes restrains peripheral Treg development by slowing the rate of FoxP3 
expression. (A)  CT6 CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP  
and CT6 CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP  
naïve cells were sorted, labeled with Cell-Trace-Violet and transferred (1x10
5
 
cells) into wild-type hosts as described in Figure 4 (replicates = 2, n = 3-4). dMLN was harvested 
and Tg cells analyzed 1 week after transfer. Cells undergoing 0 divisions or 1-4 divisions were 
distinguished based on peaks of Cell-Trace-Violet dilution, with the first peak indicating cells 
that have not yet divided. FoxP3
IRES-GFP 
and CD25
+
 percentages are based on congenically 
marked CD4
+
Va2
+ 
or CD4
+
Va2
+ 
FoxP3
IRES-GFP+ 
cells in populations of cells distinguished by 
their number of divisions. (B) CT6 CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP  and 
CT6 CD4-Cre
-
 Eomes
 
fl/fl 
FoxP3
IRES-GFP  
naïve cells were sorted and retro-orbitally transferred into wild-type hosts as 
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described above, with Tg cells analyzed from the dMLN, MLN, and Spleen (replicates = 3, n = 
3-4). Representative control and experimental groups from littermate controls were analyzed at 
1, 2, or 3 weeks post transfer. Statistical significance was calculated using Student T test, 
*P<0.05, ** P<0.005, *** P ≤0.001, **** P≤0.0001, ns = not significant; Error bars = ±SEM.   
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Figure 3.8 
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Figure 3.8: Gene set enrichment analysis of developing populations of monoclonal Tg cells. 
(A-B) GSEA analysis was performed on FoxP3
-
CD25
+
, DN, and FoxP3
hi
CD25
+
 populations as 
described in Figure 3.2. (B) Heat map illustrates expression patterns of genes from Reactome’s 
Interferon alpha/beta signaling dataset ranked by GSEA’s default signal-to-noise metric. (C) 
CD45.2 CT6 CD4-Cre
+
IFNAR
 fl/fl 
FoxP3
IRES-GFP  
and
 
CT6 CD4-Cre
-
 IFNAR
 fl/fl 
FoxP3
IRES-GFP  
naïve cells were sorted and 1.5x10
5 
naïve cells (CD44
lo
CD62L
hi
) retro-orbitally injected into 
CD45.1 wild-type hosts. Tg cells were analyzed from dMLN 1 week after transfer. Summary 
plot of FoxP3 percentages gated on congenically marked CD4
+
Va2
+
 cells. (D) CT6 FoxP3
IRES-
GFP
 CNS1
-/-
 naïve Tg cells were sorted and transferred into 6-10 CD45.1 wild-type hosts. DN and 
FoxP3
-
CD25
+
 fractions, as depicted in figure 1, were sorted and submitted for gene-chip 
hybridization as described in Figure 1 (replicate = 1, n = 3). Log2 fold values of Treg signature 
genes in the dataset are depicted. Purple dots signify genes that exhibited a 10-fold or more 
enrichment in the FoxP3
-
CD25
+
 fraction of CNS1
-/- 
Tg cells.  
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Figure 3.9 
 
Figure 3.9:  Eomes inhibition of FoxP3 is cell-intrinsic. (A) CT6 CD4-Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP  and 
CT6 CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP  
naïve cells were sorted and transferred 
into congenically marked wild-type hosts. dMLNs were harvested 1 week after transferred and 
intra-cellularly stained for Eomes expression. (B) Polyclonal wild-type naïve cells (CD4
+
FoxP3
-
CD44
lo
CD62L
hi
) were sorted and activated in Th0 conditions (see methods). Cells were 
retrovirally spinfected with an Eomes-GFP overexpression construct or empty Mig-GFP 
construct, cultured for 3 days, and intracellularly stained for Eomes and FoxP3 (replicates = 2, n 
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= 1-2).  Representative FACs plots and summary plots of FoxP3
 
percentages of the transduced 
and untransduced cells were either gated on CD4
+
GFP
+
 or CD4
+
GFP
- 
cells. (C) Polyclonal CD4-
Cre
+
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
and CD4-Cre
-
 Eomes
 fl/fl 
FoxP3
IRES-GFP 
naïve cells were sorted and 
activated in Th0 conditions (see method) and cultured for 3 days (replicates = 2, n = 1-2). 
FoxP3
IRES-GFP
 percentages of summary and representative FACs plots were gated on CD4
+
 cells. 
Statistical significance was calculated using Student T test, *P<0.05, ** P<0.005; Error bars = 
±SEM. 
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Figure 3.10 
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Figure 3.10: Transcription factor overexpression in CT6 cells induces biologically relevant 
phenotypes. (A) Schematic of retroviral transduction protocol for analysis of overexpression 
constructs. (A-E) CT6-FoxP3
IRES-Thy1.1
 naïve Tg cells were sorted, in vitro activated, and 
retrovirally transduced with overexpression constructs on the Mig-GFP backbone as described in 
Figure 4 (replicates = 2, n = 1-2).  Summary plots and representative FACs plots are of Tg cells 
isolated from the dMLN 1 week after transfer. FoxP3
IRES-Thy1.1+ 
percentages were gated on 
CD4
+Vα2+GFP+ or CD4+Vα2+GFP- cells. Statistical significance was calculated using Student T 
test, ** P<0.005; Error bars = ±SEM. (C) FACs plot illustrating CXCR3 expression in Tg cells 
transduced with an IRF8 overexpression vector or an empty Mig-GFP vector (replicates = 1, n = 
3). Cells were gated on CD4
+Vα2+GFP+.  
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Figure 3.11 
 
 
 
Figure 3.11: Eomes restraint of FoxP3 in CT6 cells extends to non-intestinal sites. (A-B) 
Spleen data are from experiments described in Figure 3.4. Shown are summary plots of 
FoxP3
IRES-GFP 
expression, CD25 expression of Tg cells, and proliferated cells (2 or more cell 
divisions based on Cell-Trace Violet dilution) isolated from the spleen 1 week after transfer. 
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Representative FACs plots are of FoxP3
IRES-GFP 
expression. Cells were gated on congenically 
marked CD4
+Vα2+ TCR Tg cells. Graphs are percentages of all Tg cells, FoxP3IRES-GFP+ or 
FoxP3
IRES-GFP- 
fractions of Tg cells. Statistical significance was calculated using Student T test 
*** P≤0.001, ns = not significant; Error bars = ±SEM. 
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Figure 3.12 
 
Figure 3.12: FoxP3 restraint by Eomes is not due to universal properties of the Tbx 
domain. (A) CT6-FoxP3
IRES-GFP 
naïve Tg cells were sorted and Tbx constructs overexpressed as 
described in Figure 3.4 and Supplemental Figure 3 (replicates = 3, n = 2). Summary plots and 
representative FACs plots are of Tg cells isolated from the dMLN 1 week after transfer. 
FoxP3
IRES-Thy1.1+ 
percentages were gated on CD4
+Vα2+GFP+ or CD4+Vα2+GFP- cells. (B) Log2 
fold change values in FoxP3
-
CD25
+
, FoxP3
hi
CD25
+
, and DN CT6 Tg cells of transcription 
factors activated by Eomes. Green dots denote genes that reached statistical significance based 
on Student T test (FDR adjusted P<0.05).  
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Figure 3.13 
 
 
Figure 3.13:  Eomes deficient polyclonal CD4
+
 T cells induce disease less effectively than 
wild-type polyclonal T cells. (A) Weight loss of hosts for experiment depicted in Figure 3.6.  
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Figure 3.14 
 
 
Figure 3.14: Eomes deficient monoclonal cells at later timepoints. (A) Representative 
summary and FACs plots of experiment performed in Figure 3.7B.  Shown are summary plots of 
FoxP3
IRES-GFP 
expression, CD25 expression of Tg cells, and CXCR3 expression isolated from the 
dMLN node 3 weeks after transfer. Representative FACs plots are of FoxP3
IRES-GFP 
expression. 
Cells were gated on congenically marked CD4
+Vα2+ TCR Tg cells. Graphs are percentages of all 
Tg cells or FoxP3
IRES-GFP+
 fractions of Tg cells. Statistical significance was calculated using 
Student T test, *P<0.05, ** P<0.005, *** P ≤0.001, **** P≤0.0001; ns = not significant. Error 
bars = ±SEM. 
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Chapter 4: Conclusions and Future Directions 
Part 1: pTreg development during intestinal inflammation 
 Environmental sources of inflammation have been correlated with increased incidence of 
intestinal diseases (172–174). A plausible hypothesis for this correlation is that intestinal insults 
impair tolerogenic responses that maintain gut homeostasis in the face of consistent insult by 
commensal, food, and self-antigen. Over time, sub-optimal tolerance mechanisms may no longer 
restrain heightened effector responses, resulting in aberrant immune responses to commensal 
antigens and the manifestation of intestinal diseases.  It has been demonstrated that effector T 
cell responses can be generated against commensal bacteria during inflammation caused by 
Toxoplasma gondii and DSS mediated colitis, which generate Th1 and Th17 cells, respectively 
(133). However, the impact of inflammation on pTreg cells has remained relatively 
uninvestigated.  
 Treg cells are well-accepted to be critical for tolerance to self-antigens, and pTreg cells 
are emerging to serve a unique function for maintaining tolerance to commensal antigens along 
mucosal surfaces (13, 22, 175). Commensal bacteria actively induce the generation of pTreg 
cells, potentially as a mechanism to prevent effector responses, which would result in damage 
both to the host and the bacteria (13, 14, 18). Work in our laboratory demonstrated a proof of 
principle--developing pTreg cells, utilizing TCR Tg cells specific to Helicobacter antigen, can 
aberrantly differentiate into Th17 cells during extreme insult in the form of DSS and α-IL10R 
treatment (18). Thus, it is possible that inflammation, which elevates effector T cell responses in 
the gut, concurrently drives disease by diverting the commensal-specific pTreg cells into pro-
inflammatory effector cells.  
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 My thesis work evaluated whether this observation is universal or relevant in select 
contexts by evaluating multiple commonly used models of colitis and infections. Surprisingly, 
pTreg development against Helicobacter was largely resilient to a spectrum of intestinal 
inflammation, which included models driven by elevated innate immune responses and/or 
effector adaptive responses. Given that Th1, Th2, and Th17 cytokines can block FoxP3 
expression in vitro, a digestible notion is that effector polarizing cytokines heightened in 
inflamed environments would overwhelm Treg signals and divert them to effector fates. 
Although the ability of effector cytokines to antagonize FoxP3 is not a point of debate, the 
observations from this study brings into question the in vivo, physiological relevance of these in 
vitro derived conclusions. Rather, the maintenance of pTreg generation against Helicobacter 
antigen during multiple different forms of inflammation suggests that pTreg development is 
largely sequestered from inflammatory cytokines elevated in gut tissue. Rather than being 
diverted to effector fates, the TCR Tg cells exhibited signs of impaired activation. Therefore, the 
environmental changes caused by intestinal infections may largely impair the strength and 
efficiency of pTreg development by modulating the levels of antigen presentation.  
 It is important to note that prior interrogation of effector cytokines’ influence on in vivo 
pTreg development were done in polyclonal contexts or with OT-II transgenic cells that require 
the administration of exogenous OVA antigen (132). Polyclonal studies have provided insight on 
how Treg populations are affected by intestinal inflammation, including the expansion of Treg 
cells in experimental models of colitis (176), or the expression of genes that enhance their 
suppressive function during insult caused by Treg depletion (54, 55). However, these studies 
were unable to distinguish the effects of inflammation on pre-existing, mature Treg cells from 
the effects on developing, immature Treg cells. Additionally, studying pTreg cells generated by 
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OT-II cells encountering OVA antigen does not accurately address the question of how pTreg 
cells generated against homeostatically accessible antigen is affected by inflammation. This is a 
critical distinction to make, given that failure to develop tolerance to antigens that are readily 
accessible can lead to sustained immune responses and long-term damage. In contrast, 
exogenously introduced antigens are eventually cleared from the host and are likely to induce 
only a short-term immune response. Our lab’s monoclonal approach against Helicobacter 
antigen circumvented these limitations and clarified that pTreg development against 
homeostatically accessible commensal antigen can persist during intestinal inflammation.  
 Given the comprehensive nature of this study, we were able to identify one model of 
intestinal inflammation that impaired pTreg development and identified key characteristics that 
distinguishes it from other models. In DSS and HFD, naïve CT2 and CT6 Tg cells responded 
differently, with CT2 Tg cells maintaining their Treg differentiation capabilities and CT6 Tg 
cells exhibiting reduced frequencies of FoxP3 expression. The phenotypes of CT2 and CT6 Tg 
cells were observed in the polyclonal Treg population based on TCR repertoire analysis, showing 
that the inflammatory environment caused by DSS and HFD does not globally inhibit pTreg 
development. It further supports our monoclonal observations— inflammation may impair pTreg 
selection by altering the delivery or presentation of antigens of different subsets of T cell clones. 
Both the mucosal and lumen bacterial communities in DSS and HFD treated mice contained a 
bloom of Enterobacter species and were generally more similar in bacteria composition than the 
mucosal and lumen in healthy mice. This was unique to DSS and HFD, suggesting that models 
that induce dramatic antigenic changes can render pTreg development vulnerable to disruption.  
 
Future directions 
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Why certain pTreg TCR subsets, and not others, are affected by DSS and HFD remains a 
question that is not fully addressed. In this study, we present the possibility that differences are in 
part influenced by 1) T cell intrinsic factors, and 2) antigen-intrinsic factors. Specifically, 1) the 
degree of cross-reactivity of a TCR and 2) the availability of antigens for presentation to cross-
reactive TCRs.  TCR cross-reactivity is a double-edged sword, facilitating effective clearance of 
invading pathogens and tolerance, but may also lead to autoimmune responses and breaches in 
tolerance (177, 178). TCR cross reactivity in effector T cell populations ensures effective 
immune responses against invading pathogens by maximizing the chance for reactivity and 
preventing the pathogen from escaping through mutations (178). In the context of autoimmune 
diseases, effector TCRs are weakly reactive to many autoantigens, and can launch weak 
responses against antigens they cross-react with when Treg mediated suppression is impaired 
(178, 179). Lastly, viral infections with epitopes that are molecularly similar to self-antigen are 
thought to generate memory effector T cell responses that later react to self-antigen (177).  
Although cross-reactivity of Treg TCRs has been less explored, Treg TCRs exhibit 
increased TCR diversity and display a broad range of affinities to antigen (35, 37, 180). These 
features support the notion that Treg TCR repertoires are broad and highly sensitive to self-
antigens to maximize the effector responses they can suppress. Philosophically, it would be 
logical that cross-reactivity can heighten Treg TCR responses to self-antigen and promote 
tolerance against both self and bacteria antigen. CT6 Tg cells react to Clostridium antigen (21), 
and were more recently found to react robustly against Helicobacter antigen (18), presumably 
due to higher affinity. We further found that CT6 Tg cells weakly react to Enterobacter antigen, 
opening up the possibility that CT6 Tg cells are reacting to Enterobacter antigen in non-Treg 
inducing environments. Notably, CT2 has not demonstrated any reactivity to other tested bacteria 
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antigen. Enterobacter antigen, but not Helicobacter typhlonius antigen, can compete with 
Helicobacter apodemus for TCR stimulation. This supports the theory that antigens can divert 
CT6 cells away from Helicobacter apodemus antigens and stimulate them in a non-Treg 
inducing environment.  This parallels studies evaluating the relationship between viral and self-
antigen—new antigens introduced during disease pathogenesis may drive aberrant T cell 
responses against homeostatically available self or non-self-antigens. Thus, TCR specificity may 
determine the outcome of pTreg development in part, due to the TCR’s level of cross-reactivity 
to antigens introduced by the inflammatory model. However, studies validating TCR reactivity to 
multiple commensal bacteria needs to be established in vivo using peptides isolated from 
multiple bacteria species. It would also be interesting to investigate the properties of these 
peptides to determine if there are molecular features, common to certain antigens expressed by 
multiple species of bacteria, which promote their stimulation of adaptive immune responses.  
 CT2 and CT6 Tg cells are unique examples of T cell clones that adopt a single fate in 
vivo. Transduction of the CT2 and CT6 TCR into T cells transgenic for a TCR that does not 
recognize any endogenous mouse epitopes, is sufficient to direct the cells to develop into pTreg 
cells. However, the extent to which CT2 and CT6 Tg cells are representative of a polyclonal 
Treg population has not been thoroughly investigated. TCR repertoire analysis shows that Treg 
TCR populations have TCRs uniquely found in Treg repertoires, but also contain TCRs that 
overlap in effector TCR repertoires. Furthermore, libraries of Treg TCRs have not been 
thoroughly tested to understand if a majority of Treg TCRs can direct cells into Treg fates, or if 
their occurrence in the Treg population is in response to variables that are independent of the 
TCR.  Determining the proportion of TCRs that direct predominantly Treg fates  would be 
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valuable for elucidating why certain TCRs direct Treg fates, others TCRs multiple fates, and why 
some TCRs are more susceptible to the volatility caused by intestinal insult.  
 Lastly, the cumulative observations of CT2 and CT6 Tg cell differentiation in multiple 
inflammatory models demonstrates that there is focused sequestration of Treg and Teffector 
inducing signals in the environment of TCR:pMHC engagement. pTreg differentiation is largely 
preserved in inflamed tissues. In the case of a defect, the defect was limited to one TCR Tg 
clone. This suggests that firstly, there are remarkable protective mechanisms in place that cannot 
be perturbed even by severe intestinal insult and secondly, that there undefined mechanisms that 
ensure the separation of these signals. This is consistent with our findings that showed strong 
separation of effector and Treg TCR repertoires. In particular, Th1 and Treg repertoires were 
most distinct, which is consistent with the robust blockade of FoxP3 by Th1 cytokines. The 
evidence is suggestive that inflammatory cytokine signals caused by environmental insults alone 
is likely not sufficient to abrogate Treg mediated suppression. Thus, failures of Treg responses 
during inflammation are unlikely to be a factor that drives autoimmune disease, but may play a 
more nuanced role in modulating disease severity. The cellular and molecular mechanisms 
preserving the sequestration of effector and regulatory T cells would be interesting to clarify in 
order to 1) further our understanding of in vivo regulators of CD4
+ 
T cell differentiation and 2) 
how these processes are endangered by risk factors for autoimmune diseases. 
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Part 2: Transcriptional profiles early and late developing in vivo pTreg cells 
 Treg development is driven by a highly orchestrated process of inducing and suppressing 
the appropriate gene networks to drive the development of a tolerogenic phenotype. 
Transcriptional regulation of FoxP3 in particular, has been an intensely studied area. Epigenetic 
regions and numerous transcription factors facilitate Treg development by inducing FoxP3, 
antagonizing effector fates, or stabilizing FoxP3 expression (12, 103, 107, 108). Additionally, 
effector transcription factor expression can antagonize FoxP3 (47, 48, 143), although the precise 
mechanisms of blockade remain unknown. One of the challenges of investigating transcriptional 
networks is that transcription factors are pleiotropically expressed in multiple cell types. Thus, 
their interrogation is restricted to in vitro studies or in vivo studies using mouse models with 
conditional deletions.  
 In vitro studies have proven invaluable for deciphering molecular mechanisms, but are 
limited due to the exclusion of additional signals in vivo that may influence gene transcription. 
This is particularly relevant for Treg differentiation studies, given that the transcriptional profiles 
of Treg cells vary from tissue to tissue (159), supporting that Treg cells in vivo process signals 
other than Tgfβ. Conditional knockouts limit gene deficiencies to T cells or Treg cells. However, 
it remains difficult to exclude cell-extrinsic effects, given that deficiencies in the T cells 
themselves can have an impact on the environment which feeds back into transcriptional changes 
in the T cells themselves. Thus, assessing the transcriptional profiles of in vivo developing Treg 
cells is valuable for efforts to understand the in vivo relevance of identified transcriptional 
regulators and identify additional networks or factors that may modulate Treg differentiation.   
 My thesis work profiles the transcriptional landscape of monoclonal Tg cells that develop 
into pTreg cells in homeostatic conditions. Other monoclonal models of pTreg induction direct 
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cells to become both effector and Treg cells, including the OVA: OTII model of oral tolerance 
(132). CT6 Tg cells in contrast, become predominantly FoxP3
+
 with percentages increasing over 
time of development (36). FoxP3
- 
CT6 Tg cells do not exhibit signs of effector cytokine 
production in homeostatic conditions (36). Thus, the feasibility of isolating monoclonal 
populations of CT6 Tg cells provided a unique opportunity to capture pure, transcriptional 
snapshots of cells that are being activated in in vivo Treg differentiation conditions.  
 Monoclonal CT6 Tg cells underwent a burst of transcriptional activity prior to FoxP3 
expression, consistent with the fact that T cells undergo significant morphological and metabolic 
changes as they are activated and clonally expand. Genes enriched in the early activated 
populations of Tg cells were positively enriched for Treg signature genes that can be amplified 
by FoxP3. This has been suggested by previous work, which found significant overlap between 
Treg signature genes and the activation profiles of both in vivo and in vitro activated CD4
+
 T 
cells (109). These differentially expressed genes however, were significantly distinct from the 
Treg signature genes enriched in FoxP3
+
 fractions of monoclonal cells. Therefore, a majority of 
the differentially expressed genes do not sustain their differential expression by FoxP3 
upregulation. Speculatively, this could mean that that a majority of the genes are generalized to T 
cell activation and not Treg differentiation. Alternatively, it can also mean that a significant 
number of genes need to be repressed in order to allow for Treg differentiation to continue, 
consistent with studies that found FoxP3 to operate mainly as a gene repressor (111).   
In our analysis, we did not observe the differential expression of genes reported to 
promote Treg development by suppressing effector fates. This brings into question the extent to 
which the function of these transcription factors are cell-intrinsic, and/or the relevance of their 
function for colon Treg cells in vivo. However, Nr4a family of transcription factors were 
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upregulated in early activated cells, but downregulated in FoxP3
+ 
cells. This supports published 
findings that Nr4a family of transcription factors are regulating the expression of FoxP3 by 
modulating transcriptional activity within the FoxP3 locus.  
In early activated Tg cells, Eomes was the transcription factor whose expression levels 
was most notably enriched. Eomes can restrict FoxP3 in a cell-intrinsic fashion and serve clear 
effector function in CD8
+ T cells and NK cells by regulating IFNγ production.  However, its role 
in CD4
+
 cells has remained murky. It can negatively regulate effector cells by controlling IL-5 
production by Th2 cells (181), and negatively regulates Th17 development (91), but can also 
enhance effector functions by cooperating with Tbet to amplify IFNγ production (126, 127). 
Thus, it is unclear what determines whether Eomes exerts both tolerance and effector promoting 
functions in CD4
+ 
T cells. In our study, Eomes was the transcription factor most highly enriched 
in early activated cells relative to FoxP3
+
 Tg cells. We further validated that Eomes can impair 
the efficiency of FoxP3 upregulation by CT6 Tg cells, but is never co-expressed with FoxP3. 
Thus, we show that Eomes-mediated mechanisms for regulating FoxP3 are restricted to cells 
during early, and not late, developmental stages upon TCR engagement. 
 Interestingly, Eomes can be downregulated by Smad-independent Tgfβ signaling in CD4+ 
T cells (91), promoting Th17 differentiation and development. Thus, it is possible that Eomes is 
universally upregulated in activated T cells upon TCR engagement, and differentiation signals 
modulate either its sustained expression or loss of expression. In the case of Treg cells, it is 
likely that Eomes is downregulated when Tgfβ signaling is initiated, ensuring the suppression of 
its FoxP3-repressive profile.  
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Future directions 
 Cumulatively, these findings clarify the in vivo relevance of transcriptional regulators 
FoxP3, including Eomes.  The absence of transcription factors that antagonize effector T cell 
fates brings to light the possibility that these transcriptional regulators may need to be triggered, 
and are thus, absent in homeostatic conditions. Thus, it is interesting to question whether the 
early activated cells undergoing significant transcriptional changes have already committed to 
becoming FoxP3
+
 cells, or are adopting the proposed “Th0” state that remains pluripotent. If 
transcriptional regulators that antagonize alternative fates are indeed upregulated by effector 
signals to promote Treg differentiation, it could suggest that these early activated cells are 
primed to adopt Treg fates prior to FoxP3 induction. Epigenetic profiling of early activated cells 
would be valuable to assess the accessibility of Treg vs. effector genes in these FoxP3
-
 activated 
cells. Interrogating these questions would complement the observations in part 1 of this thesis, 
which observed resilience of Treg cells against inflammatory signals. It would be interesting to 
understand if cell-intrinsic mechanisms that preserve Treg differentiation during inflammation 
are contributing to the preservation of CT2, but not CT6 Tg differentiation during DSS and HFD. 
 
 
 
 
 
 
 
 
 
 
124 
 
References 
 
1. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development 
and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330–336. 
2. Gavin, M. A., J. P. Rasmussen, J. D. Fontenot, V. Vasta, V. C. Manganiello, J. A. Beavo, and 
A. Y. Rudensky. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 
445: 771–775. 
3. Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. 
Rudensky. 2005. Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor 
Foxp3. Immunity 22: 329–341. 
4. Lin, W., D. Haribhai, L. M. Relland, N. Truong, M. R. Carlson, C. B. Williams, and T. A. 
Chatila. 2007. Regulatory T cell development in the absence of functional Foxp3. Nat. Immunol. 
8: 359–368. 
5. Ramsdell, F., and S. F. Ziegler. 2014. FOXP3 and scurfy: how it all began. Nat. Rev. Immunol. 
14: 343–349. 
6. Zheng, Y., and A. Y. Rudensky. 2007. Foxp3 in control of the regulatory T cell lineage. Nat. 
Immunol. 8: 457–462. 
7. RUSSELL, W. L. 1951. X-ray-induced mutations in mice. Cold Spring Harb. Symp. Quant. 
Biol. 16: 327–36. 
8. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S.-A. Yasayko, J. E. 
Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. Disruption of a new 
forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the 
scurfy mouse. Nat. Genet. 27: 68–73. 
9. Ochs, H. D., C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. 
Whitesell, T. E. Kelly, F. T. Saulsbury, and P. F. Chance. 2001. The immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. 
Nat. Genet. 27: 20–21. 
10. Powell, B. R., N. R. M. Buist, C. . F.R.C.P., and P. Stenzel. 1982. An X-linked syndrome of 
diarrhea, polyendocrinopathy, and fatal infection in infancy. J. Pediatr. 100: 731–737. 
11. Kim, J. M., J. P. Rasmussen, and A. Y. Rudensky. 2007. Regulatory T cells prevent 
catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8: 191–197. 
12. Zheng, Y., S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, and A. Y. Rudensky. 2010. 
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 
463: 808–12. 
13. Atarashi, K., T. Tanoue, T. Shima, A. Imaoka, T. Kuwahara, Y. Momose, G. Cheng, S. 
Yamasaki, T. Saito, Y. Ohba, T. Taniguchi, K. Takeda, S. Hori, I. I. Ivanov, Y. Umesaki, K. 
Itoh, and K. Honda. 2011. Induction of colonic regulatory T cells by indigenous Clostridium 
species. Science 331: 337–41. 
125 
 
14. Atarashi, K., T. Tanoue, K. Oshima, W. Suda, Y. Nagano, H. Nishikawa, S. Fukuda, T. 
Saito, S. Narushima, K. Hase, S. Kim, J. V Fritz, P. Wilmes, S. Ueha, K. Matsushima, H. Ohno, 
B. Olle, S. Sakaguchi, T. Taniguchi, H. Morita, M. Hattori, and K. Honda. 2013. Treg induction 
by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500: 
232–6. 
15. Smith, P. M., M. R. Howitt, N. Panikov, M. Michaud, C. A. Gallini, M. Bohlooly-Y, J. N. 
Glickman, and W. S. Garrett. 2013. The microbial metabolites, short-chain fatty acids, regulate 
colonic Treg cell homeostasis. Science 341: 569–73. 
16. Arpaia, N., C. Campbell, X. Fan, S. Dikiy, J. van der Veeken, P. deRoos, H. Liu, J. R. Cross, 
K. Pfeffer, P. J. Coffer, and A. Y. Rudensky. 2013. Metabolites produced by commensal bacteria 
promote peripheral regulatory T-cell generation. Nature 504: 451–5. 
17. Furusawa, Y., Y. Obata, S. Fukuda, T. a Endo, G. Nakato, D. Takahashi, Y. Nakanishi, C. 
Uetake, K. Kato, T. Kato, M. Takahashi, N. N. Fukuda, S. Murakami, E. Miyauchi, S. Hino, K. 
Atarashi, S. Onawa, Y. Fujimura, T. Lockett, J. M. Clarke, D. L. Topping, M. Tomita, S. Hori, 
O. Ohara, T. Morita, H. Koseki, J. Kikuchi, K. Honda, K. Hase, and H. Ohno. 2013. Commensal 
microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 
446–50. 
18. Chai, J. N., Y. Peng, S. Rengarajan, B. D. Solomon, T. L. Ai, Z. Shen, J. S. A. Perry, K. A. 
Knoop, T. Tanoue, S. Narushima, K. Honda, C. O. Elson, R. D. Newberry, T. S. Stappenbeck, A. 
L. Kau, D. A. Peterson, J. G. Fox, and C.-S. Hsieh. 2017. Helicobacter species are potent drivers 
of colonic T cell responses in homeostasis and inflammation. Sci. Immunol. 2: eaal5068. 
19. Round, J. L., S. M. Lee, J. Li, G. Tran, B. Jabri, T. a Chatila, and S. K. Mazmanian. 2011. 
The Toll-like receptor 2 pathway establishes colonization by a commensal of the human 
microbiota. Science 332: 974–7. 
20. Round, J. L., and S. K. Mazmanian. 2010. Inducible Foxp3 + regulatory T-cell development 
by a commensal bacterium of the intestinal microbiota. 2010. 
21. Lathrop, S. K., S. M. Bloom, S. M. Rao, K. Nutsch, C.-W. Lio, N. Santacruz, D. a Peterson, 
T. S. Stappenbeck, and C.-S. Hsieh. 2011. Peripheral education of the immune system by colonic 
commensal microbiota. Nature 478: 250–4. 
22. Josefowicz, S. Z., R. E. Niec, H. Y. Kim, P. Treuting, T. Chinen, Y. Zheng, D. T. Umetsu, 
and A. Y. Rudensky. 2012. Extrathymically generated regulatory T cells control mucosal TH2 
inflammation. Nature 482: 395–399. 
23. Frank, D. N., and N. R. Pace. 2008. Gastrointestinal microbiology enters the metagenomics 
era. Curr. Opin. Gastroenterol. 24: 4–10. 
24. Ley, R. E., M. Hamady, C. Lozupone, P. J. Turnbaugh, R. R. Ramey, J. S. Bircher, M. L. 
Schlegel, T. A. Tucker, M. D. Schrenzel, R. Knight, and J. I. Gordon. 2008. Evolution of 
Mammals and Their Gut Microbes. Science (80-. ). 320: 1647–1651. 
25. Round, J. L., and S. K. Mazmanian. 2009. The gut microbiota shapes intestinal immune 
responses during health and disease. Nat. Rev. Immunol. 9: 313–23. 
26. Macpherson, A. J., and N. L. Harris. 2004. Opinion: Interactions between commensal 
126 
 
intestinal bacteria and the immune system. Nat. Rev. Immunol. 4: 478–485. 
27. Ivanov, I. I., R. D. L. Frutos, N. Manel, K. Yoshinaga, D. B. Rifkin, R. B. Sartor, B. B. 
Finlay, and D. R. Littman. 2008. Specific microbiota direct the differentiation of IL-17-
producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4: 337–49. 
28. Ivanov, I. I., K. Atarashi, N. Manel, E. L. Brodie, T. Shima, U. Karaoz, D. Wei, K. C. 
Goldfarb, C. a Santee, S. V Lynch, T. Tanoue, A. Imaoka, K. Itoh, K. Takeda, Y. Umesaki, K. 
Honda, and D. R. Littman. Induction of intestinal Th17 cells by segmented filamentous bacteria. 
Cell 139: 485–98. 
29. Atarashi, K., T. Tanoue, M. Ando, N. Kamada, Y. Nagano, S. Narushima, W. Suda, A. 
Imaoka, H. Setoyama, T. Nagamori, E. Ishikawa, T. Shima, T. Hara, S. Kado, T. Jinnohara, H. 
Ohno, T. Kondo, K. Toyooka, E. Watanabe, S. Yokoyama, S. Tokoro, H. Mori, Y. Noguchi, H. 
Morita, I. I. Ivanov, T. Sugiyama, G. Nuñez, J. G. Camp, M. Hattori, Y. Umesaki, and K. Honda. 
2015. Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. Cell 163: 367–
380. 
30. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 Family 
Cytokines and the Expanding Diversity of Effector T Cell Lineages. Annu. Rev. Immunol. 25: 
821–852. 
31. Yang, Y., M. B. Torchinsky, M. Gobert, H. Xiong, M. Xu, J. L. Linehan, F. Alonzo, C. Ng, 
A. Chen, X. Lin, A. Sczesnak, J.-J. Liao, V. J. Torres, M. K. Jenkins, J. J. Lafaille, and D. R. 
Littman. 2014. Focused specificity of intestinal TH17 cells towards commensal bacterial 
antigens. Nature 510: 152–6. 
32. Atarashi, K., W. Suda, C. Luo, T. Kawaguchi, I. Motoo, S. Narushima, Y. Kiguchi, K. 
Yasuma, E. Watanabe, T. Tanoue, C. A. Thaiss, M. Sato, K. Toyooka, H. S. Said, H. Yamagami, 
S. A. Rice, D. Gevers, R. C. Johnson, J. A. Segre, K. Chen, J. K. Kolls, E. Elinav, H. Morita, R. 
J. Xavier, M. Hattori, and K. Honda. 2017. Ectopic colonization of oral bacteria in the intestine 
drives TH1 cell induction and inflammation. Science 358: 359–365. 
33. Cebula, A., M. Seweryn, G. A. Rempala, S. Pabla, R. A, McIndoe, T. L. Denning, L. Bry, P. 
Kraj, P. Kisielow, and L. Ignatowicz. 2013. Thymus-derived regulatory T cells contribute to 
tolerance to commensal microbiota. Nature 497: 258–262. 
34. Kullberg, M. C., D. Jankovic, P. L. Gorelick, P. Caspar, J. J. Letterio, A. W. Cheever, and A. 
Sher. 2002. Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-
induced colitis. J. Exp. Med. 196: 505–15. 
35. Lathrop, S. K., N. A. Santacruz, D. Pham, J. Luo, and C.-S. Hsieh. 2008. Antigen-specific 
peripheral shaping of the natural regulatory T cell population. J Exp Med. 205: 3105–3117. 
36. Nutsch, K., J. N. Chai, T. L. Ai, R.-G. Emilie, T. Feehley, C. R. Nagler, and C.-S. Hsieh. 
2016. Rapid and Efficient Generation of Regulatory T Cells to Commensal Antigens in the 
Periphery. Cell Rep. 17: 206–220. 
37. Solomon, B. D., and C.-S. Hsieh. 2016. Antigen-Specific Development of Mucosal 
Foxp3+RORγt+ T Cells from Regulatory T Cell Precursors. J. Immunol. 197: 3512–3519. 
38. Honda, K., and D. R. Littman. 2016. The microbiota in adaptive immune homeostasis and 
127 
 
disease. 535: 75–84. 
39. Round, J. L., S. M. Lee, J. Li, G. Tran, B. Jabri, T. A. Chatila, and S. K. Mazmanian. 2011. 
The Toll-like receptor 2 pathway establishes colonization by a commensal of the human 
microbiota. Science 332: 974–7. 
40. Nikolich-Žugich, J., M. K. Slifka, and I. Messaoudi. 2004. The many important facets of T-
cell repertoire diversity. Nat. Rev. Immunol. 4: 123–132. 
41. Koh, W.-P., E. Chan, K. Scott, G. McCaughan, M. France, and B. Fazekas de St. Groth. 
1999. TCR-Mediated Involvement of CD4+ Transgenic T cells in Spontaneous Inflammatory 
Bowel Disease in Lymphopenic Mice. J Immunol 162: 7208–7216. 
42. Mizoguchi, A., E. Mizoguchi, L. J. Saubermann, K. Higaki, R. S. Blumberg, and A. K. Bhan. 
2000. Limited CD4 T-cell diversity associated with colitis in T-cell receptor α mutant mice 
requires a T helper 2 environment. Gastroenterology 119: 983–995. 
43. Föhse, L., J. Suffner, K. Suhre, B. Wahl, C. Lindner, C.-W. Lee, S. Schmitz, J. D. Haas, S. 
Lamprecht, C. Koenecke, A. Bleich, G. J. Hämmerling, B. Malissen, S. Suerbaum, R. Förster, 
and I. Prinz. 2011. High TCR diversity ensures optimal function andhomeostasis of Foxp3 
+
 
regulatory Tcells. Eur. J. Immunol. 41: 3101–3113. 
44. Milner, J. D., J. M. Ward, A. Keane-Myers, and W. E. Paul. 2007. Lymphopenic mice 
reconstituted with limited repertoire T cells develop severe, multiorgan, Th2-associated 
inflammatory disease. Proc. Natl. Acad. Sci. U. S. A. 104: 576–81. 
45. Samy, E. T., L. A. Parker, C. P. Sharp, and K. S. K. Tung. 2005. Continuous control of 
autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the 
regional lymph node. J. Exp. Med. 202: 771–81. 
46. Bonertz, A., J. Weitz, D. - Ho Kim Pietsch, and N. N. Rahbari. 2009. Antigen - specific 
Tregs control T cell responses against a limited repertoire of tumor antigens in patients with 
colorectal carcinoma. J. Clin. Invest. 119: 3311–3321. 
47. Wei, J., O. Duramad, O. a Perng, S. L. Reiner, Y.-J. Liu, and F. X.-F. Qin. 2007. 
Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of 
Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 104: 18169–18174. 
48. Hadjur, S., L. Bruno, A. Hertweck, B. S. Cobb, B. Taylor, A. G. Fisher, and M. 
Merkenschlager. 2009. IL4 blockade of inducible regulatory T cell differentiation: The role of 
Th2 cells, Gata3 and PU.1. Immunol. Lett. 122: 37–43. 
49. Ulloa, L., J. Doody, and J. Massagué. 1999. Inhibition of transforming growth factor-
β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397: 710–713. 
50. Caretto, D., S. D. Katzman, A. V Villarino, E. Gallo, and A. K. Abbas. 2010. Cutting edge: 
the Th1 response inhibits the generation of peripheral regulatory T cells. J. Immunol. 
{(Baltimore,} Md.  1950) 184: 30–4. 
51. Zhou, L., I. I. Ivanov, R. Spolski, R. Min, K. Shenderov, T. Egawa, D. E. Levy, W. J. 
Leonard, and D. R. Littman. 2007. IL-6 programs T H -17 cell differentiation by promoting 
sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8. 
128 
 
52. Bailey-Bucktrout, S. L., M. Martinez-Llordella, X. Zhou, B. Anthony, W. Rosenthal, H. 
Luche, H. J. Fehling, and J. a Bluestone. 2013. Self-antigen-driven activation induces instability 
of regulatory T cells during an inflammatory autoimmune response. Immunity 39: 949–62. 
53. Zhou, X., S. L, Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M.-L. Marc, M. Ashby, M. 
Nakayama, W. Rosenthal, and J. a Bluestone. Instability of the transcription factor Foxp3 leads 
to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10: 1000–1007. 
54. van der Veeken, J., A. J. Gonzalez, H. Cho, A. Arvey, S. Hemmers, C. S. Leslie, and A. Y. 
Rudensky. 2016. Memory of Inflammation in Regulatory T Cells. Cell 166: 977–990. 
55. Arvey, A., J. van der Veeken, R. M. Samstein, Y. Feng, J. A. Stamatoyannopoulos, and A. Y. 
Rudensky. 2014. Inflammation-induced repression of chromatin bound by the transcription 
factor Foxp3 in regulatory T cells. Nat. Immunol. 15: 580–587. 
56. Thompson, L. J., J.-F. Lai, A. C. Valladao, T. D. Thelen, Z. L. Urry, and S. F. Ziegler. 2016. 
Conditioning of naive CD4(+) T cells for enhanced peripheral Foxp3 induction by nonspecific 
bystander inflammation. Nat. Immunol. 17: 297–303. 
57. Geem, D., V. Ngo, A. Harusato, B. Chassaing, A. T. Gewirtz, R. D. Newberry, and T. L. 
Denning. 2016. Contribution of Mesenteric Lymph Nodes and {GALT} to the Intestinal Foxp3+ 
Regulatory {T-Cell} Compartment. 2: 274–280.e3. 
58. Crepin, V. F., J. W. Collins, M. Habibzay, and G. Frankel. 2016. Citrobacter rodentium 
mouse model of bacterial infection. Nat. Protoc. 11: 1851–1876. 
59. Zheng, Y., P. A. Valdez, D. M. Danilenko, Y. Hu, S. M. Sa, Q. Gong, A. R. Abbas, Z. 
Modrusan, N. Ghilardi, F. J. de Sauvage, and W. Ouyang. 2008. Interleukin-22 mediates early 
host defense against attaching and effacing bacterial pathogens. Nat. Med. 14: 282–289. 
60. Shiomi, H., A. Masuda, S. Nishiumi, M. Nishida, T. Takagawa, Y. Shiomi, H. Kutsumi, R. S. 
Blumberg, T. Azuma, and M. Yoshida. 2010. Gamma interferon produced by antigen-specific 
CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection. Infect. 
Immun. 78: 2653–66. 
61. Collins, J. W., K. M. Keeney, V. F. Crepin, V. a K. Rathinam, K. a Fitzgerald, B. B. Finlay, 
and G. Frankel. 2014. Citrobacter rodentium: infection, inflammation and the microbiota. Nat. 
Rev. Microbiol. 12: 612–623. 
62. Zheng, Y., P. A. Valdez, D. M. Danilenko, Y. Hu, S. M. Sa, Q. Gong, A. R. Abbas, Z. 
Modrusan, N. Ghilardi, F. J. de Sauvage, and W. Ouyang. 2008. Interleukin-22 mediates early 
host defense against attaching and effacing bacterial pathogens. 14: 282–289. 
63. Bry, L., M. Brigl, and M. B. Brenner. 2006. CD4+-T-cell effector functions and 
costimulatory requirements essential for surviving mucosal infection with Citrobacter rodentium. 
Infect. Immun. 74: 673–81. 
64. Grashoff, C., B. D. Hoffman, M. D. Brenner, R. Zhou, M. Parsons, M. T. Yang, M. a 
McLean, S. G. Sligar, C. S. Chen, T. Ha, and M. a Schwartz. 2010. Measuring mechanical 
tension across vinculin reveals regulation of focal adhesion dynamics. Nature 466: 263–6. 
65. Bry, L., and M. B. Brenner. 2004. Critical Role of T Cell-Dependent Serum Critical Role of 
129 
 
T Cell-Dependent Serum Antibody, but Not the Gut-Associated Lymphoid Tissue, for Surviving 
Acute Mucosal Infection with Citrobacter rodentium, an Attaching and Effacing Pathogen. J 
Immunol J. Immunol-ogy 172: 433–441. 
66. Denkers, E. Y., and R. T. Gazzinelli. 1998. Regulation and function of T-cell-mediated 
immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11: 569–88. 
67. Mordue, D. G., F. Monroy, M. La Regina, C. A. Dinarello, and L. D. Sibley. 2001. Acute 
Toxoplasmosis Leads to Lethal Overproduction of Th1 Cytokines. J. Immunol. 167: 4574–4584. 
68. Gazzinelli, R. T., M. Wysocka, S. Hieny, T. Scharton-Kersten, A. Cheever, R. Kühn, W. 
Müller, G. Trinchieri, and A. Sher. 1996. In the absence of endogenous IL-10, mice acutely 
infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T 
cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 
157: 798–805. 
69. Yap, G., M. Pesin, and A. Sher. 2000. Toxoplasma gondii Intracellular Pathogen, Mediating 
Chronic Resistance to the Production in T Cells γ Maintenance of IFN- Cutting Edge: IL-12 Is 
Required for the Cutting Edge: IL-12 Is Required for the Maintenance of IFN-␥ Production in T 
Cells Mediating Chronic Resistance to the Intracellular Pathogen, Toxoplasma gondii. J 
Immunol 165: 628–631. 
70. Solomon, L., S. Mansor, P. Mallon, E. Donnelly, M. Hoper, M. Loughrey, S. Kirk, and K. 
Gardiner. 2010. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp. Clin. 
Path. 19: 235–239. 
71. Araki, Y., K. Mukaisyo, H. Sugihara, Y. Fujiyama, and T. Hattorie. 2010. Increased 
apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced 
colitis in mice YOSHIO. Oncol. Rep. 24: 869–874. 
72. Wirtz, S., C. Neufert, B. Weigmann, and M. F. Neurath. 2007. Chemically induced mouse 
models of intestinal inflammation. Nat. Protoc. 2: 541–546. 
73. Dieleman, Palmen, Akol, Bloemena, PENA, Meuwissen, and Van Rees. 1998. Chronic 
experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 
cytokines. Clin. Exp. Immunol. 114: 385–391. 
74. Kim, K.-A., W. Gu, I.-A. Lee, E.-H. Joh, and D.-H. Kim. 2012. High Fat Diet-Induced Gut 
Microbiota Exacerbates Inflammation and Obesity in Mice via the TLR4 Signaling Pathway. 
PLoS One 7: e47713. 
75. Ding, S., M. M. Chi, B. P. Scull, R. Rigby, N. M. J. Schwerbrock, S. Magness, C. Jobin, and 
P. K. Lund. 2010. High-Fat Diet: Bacteria Interactions Promote Intestinal Inflammation Which 
Precedes and Correlates with Obesity and Insulin Resistance in Mouse. PLoS One 5: e12191. 
76. Park, E. J., J. H. Lee, G.-Y. Yu, G. He, S. R. Ali, R. G. Holzer, C. H. Österreicher, H. 
Takahashi, and M. Karin. 2010. Dietary and Genetic Obesity Promote Liver Inflammation and 
Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell 140: 197–208. 
77. Moreira, A. P. B., T. F. S. Texeira, A. B. Ferreira, M. do Carmo Gouveia Peluzio, and R. de 
Cássia Gonçalves Alfenas. 2012. Influence of a high-fat diet on gut microbiota, intestinal 
permeability and metabolic endotoxaemia. Br. J. Nutr. 108: 801–809. 
130 
 
78. Miele, L., V. Valenza, G. La Torre, M. Montalto, G. Cammarota, R. Ricci, R. Mascianà, A. 
Forgione, M. L. Gabrieli, G. Perotti, F. M. Vecchio, G. Rapaccini, G. Gasbarrini, C. P. Day, and 
A. Grieco. 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic 
fatty liver disease. Hepatology 49: 1877–1887. 
79. Schulz, M. D., Ç. Atay, J. Heringer, F. K. Romrig, S. Schwitalla, B. Aydin, P. K. Ziegler, J. 
Varga, W. Reindl, C. Pommerenke, G. Salinas-Riester, A. Böck, C. Alpert, M. Blaut, S. C. 
Polson, L. Brandl, T. Kirchner, F. R. Greten, S. W. Polson, and M. C. Arkan. 2014. High-fat-
diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature 514: 
508–512. 
80. Godfrey, V. L., J. E. Wilkinson, E. M. Rinchik, and L. B. Russell. 1991. Fatal 
lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic 
environment: potential model for thymic education. Proc. Natl. Acad. Sci. U. S. A. 88: 5528–32. 
81. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of Regulatory T cell Development by 
the Transcription Factor FoxP3. Science 299: 1057–1061. 
82. Wan, Y. Y., and R. A. Flavell. 2005. Identifying Foxp3-expressing suppressor T cells with a 
bicistronic reporter. Proc. Natl. Acad. Sci. U. S. A. 102: 5126–31. 
83. Kuczma, M., R. Podolsky, N. Garge, D. Daniely, R. Pacholczyk, L. Ignatowicz, and P. Kraj. 
2009. Foxp3-deficient regulatory T cells do not revert into conventional effector CD4+ T cells 
but constitute a unique cell subset. J. Immunol. 183: 3731–41. 
84. Zhang, Y. E. 2009. Non-Smad pathways in TGF-β signaling. Cell Res. 19: 128–139. 
85. Chen, W., W. Jin, N. Hardegen, K.-J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 
2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by 
TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875–86. 
86. Gu, A.-D., Y. Wang, L. Lin, S. S. Zhang, and Y. Y. Wan. 2012. Requirements of 
transcription factor Smad-dependent and -independent TGF-β signaling to control discrete T-cell 
functions. Proc. Natl. Acad. Sci. U. S. A. 109: 905–10. 
87. Lu, L.-F., M. P. Boldin, A. Chaudhry, L.-L. Lin, K. D. Taganov, T. Hanada, A. Yoshimura, 
D. Baltimore, and A. Y. Rudensky. Function of {miR-146a} in controlling Treg cell-mediated 
regulation of Th1 responses. Cell 142: 914–29. 
88. Delisle, J.-S., M. Giroux, G. Boucher, J.-R. Landry, M.-P. Hardy, S. Lemieux, R. G. Jones, 
B. T. Wilhelm, and C. Perreault. 2013. The TGF-β-Smad3 pathway inhibits CD28-dependent 
cell growth and proliferation of CD4 T cells. Genes Immun. 14: 115–126. 
89. Takimoto, T., Y. Wakabayashi, T. Sekiya, N. Inoue, R. Morita, K. Ichiyama, R. Takahashi, 
M. Asakawa, G. Muto, T. Mori, E. Hasegawa, S. Saika, S. Shizuya, T. Hara, M. Nomura, and A. 
Yoshimura. 2010. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated 
regulation of regulatory T plasticity and Th1 development. J. Immunol. 185: 842–55. 
90. Lu, L., J. Wang, F. Zhang, Y. Chai, D. Brand, X. Wang, D. a Horwitz, W. Shi, and S. G. 
Zheng. 2010. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory 
T cells. J. Immunol. 184: 4295–306. 
131 
 
91. Ichiyama, K., T. Sekiya, N. Inoue, T. Tamiya, I. Kashiwagi, A. Kimura, R. Morita, G. Muto, 
T. Shichita, R. Takahashi, and A. Yoshimura. 2011. Transcription factor Smad-independent T 
helper 17 cell induction by transforming-growth factor-β is mediated by suppression of 
eomesodermin. Immunity 34: 741–54. 
92. Hill, J. A., J. A. Hall, C.-M. Sun, Q. Cai, N. Ghyselinck, P. Chambon, Y. Belkaid, D. Mathis, 
and C. Benoist. 2008. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition 
from CD4+CD44hi Cells. Immunity 29: 758–70. 
93. Coombes, J. L., K. R. R. Siddiqui, C. V Arancibia-Cárcamo, J. Hall, C.-M. Sun, Y. Belkaid, 
and F. Powrie. 2007. A functionally specialized population of mucosal CD103+ DCs induces 
Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 
204: 1757–64. 
94. Elias, K. M., A. Laurence, T. S. Davidson, G. Stephens, Y. Kanno, E. M. Shevach, and J. J. 
O’Shea. 2008. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a 
Stat-3/Stat-5 independent signaling pathway. Blood 111: 1013–20. 
95. Mucida, D., Y. Park, G. Kim, O. Turovskaya, I. Scott, M. Kronenberg, and H. Cheroutre. 
2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 
317: 256–60. 
96. Xiao, S., H. Jin, T. Korn, S. M. Liu, M. Oukka, B. Lim, and V. K. Kuchroo. 2008. Retinoic 
acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing 
TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. 
Immunol. 181: 2277–84. 
97. Quintana, F. J., A. S. Basso, A. H. Iglesias, T. Korn, M. F. Farez, E. Bettelli, M. Caccamo, 
M. Oukka, and H. L. Weiner. 2008. Control of Treg and TH17 cell differentiation by the aryl 
hydrocarbon receptor. Nature 453: 65–71. 
98. Mezrich, J. D., J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, and C. A. 
Bradfield. 2010. An interaction between kynurenine and the aryl hydrocarbon receptor can 
generate regulatory T cells. J. Immunol. 185: 3190–8. 
99. Murphy, K. A., C. M. Villano, R. Dorn, and L. A. White. 2004. Interaction between the aryl 
hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 
expression in keratinocytes. J. Biol. Chem. 279: 25284–93. 
100. Arpaia, N., C. Campbell, X. Fan, S. Dikiy, J. van der Veeken, P. deRoos, H. Liu, J. R. 
Cross, K. Pfeffer, P. J. Coffer, and A. Y. Rudensky. 2013. Metabolites produced by commensal 
bacteria promote peripheral regulatory T-cell generation. Nature 504: 451–455. 
101. Waldecker, M., T. Kautenburger, H. Daumann, C. Busch, and D. Schrenk. 2008. Inhibition 
of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites 
formed in the colon. J. Nutr. Biochem. 19: 587–593. 
102. Sekiya, T., I. Kashiwagi, N. Inoue, R. Morita, S. Hori, H. Waldmann, A. Y. Rudensky, H. 
Ichinose, D. Metzger, P. Chambon, and A. Yoshimura. 2011. The nuclear orphan receptor Nr4a2 
induces Foxp3 and regulates differentiation of {CD4+} T cells. 2: 269. 
103. Bandukwala, H. S., and A. Rao. 2013. “Nurr”ishing Treg cells: Nr4a transcription factors 
132 
 
control Foxp3 expression. Nat. Immunol. 14: 201–203. 
104. Sekiya, T., I. Kashiwagi, R. Yoshida, T. Fukaya, R. Morita, A. Kimura, H. Ichinose, D. 
Metzger, P. Chambon, and A. Yoshimura. 2013. Nr4a receptors are essential for thymic 
regulatory T cell development and immune homeostasis. Nat. Immunol. 14: 230–237. 
105. Fassett, M. S., W. Jiang, A. M. D’Alise, D. Mathis, and C. Benoist. 2012. Nuclear receptor 
Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. Proc. Natl. 
Acad. Sci. U. S. A. 109: 3891–6. 
106. Sekiya, T., I. Kashiwagi, N. Inoue, R. Morita, S. Hori, H. Waldmann, A. Y. Rudensky, H. 
Ichinose, D. Metzger, P. Chambon, and A. Yoshimura. 2011. The nuclear orphan receptor Nr4a2 
induces Foxp3 and regulates differentiation of CD4+ T cells. Nat. Commun. 2: 269. 
107. Wu, C., Z. Chen, V. Dardalhon, S. Xiao, T. Thalhamer, M. Liao, A. Madi, R. F. Franca, T. 
Han, M. Oukka, and V. Kuchroo. 2017. The transcription factor musculin promotes the 
unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional 
program. Nat. Immunol. 18: 344–353. 
108. Clever, D., R. Roychoudhuri, M. G. Constantinides, M. H. Askenase, M. Sukumar, C. A. 
Klebanoff, R. L. Eil, H. D. Hickman, Z. Yu, J. H. Pan, D. C. Palmer, A. T. Phan, J. Goulding, L. 
Gattinoni, A. W. Goldrath, Y. Belkaid, and N. P. Restifo. 2016. Oxygen Sensing by T Cells 
Establishes an Immunologically Tolerant Metastatic Niche. Cell 166: 1117–1131.e14. 
109. Hill, J. A., M. Feuerer, K. Tash, S. Haxhinasto, J. Perez, R. Melamed, D. Mathis, and C. 
Benoist. 2007. Foxp3 Transcription-Factor-Dependent and -Independent Regulation of the 
Regulatory T Cell Transcriptional Signature. Immunity 27: 786–800. 
110. Oh, S. A., M. Liu, B. G. Nixon, D. Kang, A. Toure, M. Bivona, and M. O. Li. 2017. Foxp3-
independent mechanism by which TGF-β controls peripheral T cell tolerance. Proc. Natl. Acad. 
Sci. U. S. A. 114: E7536–E7544. 
111. Zheng, Y., S. Z. Josefowicz, A. Kas, T.-T. Chu, M. A. Gavin, and A. Y. Rudensky. 2007. 
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. 
Nature 445: 936–940. 
112. Probst, S., and S. J. Arnold. 2017. Eomesodermin—At Dawn of Cell Fate Decisions During 
Early Embryogenesis. Curr. Top. Dev. Biol. 122: 93–115. 
113. Teo, A. K. K., S. J. Arnold, M. W. B. Trotter, S. Brown, L. T. Ang, Z. Chng, E. J. 
Robertson, N. R. Dunn, and L. Vallier. 2011. Pluripotency factors regulate definitive endoderm 
specification through eomesodermin. Genes Dev. 25: 238–50. 
114. Kidder, B. L., and S. Palmer. 2010. Examination of transcriptional networks reveals an 
important role for TCFAP2C, SMARCA4, and EOMES in trophoblast stem cell maintenance. 
Genome Res. 20: 458–72. 
115. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A 
Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment. Cell 100: 655–669. 
116. Daussy, C., F. Faure, K. Mayol, S. Viel, G. Gasteiger, E. Charrier, J. Bienvenu, T. Henry, E. 
Debien, U. a Hasan, J. Marvel, K. Yoh, S. Takahashi, I. Prinz, S. de Bernard, L. Buffat, and T. 
133 
 
Walzer. 2014. T-bet and Eomes instruct the development of two distinct natural killer cell 
lineages in the liver and in the bone marrow. J. Exp. Med. 211: 563–77. 
117. Pearce, E. L. 2003. Control of Effector CD8+ T Cell Function by the Transcription Factor 
Eomesodermin. Science (80-. ). 302: 1041–1043. 
118. Ichiyama, K., T. Sekiya, N. Inoue, T. Tamiya, I. Kashiwagi, A. Kimura, R. Morita, G. 
Muto, T. Shichita, R. Takahashi, and A. Yoshimura. Transcription factor Smad-independent T 
helper 17 cell induction by transforming-growth factor-β is mediated by suppression of 
eomesodermin. Immunity 34: 741–54. 
119. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. 
Kuchroo. Reciprocal developmental pathways for the generation of pathogenic effector {TH17} 
and regulatory T cells. Nature 441: 235–8. 
120. Endo, Y., C. Iwamura, M. Kuwahara, A. Suzuki, K. Sugaya, D. J. Tumes, K. Tokoyoda, H. 
Hosokawa, M. Yamashita, and T. Nakayama. 2011. Eomesodermin controls interleukin-5 
production in memory T helper 2 cells through inhibition of activity of the transcription factor 
GATA3. Immunity 35: 733–45. 
121. Lupar, E., M. Brack, L. Garnier, S. Laffont, K. S. Rauch, K. Schachtrup, S. J. Arnold, J.-C. 
Guéry, and A. Izcue. 2015. Eomesodermin Expression in CD4+ T Cells Restricts Peripheral 
Foxp3 Induction. J. Immunol. 195: 4742–52. 
122. Zhang, P., J. S. Lee, K. H. Gartlan, I. S. Schuster, I. Comerford, A. Varelias, M. A. Ullah, S. 
Vuckovic, M. Koyama, R. D. Kuns, K. R. Locke, K. J. Beckett, S. D. Olver, L. D. Samson, M. 
Montes de Oca, F. de Labastida Rivera, A. D. Clouston, G. T. Belz, B. R. Blazar, K. P. 
MacDonald, S. R. McColl, R. Thomas, C. R. Engwerda, M. A. Degli-Esposti, A. Kallies, S.-K. 
Tey, and G. R. Hill. 2017. Eomesodermin promotes the development of type 1 regulatory T 
(TR1) cells. Sci. Immunol. 2: eaah7152. 
123. Intlekofer, A. M., A. Banerjee, N. Takemoto, S. M. Gordon, C. S. Dejong, H. Shin, C. A. 
Hunter, E. J. Wherry, T. Lindsten, and S. L. Reiner. 2008. Anomalous type 17 response to viral 
infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408–11. 
124. Aranami, T., and T. Yamamura. 2008. Th17 Cells and Autoimmune Encephalomyelitis 
(EAE/MS). Allergol. Int. 57: 115–120. 
125. Bommiasamy, H., M. West, B. Stockinger, J. M. Coghill, and J. S. Serody. 2014. Plasticity 
of Th17 Cells and Conversion to Th1 Cells during Acute GvHD. Blood 124. 
126. Yang, Y., J. Xu, Y. Niu, J. S. Bromberg, and Y. Ding. 2008. T-bet and eomesodermin play 
critical roles in directing T cell differentiation to Th1 versus Th17. J. Immunol. 181: 8700–10. 
127. Suto, A., A. L. Wurster, S. L. Reiner, and M. J. Grusby. 2006. IL-21 inhibits IFN-gamma 
production in developing Th1 cells through the repression of Eomesodermin expression. J. 
Immunol. 177: 3721–7. 
128. Edwards, E. S., C. Smith, and R. Khanna. 2014. Phenotypic and transcriptional profile 
correlates with functional plasticity of antigen-specific CD4+ T cells. Immunol. Cell Biol. 92: 
181–190. 
134 
 
129. Maynard, C. L., L. E. Harrington, K. M. Janowski, J. R. Oliver, C. L. Zindl, A. Y. 
Rudensky, and C. T. Weaver. 2007. Regulatory T cells expressing interleukin 10 develop from 
Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 8: 931–41. 
130. Schiering, C., T. Krausgruber, A. Chomka, A. Fröhlich, K. Adelmann, E. Wohlfert, J. Pott, 
T. Griseri, J. Bollrath, A. N. Hegazy, O. J. Harrison, B. M. J. Owens, M. Löhning, Y. Belkaid, P. 
G. Fallon, and F. Powrie. The alarmin IL-33 promotes regulatory T-cell function in the intestine. 
Nature . 
131. Hadis, U., B. Wahl, O. Schulz, H.-W. Matthias, A. Schippers, N. Wagner, W. Müller, T. 
Sparwasser, R. Förster, and O. Pabst. 2011. Intestinal Tolerance Requires Gut Homing and 
Expansion of FoxP3+ Regulatory T Cells in the Lamina Propria. 34: 237–246. 
132. Worbs, T., U. Bode, S. Yan, M. W. Hoffmann, G. Hintzen, G. Bernhardt, R. Förster, and O. 
Pabst. 2006. Oral tolerance originates in the intestinal immune system and relies on antigen 
carriage by dendritic cells. 203: 519–527. 
133. Hand, T. W., L. M. Santos, N. Bouladoux, M. J. Molloy, A. J. Pagán, M. Pepper, C. L. 
Maynard, C. O. Elson, and Y. Belkaid. 2012. Acute Gastrointestinal Infection Induces Long-
Lived Microbiota-Specific T Cell Responses. 337: 1553–1556. 
134. Hayashi, A., T. Sato, N. Kamada, Y. Mikami, K. Matsuoka, T. Hisamatsu, T. Hibi, A. 
Roers, H. Yagita, T. Ohteki, A. Yoshimura, and T. Kanai. 2013. A Single Strain of Clostridium 
butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental 
Colitis in Mice. 13: 711–722. 
135. Wurzelmann, J. I., C. M. Lyles, and R. S. Sandler. Childhood infections and the risk of 
inflammatory bowel disease. Dig Dis Sci 39: 555–560. 
136. Bautista, J. L., C.-W. J. Lio, S. K. Lathrop, K. Forbush, Y. Liang, J. Luo, A. Y. Rudensky, 
and C.-S. Hsieh. 2009. Intraclonal competition limits the fate determination of regulatory T cells 
in the thymus. Nat. Immunol. 10: 610–617. 
137. Liston, A., K. M. Nutsch, A. G. Farr, J. M. Lund, J. P. Rasmussen, P. A. Koni, and A. Y. 
Rudensky. 2008. Differentiation of regulatory Foxp3+ T cells in the thymic cortex. Proc. Natl. 
Acad. Sci. U. S. A. 105: 11903–8. 
138. Reinhardt, R. L., H.-E. Liang, and R. M. Locksley. 2009. Cytokine-secreting follicular T 
cells shape the antibody repertoire. Nat. Immunol. 10: 385–393. 
139. Hsieh, C.-S., Y. Zheng, Y. Liang, J. D. Fontenot, and A. Y. Rudensky. 2006. An 
intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. 
Nat. Immunol. 7: 401–410. 
140. Devkota, S., Y. Wang, M. W. Musch, V. Leone, F.-P. Hannah, A. Nadimpalli, D. A. 
Antonopoulos, B. Jabri, and E. B. Chang. 2012. Dietary-fat-induced taurocholic acid promotes 
pathobiont expansion and colitis in Il10-/- mice. Nature 487: 104–108. 
141. Ise, W., M. Kohyama, K. M. Nutsch, H. M. Lee, A. Suri, E. R. Unanue, T. L. Murphy, and 
K. M. Murphy. 2010. CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by 
cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 11: 129–135. 
135 
 
142. Hall, A., D. P. Beiting, C. Tato, B. John, G. Oldenhove, C. Lombana, G. Pritchard, J. S. 
Silver, N. Bouladoux, J. S. Stumhofer, T. H. Harris, J. Grainger, E. D. Wojno, S. Wagage, D. S. 
Roos, P. Scott, L. A. Turka, S. Cherry, S. L. Reiner, D. Cua, Y. Belkaid, M. M. Elloso, and C. A. 
Hunter. 2012. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell 
populations required to limit infection-induced pathology. 37: 511–523. 
143. Caretto, D., S. D. Katzman, A. V Villarino, E. Gallo, and A. K. Abbas. 2010. Cutting edge: 
the Th1 response inhibits the generation of peripheral regulatory T cells. J. Immunol. 184: 30–4. 
144. Mantel, P. Y., H. Kuipers, O. Boyman, C. Rhyner, N. Ouaked, B. Rückert, C. 
Karagiannidis, B. N. Lambrecht, R. W. Hendriks, R. Crameri, C. A. Akdis, K. Blaser, and C. B. 
Schmidt-Weber. 2007. GATA3-driven Th2 responses inhibit TGF-β1-induced FOXP3 
expression and the formation of regulatory T cells. PLoS Biol. 5: 2847–2861. 
145. Boehm, F., M. Martin, R. Kesselring, G. Schiechl, E. K. Geissler, H.-J. Schlitt, and F.-F. 
Stefan. 2012. Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports 
development of intestinal inflammation. 12: 1–11. 
146. Lewis, M. D., S. a Miller, M. M. Miazgowicz, K. M. Beima, and A. S. Weinmann. 2007. T-
bet’s ability to regulate individual target genes requires the conserved T-box domain to recruit 
histone methyltransferase activity and a separate family member-specific transactivation domain. 
Mol. Cell. Biol. 27: 8510–21. 
147. Miller, S. a, A. C. Huang, M. M. Miazgowicz, M. M. Brassil, and A. S. Weinmann. 2008. 
Coordinated but physically separable interaction with H3K27-demethylase and H3K4-
methyltransferase activities are required for T-box protein-mediated activation of developmental 
gene expression. Genes Dev. 22: 2980–93. 
148. Lin, S., T. C. Thomas, L. H. Storlien, and X. F. Huang. 2000. Development of high fat diet-
induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. 24: 639–646. 
149. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. 
Cua, and D. R. Littman. 2006. The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121–33. 
150. Ma, X., M. Torbenson, A. R. A. Hamad, M. J. Soloski, and Z. Li. 2007. High-fat diet 
modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and 
exacerbates experimental colitis. Clin. Exp. Immunol. 151: 130–138. 
151. Gruber, L., S. Kisling, P. Lichti, F.-P. Martin, S. May, M. Klingenspor, M. Lichtenegger, 
M. Rychlik, and D. Haller. 2013. High Fat Diet Accelerates Pathogenesis of Murine Crohn’s 
Disease-Like Ileitis Independently of Obesity. PLoS One 8: e71661. 
152. Gottschalk, R. A., E. Corse, and J. P. Allison. 2010. TCR ligand density and affinity 
determine peripheral induction of Foxp3 in vivo. J. Exp. Med. 207: 1701–11. 
153. Winter, S. E., M. G. Winter, M. N. Xavier, P. Thiennimitr, V. Poon, M. A. Keestra, R. C. 
Laughlin, G. Gomez, J. Wu, S. D. Lawhon, I. Popova, S. J. Parikh, G. L. Adams, R. M. Tsolis, 
V. J. Stewart, and A. J. Bäumler. 2013. Host-derived nitrate boosts growth of E. coli in the 
inflamed gut. Sci New York N Y 339: 708. 
154. Houston, S. A., V. Cerovic, C. Thomson, J. Brewer, A. M. Mowat, and S. Milling. 2015. 
136 
 
The lymph nodes draining the small intestine and colon are anatomically separate and 
immunologically distinct. Mucosal Immunol 9: 468–478. 
155. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T 
lymphocytes. Nature 383: 787–793. 
156. Ho, I.-C., and L. H. Glimcher. 2002. Transcription: Tantalizing Times for T Cells. Cell 109: 
S109–S120. 
157. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T Cells and 
Immune Tolerance. Cell 133: 775–787. 
158. Fontenot, J. D., J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky. 2005. A function for 
interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6: 1142–1151. 
159. Feuerer, M., J. A. Hill, D. Mathis, and C. Benoist. 2009. Foxp3+ regulatory T cells: 
differentiation, specification, subphenotypes. Nat. Immunol. 10: 689–695. 
160. Burzyn, D., W. Kuswanto, D. Kolodin, J. L. Shadrach, M. Cerletti, Y. Jang, E. Sefik, T. G. 
Tan, A. J. Wagers, C. Benoist, and D. Mathis. 2013. A Special Population of regulatory T Cells 
Potentiates muscle repair. Cell 155. 
161. Burzyn, D., C. Benoist, and D. Mathis. 2013. Regulatory T cells in nonlymphoid tissues. 
Nat. Immunol. 14: 1007–1013. 
162. Kalekar, L. A., S. E. Schmiel, S. L. Nandiwada, W. Y. Lam, L. O. Barsness, N. Zhang, G. 
L. Stritesky, D. Malhotra, K. E. Pauken, J. L. Linehan, M. G. O’Sullivan, B. T. Fife, K. A. 
Hogquist, M. K. Jenkins, and D. L. Mueller. 2016. CD4+ T cell anergy prevents autoimmunity 
and generates regulatory T cell precursors. Nat. Immunol. 17: 304–314. 
163. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. 
Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov. 2005. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proc. Natl. Acad. Sci. U. S. A. 102: 15545–50. 
164. Mootha, V. K., C. M. Lindgren, K.-F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. 
Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. 
Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. Hirschhorn, D. Altshuler, 
and L. C. Groop. 2003. PGC-1α-responsive genes involved in oxidative phosphorylation are 
coordinately downregulated in human diabetes. Nat. Genet. 34: 267–273. 
165. Pot, C., L. Apetoh, and V. K. Kuchroo. 2011. Type 1 regulatory T cells (Tr1) in 
autoimmunity. Semin. Immunol. 23: 202–8. 
166. Mascanfroni, I. D., M. C. Takenaka, A. Yeste, B. Patel, Y. Wu, J. E. Kenison, S. Siddiqui, 
A. S. Basso, L. E. Otterbein, D. M. Pardoll, F. Pan, A. Priel, C. B. Clish, S. C. Robson, and F. J. 
Quintana. 2015. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-
α. Nat. Med. 21: 638–646. 
167. Obata, Y., Y. Furusawa, T. A. Endo, J. Sharif, D. Takahashi, K. Atarashi, M. Nakayama, S. 
Onawa, Y. Fujimura, M. Takahashi, T. Ikawa, T. Otsubo, Y. I. Kawamura, T. Dohi, S. Tajima, 
H. Masumoto, O. Ohara, K. Honda, S. Hori, H. Ohno, H. Koseki, and K. Hase. 2014. The 
137 
 
epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T 
cells. Nat. Immunol. 15: 571–579. 
168. Moran, A. E., K. L. Holzapfel, Y. Xing, N. R. Cunningham, J. S. Maltzman, J. Punt, and K. 
A. Hogquist. 2011. T cell receptor signal strength in Treg and iNKT cell development 
demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208: 1279–89. 
169. Choi, Y. S., R. Kageyama, D. Eto, T. C. Escobar, R. J. Johnston, L. Monticelli, C. Lao, and 
S. Crotty. 2011. ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell 
Differentiation via Induction of the Transcriptional Repressor Bcl6. Immunity 34: 932–946. 
170. Lee, W., H. S. Kim, S. Y. Baek, and G. R. Lee. 2016. Transcription factor IRF8 controls 
Th1-like regulatory T-cell function. Cell. Mol. Immunol. 13: 785–794. 
171. Feuerer, M., J. A. Hill, D. Mathis, and C. Benoist. 2009. Foxp3+ regulatory T cells: 
differentiation, specification, subphenotypes. Nat. Immunol. 10: 689–695. 
172. Maslowski, K. M., and C. R. Mackay. 2011. Diet, gut microbiota and immune responses. 
Nat. Immunol. 12: 5–9. 
173. Molodecky, N. A., I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. 
Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema, and G. G. Kaplan. 2012. Increasing 
Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic 
Review. Gastroenterology 142: 46–54.e42. 
174. Walter, J., and R. Ley. 2011. The Human Gut Microbiome: Ecology and Recent 
Evolutionary Changes. Annu. Rev. Microbiol. 65: 411–429. 
175. Ivanov, I. I., K. Atarashi, N. Manel, E. L. Brodie, T. Shima, U. Karaoz, D. Wei, K. C. 
Goldfarb, C. a Santee, S. V Lynch, T. Tanoue, A. Imaoka, K. Itoh, K. Takeda, Y. Umesaki, K. 
Honda, and D. R. Littman. 2009. Induction of intestinal Th17 cells by segmented filamentous 
bacteria. Cell 139: 485–98. 
176. Yamada, A., R. Arakaki, M. Saito, T. Tsunematsu, Y. Kudo, and N. Ishimaru. 2016. Role of 
regulatory T cell in the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 22: 
2195–205. 
177. Kamradt, T., and R. Volkmer-Engert. 2004. Cross-reactivity of T lymphocytes in infection 
and autoimmunity. Mol. Divers. 8: 271–280. 
178. Anderson, A. C., H. Waldner, V. Turchin, C. Jabs, M. Prabhu Das, V. K. Kuchroo, and L. 
B. Nicholson. 2000. Autoantigen-Responsive T Cell Clones Demonstrate Unfocused TCR Cross-
Reactivity toward Multiple Related Ligands: Implications for Autoimmunity. Cell. Immunol. 
202: 88–96. 
179. Stephens, L. A., D. Gray, and S. M. Anderton. 2005. CD4+CD25+ regulatory T cells limit 
the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc. Natl. Acad. Sci. 
U. S. A. 102: 17418–23. 
180. Lee, H.-M., J. L. Bautista, J. Scott-Browne, J. F. Mohan, and C.-S. Hsieh. 2012. A Broad 
Range of Self-Reactivity Drives Thymic Regulatory T Cell Selection to Limit Responses to Self. 
Immunity 37: 475–486. 
138 
 
181. Endo, Y., C. Iwamura, M. Kuwahara, A. Suzuki, K. Sugaya, D. J. Tumes, K. Tokoyoda, H. 
Hosokawa, M. Yamashita, and T. Nakayama. Eomesodermin controls interleukin-5 production 
in memory T helper 2 cells through inhibition of activity of the transcription factor {GATA3.}. 
Immunity 35: 733–45. 
 
